Metabolic Syndrome, Weight and Cardiovascular Co-Morbidities:A Randomised Study Comparing the Effect of Three Dietary Approaches on Cardiovascular Risk in Subjects with the Metabolic Syndrome by Mukhtar, Rasha
        
University of Bath
DOCTOR OF MEDICINE
Metabolic Syndrome, Weight and Cardiovascular Co-Morbidities
A Randomised Study Comparing the Effect of Three Dietary Approaches on








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. May. 2019










Metabolic Syndrome, Weight and Cardiovascular  
Co-Morbidities 
A Randomised Study Comparing the Effect of Three 
Dietary Approaches on Cardiovascular Risk in Subjects 
with the Metabolic Syndrome 
 
Rasha Younis Abdalla Mukhtar 
 
 
A thesis submitted for the degree of  
Doctor of Medicine 
University of Bath 











The metabolic syndrome is a cluster of disorders (obesity, dyslipidaemia, 
hyperinsulinaemia and hypertension) which individually or collectively lead to an 
increase in the risk of cardiovascular disease. Over the years it has been associated 
with endothelial dysfunction, raised markers of chronic inflammation, insulin 
resistance and clotting dysregulation. 
Studies have shown that the prevalence of the metabolic syndrome in adults 
over the age of 20 years to be 24%, with approximately 12 million adults within the 
United Kingdom fulfilling the criteria for diagnosis. Numbers of individuals with the 
metabolic syndrome continue to rise following population trends of increasing 
sedentary lifestyle, high calorie intake, smoking, and stress. Associated is an increase 
in obesity, type 2 diabetes, cardiac disease, stroke and death. The increase is such that 
we can no longer be complacent about how we address the metabolic syndrome or its 
associated components. 
The management of the metabolic syndrome is varied and includes alterations 
in diet, physical exercise, and oral medication. It is well documented that a 10% 
reduction in weight leads to reductions in lipid abnormalities, diabetes and diabetes-
related deaths, other total morbidity and deaths. Many dietary regimens have been 
postulated to benefit not only weight gain but improve cardiovascular risk. To address 
this we investigated the effect three different diets (low fat; low carbohydrate, high 
fat; and low glycaemic load) had on the metabolic syndrome to assess whether it is 
the changes in dietary caloric or macronutrient intake, or overall weight loss that had 
the greater influences on those aspects of metabolic syndrome which could 
potentially reduce cardiovascular risk. 
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Our primary outcome was to identify which diet had the greatest effect on 
weight. The secondary outcome was to identify the changes seen in the parameters 
which make up the components of the metabolic syndrome. Tertiary outcomes 
included changes in cardiovascular risk, inflammatory markers and cytokines. 
 
Methods: 
One hundred and twenty one individuals fulfilling the criteria for metabolic 
syndrome were recruited to take part in a randomised controlled dietary intervention 
study. They were allocated to one of three weight-reducing dietary regimens and 
followed for twelve months: 1) a traditional low fat, carbohydrate loaded hypocaloric 
diet (LFD), 2) a low glycaemic load hypocaloric diet in which the fat intake was 
primarily in the form of monounsaturated fats (LGL), and 3) a high fat, low 
carbohydrate ad libitum diet (LCD).Anthropometric measurements, and blood 
samples for markers of insulin resistance, lipids, and adipocytokines were regularly 
taken. 
Statistical analysis was completed using analysis of variance to compare the 
differences in results between the three groups at each of the study time intervals and 
the paired student t-test for within group comparisons. Statistical significance was 
considered to be p<0.01 for differences between the groups. Subjects included within 
the analysis were those who completed the twelve months of the study. An intention 
to treat analysis of weight loss was included to compare the overall outcome. 
Results: 
Per protocol analyses showed that all three groups lost significant amounts of 
weight at 3, 6, and 12 months (all p<0.001) with reductions for LGL and LCD being 
greater than for LFD (Table 1). Reductions in waist circumference were significant 
among the study groups. 
At baseline all subjects fulfilled the criteria for metabolic syndrome with the 
majority displaying three components (73%). A fall in the number of individuals with 
the criteria for metabolic syndrome was noted in all three groups with only 17% in 
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LCD, 50% in LFD and 38% in LGL still displaying 3 or more components of the 
syndrome. 




Low Fat Low Glycaemic 
Load 
Weight loss (kg)    
3 months -8.4 ± 4.4♥ -4.0 ± 3.0♥ -6.3 ± 3.5♥ 
6 months -9.7 ± 6.1♥ -4.6 ± 4.5♥ -7.7 ± 4.5♥ 
12 months -8.9 ± 8.1♥ -4.4 ± 5.9♥ -6.7 ± 6.3♥ 
Waist reduction (cm) ((cm)    
3 months -7.3 ± 13.3♥ -4.7 ± 2.1♥ -6.5 ± 3.5♥ 
6 months -9.7 ± 4.9♥ -6.7 ± 3.6♥ -7.8 ± 4.5♥ 
12 months -10.4 ± 7.0♥ -7.8 ± 4.6♥ -6.6 ± 6.3♥ 
Total-cholesterol (mmol/l)    
3 months 0.18 ± 0.73 -0.01 ± 0.59 -0.37 ± 0.63* 
6 months 0.32 ± 0.84 -0.09 ± 0.65 -0.24 ± 0.78 
12 months 0.19 ± 0.92 0.05 ± 0.62 -0.22 ± 0.71 
HDL-cholesterol (mmol/l)    
3 months 0.23 ± 0.16♥ -0.00 ± 0.16 0.02 ± 0.18 
6 months 0.26 ± 0.35* 0.06 ± 0.21 0.08 ± 0.16* 
12 months 0.27 ± 0.32* 0.09 ± 0.19♦ 0.18 ± 0.32* 
LDL-cholesterol (mmol/l)    
3 months 0.21 ± 0.64 -0.08 ± 0.45 -0.20 ± 0.53♦ 
6 months 0.28 ± 0.72 -0.02 ± 0.51 -0.07 ± 0.61 
12 months 0.12 ± .076 0.05 ± 0.53 -0.20 ± 0.63 
Triglycerides (mmol/l)    
3 months -0.59 ± 0.84* -0.36 ± 0.71* -0.34 ± 0.55♥ 
6 months -0.47 ± 1.05♦ -0.41 ± 0.87♦ -0.51 ± 0.73♥ 
12 months -0.41 ± 0.77♦ -0.36 ± 0.99 -0.37 ± 0.75* 
HOMA-IR (%)    
3 months -23 ± 23♥ -19 ± 30♥ -20 ± 26* 
6 months -24 ± 41♦  -23 ± 26♥ -18 ± 37* 
12 months -28 ± 26* -16 ± 32* -28 ± 23♥ 
Systolic Blood pressure    
3 months -3.3 ± 14.4 -4.0 ± 15.0 -2.5 ± 17.2 
6 months -7.3 ± 13.3♥ -3.5 ± 15.1 -7.8 ± 16.7♦ 
12 months -8.8 ± 15.8♦ -2.5 ± 12.2 -8.7 ± 16.3 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values refer to within group changes from baseline) 
 
Mean baseline total-cholesterol, HDL-cholesterol, LDL-cholesterol and 
triglycerides were 5.69, 1.35, 3.41 and 2.01mmol/l respectively. Total and LDL-
cholesterol (-0.37, -0.24, -0.22mmol/l; p<0.01 at 3 months) and (-0.20, -0.07, -0.20; 
p<0.05 at 3 months) fell with LGL at 3, 6 and 12 months, rose with LCD but was not 
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significant (0.09, 0.22, 0.12; all p=NS) and (0.57, 0.25, 0.19; all p=NS) for the same 
time intervals. HDL-cholesterol improved in all three groups with rises significant in 
the LCD and LGL groups. A significant fall in triglycerides was noted in all three 
diets with the changes persisting up to 12 months for LCD and LGL. 
Systolic blood pressure fell numerically in all three groups although changes 
were only significant among the LCD group (-3.3, -7.3, & -8.8mmHg, p<0.001 at 6 
months).  
Reductions in insulin resistance was seen in all three groups with a fall in 
HOMA-IR of 19, 23, & 16% (all p<0.01) for LFD, 20, 18 & 28% (all p<0.01) for 
LGL, and 23, 24, & 28% (all p<0.01) for LCD at 3, 6 and 12 months respectively. 
At 3, 6 and 12 months adiponectin rose 9.5, 9.2 & 28.8% (p=NS) for LFD, 
9.5, 31.2 & 29.6% (p<0.001 at 6 and 12 month) for LGL, and 24.9, 49.6 & 41.2% (all 
p<0.01) for LCD.  At 3, 6 and 12 months leptin levels fell by 15, 17 & 9% (all p<0.05) 
for LFD, by 33, 32 & 29% (all p<0.001) for LGL, and 35, 39 & 24% (all p<0.01) for 
LCD.  There were no correlations between leptin and adiponectin.  Changes among 
the other cytokines and inflammatory markers were non-specific and failed to show 
any correlation to anthropometric measures or the other cytokines. 
Conclusion: 
All three dietary interventions produced clinically meaningful reductions 
weight and in other anthropometric measures. There was a fall in the number of 
individuals who met the criteria for metabolic syndrome in all three groups with 
reductions being highest among the LCD group.   Markers of insulin resistance 
improved among the three study groups. The LCD was superior at blood pressure 
reduction, cardiovascular risk reduction and positively influencing cytokines and 
inflammatory markers.  The LGL group demonstrated more favourable effects on 
lipid profile in addition to its positive role on blood pressure, cardiovascular risk 
reduction and some of the inflammatory markers. The long term effect of such 
interventions on cardiovascular outcomes needs further study.  
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Obesity is defined as an abnormal or excessive accumulation of fat to a level 
that may negatively impact on health. It is the physiological response to an 
environment in which energy intake exceeds energy output. 
The prevalence of obesity worldwide has progressively risen over the past 
century reaching epidemic proportions. Data published by the World Health 
Organization (WHO) in 2011 showed that the estimated prevalence of obesity had 
more than doubled since 1980 with 1.5 billion adults classified as overweight, of 
whom approximately 500 million fell within the obese category. Without intervention 
these figures are expected to rise to 2.3 billion individuals classified as overweight 
and 700 million as obese by 2015582. 
Initially an affliction of developed countries, obesity is increasing in 
developing countries particularly within urban areas where cultural and behavioural 
changes have altered as they adopt the life styles of developed countries.  
 
1.1.1. Historical 
Many beliefs and theories regarding the evolution of obesity exist. One 
argument claims obesity to be the disease of modernisation, claiming that  it barely 
existed in the ancient world where man depended on scavenging skills to overcome 
food scarcity, disease, and a hostile environment78. Others believe that the 
accumulation of fat was due to environmental and genetic adaptations equipping 
individuals with the best means of survival for their circumstances. 
For thousands of years, obesity was exceptional, and poorly studied although 
figurines of abdominally obese females such as the ‘Venus of Willendorf’ (Figure 1) 
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have been present from as far back as 30,000 years. The history of these statuettes is 
hotly debated. Some believe them to represent the earth goddess, others classified 
them as symbols of fertility, while a third group have implied that these palm sized 
figurines were the predecessors of Playboy magazine 225. 
Figure 1: Venus of Willendorf 
 
Accessed online 5 
 
Man originally developed as a hunter gather. No anthropometric studies of 
these groups have shown evidence of obesity in these individuals. They are 
considered to have led active lives and enjoyed a highly varied diet rich in protein but 
limited in carbohydrate, based on wild game and plants which they would procure. 
Eating patterns were cyclical depending on luck and availability. With the 
development of settlements and domestication, a steady nutritional supply became 
available based on crops which were higher in carbohydrate content, and lower in 
protein and fats. This new calorie-richer, but less varied diet led to a higher morbidity 
and reduced lifespan. As new communities flourished and sub-divided into social 
stratifications, an elite upper class evolved which maintained a constant nutritional 
supply with minimal physical exertion breaking the feed-fast cycle and linked 
affluence to obesity 319. 
One of the first documentations of the vices of obesity and diet comes from 
the ancient Greeks. Hippocrates described many ailments which he ascribed to poor 
health and made an observation which later became the basis for energy intake 
balance: 
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‘It is very injurious to health to take in more food than the constitution will bear, 
when, at the same time one uses no exercise to carry off this excess . . . . 
For as aliment fills, and exercise empties the body, the result of an exact equipoise 
between them must be to leave the body in the same state they found it, that is, in 
perfect health’. 
His son-in-law, Polybus went on to suggest that diet and exercise would be an 
effective measure for overweight individuals225. Acceptance of obesity as a medical 
phenomenon requiring treatment has been slow. Tobias Venner was the first 
physician to use the word ‘obesity’ in a medical context. He discussed the need for 
treatment in his publication in 1660 where he recommended the waters at Bath as 
treatment, stating:  
‘beneficial to such individuals: to make slender such bodies as are too grosse . . . 
Wherefore let those that feared obesity, that is, would not wax grosse, 
be careful to come often to our Baths: for by the use of them, according as the 
learned Physician shall direct, they may not only preserve their health, 
but also keep their bodies from being unseemly corpulent’556. 
 
With the commencement of the industrial revolution, an increase in body 
mass, particularly muscle, was linked to improvements in health, greater productivity 
and efficiency. Developed countries were then still struggling with poverty and 
malnutrition and to help overcome this poor children’s’ diets were supplemented with 
sugar and fat following observations by Lord Boyd Orr 400;401. Consequently, the 
population progressively increased in height and weight and then began expanding 
outwards, once the full potential to grow in height was realised, and individuals began 
accumulating weight and girth220. 
Initially body weight was compared to an “ideal body weight” derived from 
tables maintained by insurance companies as their measure for obesity. In the 1980s, 
the Body Mass Index (BMI), a statistical measure which compares a person's weight 
and height, replaced this. Parameters were fixed with “normal” BMI defined as 20-
<25kg/m2 and “obesity “defined as BMI ≥ 30 kg/m2 for both men and women. 
Although a useful tool for the measurement of adiposity within a population base, 
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there are limitations to the BMI as it is dependent on weight, not adiposity, and thus 
does not correspond to the same level of fatness in different individuals (e.g. athletes 
have raised BMI due to muscle mass), and the cut off parameters for morbidity and 
mortality risk vary between ethnic groups,  (e.g. a cut off of 23 rather than <25 for 
Asians who are more prone to visceral obesity and higher cardiovascular risk).  
The United States is one of the countries with the highest degree of obesity. 
To help address this, dietary and life-style modifications in the form of advice on 
caloric restrictions, reduction in fat intake and exercise were introduced. Despite 
reductions in fat content, an increase in low calorie food, and weight loss clubs, the 
average population weight has continued to rise. The easy availability of transport 
and gadgets which reduce work load encourage a more sedentary lifestyle with less 
requirement for energy expenditure. In combination with the easy availability and 
low cost of energy dense food, these provide an environment conducive to weight 
gain and obesity. 
By the year 2000, the human race “achieved” an historical landmark, where 
for the first time in human evolution the number of overweight (BMI >25kg/m2) 
adults surpassed the number of those who were underweight (BMI <18.5kg/m2). 
Accompanying the increase in weight are a number of health issues including 
cardiovascular disease, arthritis, cancer and respiratory dysfunction which result in a 
greater burden both physical and economical upon society. Cardiovascular disease 
and its associated risk factors, has been extensively studied and over the years has 
been interlinked in what is now known as the metabolic syndrome. 
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1.1.2. Rising Prevalence of Obesity 
Since the 1960s, the prevalence rate of overweight individuals has increased 
by 50% across all population groups. Now, one in two adults and one in four children 
are overweight60.  The National Health and Nutrition Examination Survey 
(NHANES) is a national program developed in the early 1960s in the United States 
looking at a number of health issues among the population. It consists of sequential 
surveys which focus on the nutritional and health aspects of the population which is 
meant to collect data that will help look into and address issues related to the health 
of the nation. Data from 2003-2004 NHANES estimate that two thirds of the adult 
US population are overweight, (BMI ≥25 kg/m2); with just over 32% meeting the 
criteria for obesity (BMI ≥30 kg/m2), while 4.8% fit in the extreme obesity category 
(BMI ≥40 kg/m2) 397. 
Data from the NHS information centre  state that in the UK approximately 
35% of men and women aged 16 years and over were considered to be overweight 
while a further  26%  were obese (BMI ≥30 kg/m2)4. Furthermore, the rise in obesity 
prevalence has not been the privilege of adults only. Childhood and adolescence 
obesity is on the rise, promoting the onset of risk factors for chronic disease in their 
youth. Up until the 1970s, obesity prevalence in children aged 2 to 19 years was static 
at approximately 5%268. Since 1980, it has increased threefold in individuals aged 20 
years or younger. Current estimates report the prevalence of obesity to be 17.1% 
among the teenagers of the United States with figures for the United Kingdom being 
little different.  
Despite obesity becoming a universal epidemic, certain patterns and 
discrepancies were observed which affected particular demographics more than 
others. In developed countries obesity particularly in females was associated with 
lower income and education, whereas the reverse was true for developing countries.  
NHANES data identified that black and/or Hispanic females were generally larger 
than their Caucasians counter-parts even when income and education were accounted 
for. UK data similarly identified individuals  from Caribbean, Pakistani or Irish 
descent to be more likely be obese with the prevalence higher among females445(Table 
2). Unlike females, males did not seem to be greatly affected by any particular 
parameter apart from a tendency to an increased girth with rising wealth. 
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Epidemiological studies in children were similarly non-polarised although the general 
acceptance appears to be that in developed countries children from lower 
socioeconomic backgrounds tended to have higher BMIs than their privileged, better 
educated,  and financially  comfortable colleagues55;360;445 . 
Table 2: Prevalence of obesity in adults 
 Men (n = 3204) Women (n = 3699) 
Black Caribbean 18.3 31.9 
Indian 11.9 19.6 
Pakistani 12.6 25.6 
Bangladeshi 5.4 9.5 
Chinese 6.2 4.5 
Irish 20.4 21.2 
General population 18.9 20.9 
Prevalence of obesity (% with BMI > 30 kg m−2) in adults (16 years and over) by ethnic group in 
Health Survey for England 1999. Adapted from445  
 
Certainly within developed countries geographical variations in the 
distribution of obesity were noted. In the US the prevalence is highest within the 
central southern states, areas renowned for higher numbers of both blacks and 
Hispanics, as well as a greater percentage of individuals classified as being low 
income earners. 
Within the UK, the highest prevalence of obesity is in Scotland followed by 
Northern Ireland, England and finally Wales (Figure 3 & Figure 4). Similarly to the US, 
areas with well documented social deprivation including the  north east, west 
midlands and east London had a higher prevalence of obesity24. In contrast, 
developing countries have seen the distribution of obesity rising within their 
wealthier, urban regions266;492. What is irrefutable is that obesity is increasing 
worldwide and if unregulated will be a large burden both financially and physically 
upon society (Figure 3 - 6).
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Figure 2: UK Obesity Trends 1995 - 2003 (Females) 
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Taken from:  http://www.iaso.org/site_media/library/resource_images/Trend_in_UK_by_Health_Authority_April_2012.pdf 
Figure 3: UK Obesity Trends 1995 - 2003 (Males) 
Page | 25 
 
Figure 4: Prevalence of obesity (BMI>30kg/m2) among males 2010 
 
These are data from the WHO website showing that most developed countries have a >20% prevalence of obesity (orange and red areas) whereas in Asian and 
African countries, and the Far East levels are less than 10%583
Page | 26 
 
Changes in obesity prevalence in a 30 year span the West, East and Middle East (Adapted from data on the WHO website where available 
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1.2. Effects of Obesity on Individuals and Society 
Obesity is now widely recognized as one of today's leading health threats in 
most countries and as a major risk factor for type 2 diabetes, cardiovascular disease, 
and hypertension. Mortality data from NHANES report that the number of deaths in 
the USA in 2000 attributed to obesity was 112,000 in excess of that in individuals 
with a normal BMI158. The effect of obesity on an individual can be profound 
affecting not only general health but social and psychological well-being. Listed 
below are a series of such factors: 
1. An increase in cardiovascular disease including myocardial infarction, and 
stroke. 
2. An increased incidence of Type 2 Diabetes 
3. An association with neoplastic disorders (i.e. colon, breast and endometrial). 
4. Gastrointestinal dysfunctions (i.e. gallstones, gastro-oesophageal reflux, and 
non-alcoholic fatty liver disease) 
5. Physical dysfunction due to arthritis, associated pain and reduced mobility 
6. Obstructive sleep apnoea 
7. Social withdrawal, isolation,  and depression 
8. Economic pressures secondary to loss of earnings due to decreased ability to 
work, food costs and clothing 
In the Prospective Studies Collaboration, a meta-analysis of 57 studies, the 
lowest incidence for all-cause mortality was at a BMI of 22.5 – 25kg/m2 with each 
categorical increment in BMI associated with an increase in CV mortality by 40%, 
neoplastic risk by 10%, and overall mortality by 30%431.  
Type 2 diabetes and obesity have been closely linked, with the latter 
repeatedly blamed for the rising incidence of the former. Individuals with a BMI of 
25kg/m2 have a 5 times greater risk for developing diabetes than those with a BMI 
<20kg/m2 with increments rising up to 93 times for those with a BMI >35kg/m2.  The 
two conditions share causative factors, but do not necessarily lead to one another. 
However the development of diabetes/insulin resistance in the obese leads to an 
exponential rise in CV mortality39.  
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1.2.1. Financial Burden of Obesity 
 
Prevalence of overweight and obesity has escalated during the past few 
decades, and this is contributing to the overall cost of health care. These costs do not 
only include expenses related to illness and medical treatment but also further out-
reach costs including reduced productivity due to higher levels of absence from work, 
increased social care costs and higher government expenditure on disability and 
unemployment benefits. In 2002, the House of Commons Health Select Committee 
calculated the annual bill for the management of the obese and their co-morbidities 
to be £3.3–3.7 billion with figures doubling to £6.6–7.4 billion if the overweight 
(BMI 25–30kg/m2) were also taken into account.  If broken down into segments, a 
sixth (£991–1124 million) is incurred in the direct management of obesity, whilst the 
remainder (£5.5–6.2 billion) is spent on the secondary consequences. 
A further financial burden is as a consequence of loss of earnings, and income 
support. Lost earnings attributable to obesity were estimated to be £2.3–2.6 billion of 
which £1.3–1.5 billion is certified sick leave. If obesity levels continue to rise then 
the predicted National Health Service spending will almost double by 2050. In the 
USA, a 1998 article demonstrated that 17% of the costs of CHD were related to 
obesity with the overall medical expenditure estimated at $78.5 billion, half of which 
was covered by health insurance companies including Medicare and Medicaid. Data 
from 2009 estimated the annual medical cost of obesity to be approximately $147 
billion per year (10% of the total US Healthcare bill). These figures are predicted to 
rise by a further $48-66 billion per annum by 2050 if obesity continues to rise157.  
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1.3. Metabolic Syndrome 
Obesity is well recognised as the presence of excessive body fat. Depending 
on where the excess fat has been deposited divides obesity into subcutaneous 
(peripheral) or visceral (central) adiposity. It is the visceral fat which is believed to 
be most influential in cardiovascular risk. Visceral fat is generally deposited within 
the abdominal cavity surrounding the organs within. The metabolic dysfunction 
created by excess visceral fat mass influences multiple factors of disease risk. These 
have been identified from as far back as the 1920’s and eventually grouped together 
into a cluster including abdominal obesity, dyslipidaemia, hyperinsulinaemia and 
hypertension, all of which may independently or collectively lead to an increase in 
the risk of cardiovascular disease. In 1988, Gerald Reaven presented the 
accumulation of his work at the “Banting” lecture identifying this group of risk 
factors as “Syndrome X” and proposing that insulin resistance was the underlying 
causative element. At this point he did not include obesity in his definition441. 
Over the years the clustering has been referred to as Reaven’s syndrome, the 
deadly quartet, insulin resistance syndrome, and more recently, the metabolic 
syndrome (MS).  The presence of all of the components of MS, in an individual 
increases the risk of cardiovascular morbidity and mortality by two-threefold. Over 
the years MS has also been associated with hypertriglyceridaemia, low HDL 
cholesterol, hyperuricaemia, abnormalities of fibrinolysis and clotting, endothelial 
dysfunction, raised markers of chronic inflammation, polycystic ovary syndrome and 
obstructive sleep apnoea103;560;570.  
With the global rise in overweight and obese individuals, following 
population trends of increasing sedentary lifestyle, a disproportionately high calorie 
intake, smoking, and stress, the prevalence of MS has risen dramatically and 
associated is the threat of an increase in atherosclerotic disease, type 2 diabetes and 
death39. The increase is such that we can no longer be complacent about how we 
address the metabolic syndrome or associated components.  
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1.3.1. Metabolic Syndrome – Diagnosis 
Although accepted as a clinical entity it has been difficult to define MS as its 
components are abnormalities which may occur individually or collectively in 
varying degrees of severity. It therefore became necessary to attempt to provide a 
universal definition of MS in order to identify and target those individuals at risk. 
The first definition was produced by the WHO in 1998. This group placed a 
large emphasis on insulin resistance being a major risk factor and considered it to be 
an essential requirement for the diagnosis in addition to two other criteria which 
included waist to hip ratio, hypertriglyceridaemia, low HDL-cholesterol, 
hypertension and microalbuminuria. The WHO criteria was criticised as it was felt to 
be impractical in clinical or epidemiological settings to measure insulin resistance 
through clamp methods. Further dissention existed on what was the appropriate 
measure for obesity (i.e. waist to hip ratio versus abdominal girth), and the inclusion 
of microalbuminuria as one of the criteria14. In 1999, the European Group for Study 
of Insulin Resistance (EGIR) produced a modification of the WHO definition 
excluding those with type 2 diabetes as insulin resistance was considered to be a risk 
factor for diabetes.  
Two years later, the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATP III) (Table 3) introduced an alternative set of criteria for 
defining the metabolic syndrome. They aimed to identify individuals at risk of 
developing cardiovascular disease who thus qualified for intervention of one form or 
another. Insulin resistance, although a component, was no longer an essential criterion 
for diagnosis and was identified as a fasting glucose sample rather than the more 
laborious clamps, or glucose tolerance test which are not standardized measures of 
testing in general clinical practice.  The ATP III required the presence 3 of 5 factors 
as the basis for diagnosis, assuming all risk factors were equal. These were abdominal 
obesity, hypertriglyceridaemia, reduced HDL-cholesterol, hypertension, and 
impaired fasting glucose26.  
In 2003, the American Association of Clinical Endocrinologists (AACE) 
modified ATP III criteria refocusing on insulin resistance. Their criteria included 
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impaired glucose tolerance (IGT)1, hypertriglyceridaemia, reduced HDL-cholesterol, 
hypertension, and obesity. The diagnosis was left to the physician’s clinical 
judgement with encouragement to take external factors into account including family 
history of CVD, type 2 diabetes mellitus, polycystic ovary syndrome, and 
hyperuricaemia. 
Table 3: NCEP-ATP III Criteria for the diagnosis of the Metabolic Syndrome 
 
Measure Categorical cut-off points 
 
Elevated waist circumference >102cm (40in) Male 
>88cm (35in)   Female 
Elevated triglycerides  >150mg/dl (1.7mmol/l) 
Reduced HDL cholesterol  <40mg/dl (1.03mmol/l)    male 
<50mg/dl (1.3mmol/l)    female 
Elevated blood pressure  Systolic >130 mm Hg and/or diastolic >85 mm Hg 
Elevated fasting glucose  >110 mg/dl (6.1mmol/l) 
Or on treatment for diabetes 
Need 3 out of 5 to fulfil criteria to diagnose the syndrome 
Although the above definitions were intended to detect the majority of 
individuals with MS, it soon became apparent that different sectors were being 
targeted by each. When the subjects in the AusDiab study were classified to have 
metabolic syndrome or not, three of the classifications were adopted, the WHO, 
EGIR, and ATP III. Each definition identified approximately 15–20% of the 
population to fulfil criteria for MS, but only 9.2% met the collective criteria from all 
three classifications130.  
In 2005, the International Diabetes Foundation (IDF) published new criteria 
modifying the ATP III definition aiming to establish a universal definition and 
method for clinical diagnosis251.  
They considered that abdominal obesity was highly correlated with insulin 
resistance and made the presence of abdominal obesity necessary for the diagnosis in 
addition to one of the four previously used criteria. IDF recognized the ethnic 
differences in the correlation between abdominal obesity and other MS risk factors 
and specified that waist measurement be specific to each racial group.  With these 
                                                          
1 IGT is defined a 2 hour post glucose load of >7.8mmol/l and <11.1mmol/l (in the presence of a 
normal or elevated fasting glucose), and impaired fasting glucose (IFG) is defined as glucose levels 
>6.1mmol/l and <6.9mmol/l. 
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recommendations abdominal obesity thresholds were set at waist circumferences 94 
cm in men and 80 cm in women. For Asian populations, except Japan, thresholds 
were 90 cm in men and 80 cm in women; for Japanese they were 85 cm for men 
and 90 cm for women13;251. At about the same time the ADA and EASD issued their 
combined statement in Diabetes Care September 2005 reporting:-  
"Our analysis indicates that too much critically important information is missing to 
warrant its designation as a syndrome. Until much needed research is completed, 
clinicians should evaluate and treat all cardiovascular risk factors 
without regard to whether somebody has the metabolic syndrome or not272. 
 
Therefore disagreements persisted as to how best to define and diagnose MS until 
2009, when the major institutions once more assembled to release an updated 
statement and definition which no longer placed abdominal adiposity as a requisite 
for the diagnosis, but once more reverted to a diagnosis being established on the 
presence of 3 of the 5 criteria15 (Table 4).  
 
Table 4: International Diabetes Federation 2009 revised criteria for the diagnosis of Metabolic Syndrome 
 
Measure Categorical cut points 
Elevated waist circumference Population- and country-specific definitions 
Elevated triglycerides (drug treatment for elevated 
triglycerides is an alternate indicator) 
>150 mg/dL (1.7mol/l) 
Reduced HDL cholesterol (drug treatment for 
reduced HDL cholesterol is an alternate indicator) 
<40 mg/dL (1.0mmol/l) for males  
<50 mg/dL (1.3mmol/l) for females 
Elevated blood pressure (drug treatment for elevated 
blood pressure is an alternate indicator) 
Systolic >130 mm Hg and/or diastolic >85 mm 
Hg 
Elevated fasting glucose (drug treatment for elevated 
glucose is an alternate indicator) 
>100 mg/dL (5.6mmol/l) 
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1.3.2. Waist-Hip Ratio 
Despite the changes in diagnostic criteria for MS, abdominal girth remains a 
major indicator of adiposity and CV risk. Yusuf et al, in the INTERHEART study 
identified the waist-hip ratio (WHR) to be a strong risk factor for CHD increasing the 
risk by up to 2–3 times597. Theoretically the WHR is the ratio of waist circumference 
measured at the midpoint between the lower margin of the last palpable rib and the 
top of the iliac crest, to the hip circumference measured around the widest portion of 
the buttocks. Practically it is taken as the narrowest waist measurement to the widest 
hip measurement. Several sources have identified it to be a more reliable identifier 
for CV risk as it helps stratify individuals into “apple” (abdominal adiposity) or 
“pear” (fat on hips) which BMI and waist measurements are unable to discriminate. 
However in the WHO consensus it was felt that waist measurement was practically 
easier to perform and would therefore be subject to less errors102(Table 5 ). Desirable 
WHR figures should be <0.75 for females and <0.90 for males to maintain optimum 
health with a 0.01 U increase in WHR, being considered to directly increase the risk 
of CVD by 5% (Table 6)115. 
Table 5: Recommended Waist Circumference Thresholds by Organization 
 
Population Organization 
Recommended Waist Circumference 
Threshold for Abdominal Obesity 
Men  Women 
European IDF 94 cm 80 cm 
Caucasian WHO 
94 cm (increased 
risk) 
80 cm (increased 
risk) 
  
102 cm (still higher 
risk) 
88 cm (still higher 
risk) 
United States AHA/NHLBI (ATP III)* 102 cm 88 cm 




102 cm 88 cm 
Asian (including Japanese) IDF 90 cm 80 cm 
Asian WHO 90 cm 80 cm 
Japanese Japanese Obesity Society 85 cm 90 cm 
China Cooperative Task Force 85 cm 80 cm 
Middle East, 
Mediterranean 
IDF 94 cm 80 cm 
Sub-Saharan African IDF 94 cm 80 cm 
Ethnic Central and South 
American 
IDF 90 cm 80 cm 
 
*Recent AHA/NHLBI guidelines for metabolic syndrome recognize an increased risk for CVD and 
diabetes at waist-circumference thresholds of 94 cm in men and 80 cm in women and identify these 
as optional cut points for individuals or populations with increased insulin resistance. Adapted from15  






Table 6: WHO, EGIR, NCEP, AHA/NHLBI and IDF definitions of Metabolic Syndrome 
 
 WHO (1998) 
 
EGIR (1999) NCEP-ATP III (2001) AHA/NHLBI (2005) IDF (2005) 
 Insulin resistance, glucose 
intolerance , type 2 diabetes + 
any 2 from below 
Insulin resistance (defined as 
hyperinsulinaemia—top 25% 
of fasting insulin values among 
the non-diabetic population) + 
any 2 from below 
 3 of 5 criteria Insulin resistance diagnosed on 
clinical judgement* 
Waist measurement + 2 criteria 
Waist 
circumference 
Waist to hip ratio >0.9 Male 
Waist to hip ratio >0.84 Female 
And/or BMI >30kg/m2 
≥ 94 cm (37in) Male 
 
≥ 80 cm (31.5in) Female 
>102cm (40in) Male 
 
>88cm (35in)   Female 
 
 Increased waist circumference 
depending on ethnic differences 
Triglyceride  >150mg/dl (1.7mmol/l) >178 mg/dl (2mmol/l) 
Or on treatment 
>150mg/dl (1.7mmol/l) >150mg/dl (1.7mmol/l) >150mg/dl (1.7mmol/l) 
Or on treatment 
 
HDL-cholesterol <35mg/dL (0.9mmol/l) male 
<39mg/dL (1mmol/l) females 
<39mg/dL (1mmol/l) 
Or on treatment 
<40mg/dl (1.03mmol/l)    male 
<50mg/dl (1.3mmol/l)    female 
<40mg/dl (1.03mmol/l)    male 
<50mg/dl (1.3mmol/l)    female 
<40mg/dl (1.03mmol/l)    male 
<50mg/dl (1.3mmol/l)    female 
Or on treatment 
Glucose As mentioned above ≥ 6.1 mmol/l (110 mg/dl) but 
non-diabetic 
>110mg/dl  (6.1mmol/l)  
or diabetic 
 
Fasting 6.1–6.9 mmol/l (110–
125 mg/dl) 
2hr  post glucose load 8–
11.1 mmol/l (140–200 mg/dl) 
 
>110mg/dl  (6.1mmol/l) 
or diabetic 
Blood pressure ≥ 140/90mmHg ≥ 140/90 mmHg or on treatment >130/85mmHg >130/85mmHg >130/85mmHg  
Or on treatment 
Other Microalbuminuria  
 
   
*Diagnosis of the insulin resistance is based on clinical judgement. Other factors to be considered in the diagnosis are obesity, family history of diabetes, polycystic ovary syndrome, lifestyle, 
advancing age and ethnic groups susceptible to Type 2 diabetes. Adapted from14;201 
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1.3.3. Metabolic Syndrome – The Expanding Problem 
It is reasonable to assume that with the alarming rise in obesity worldwide, a 
MS epidemic may also be upon us. The prevalence of MS can alter depending upon 
the diagnostic criteria used, and has been reported to be as high as 50% in adults aged 
60 years and over in the latest data from NHANES in 2009137. Within the United 
Kingdom, approximately 12 million adult men and women fulfil the diagnostic 
criteria of MS suggesting that prevalence is approximately 20-25% of the adult UK 
population. 
United States 
Most of the information on the prevalence of MS is sourced from the 
American National Health and Nutrition Examination Surveys (NHANES). Ford et 
al estimated that approximately 50 million Americans fulfilled the criteria for MS in 
1990 with numbers rising to 64 million by 2000160. Two factors appeared to account 
for this increase. The first being obesity, which had risen from 22.5% to 30.5%. The 
second was an aging population, as the data revealed an increasing prevalence of MS 
with rising age groups regardless of BMI17;137. Hispanics being more prone to insulin 
resistance had a much higher incidence of MS as compared to other ethnic groups in 
the USA including Caucasians and Blacks. MS was more prevalent among Black and 
Hispanic females as compared to their male counterpart160, an observation which 
contrasts with findings noted among Caucasians where the prevalence was higher 
among males. Black men particularly had a relatively low prevalence when compared 
to other ethnic groups, which is believed to be due to their lower waist circumference, 
lower triglycerides, and higher HDL-cholesterol levels. Black men are known to be 
more insulin-resistant and prone to hypertension although their other characteristics 
may potentially underestimate the prevalence of MS among them. The discrepancies 
have resulted in some suggesting that alternative parameters for the identification of 
MS within the Black African sub-division be used, although such alterations may no 
longer identify those with MS but those with high CV risk204. 
Of particular concern is the rising prevalence of the MS among the younger 
generation which has been attributed to the increase in obesity. NHANES, from data 
collected between 1988 and 1994, estimated the prevalence among adults aged 20 
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years as 24% with 7% of the overweight and 29%  of obese adolescents fulfilling the 
criteria. A more recent study has shown that the prevalence has risen with 39% of the 
moderately obese adolescents, and 50% of the severely obese fulfilling the criteria. 
In total numbers this equates to approximately 1 million (4%) of all US 
adolescents107;458;567.  
Europe  
A series of studies on the occurrence of the MS in Europe have been reported. 
The prevalence has varied depending upon which criteria have been applied to define 
MS. The data suggest that approximately 25% of Europeans meet the criteria for MS 
with prevalence varying depending on the age group, nationality, and population 
characteristics. The prevalence was usually higher if IDF (50%) criteria were used as 
compared to NCEP (17.1%) or WHO (34.1%). These differences were attributed to 
the lower waist circumference threshold used to define abdominal obesity65;337.  
Worldwide 
As with attempts in assessing the prevalence of MS among the European 
population, results for worldwide populations are variable. There are several 
variations depending on classification used, ethnicity, populations, and age groups. 
Among Turkish and Indian populations, the prevalence of MS has been estimated to 
be greater than 30%, whereas figures from Far Eastern populations were as low as 
5%. As with Hispanics and Blacks, female prevalence of MS was higher among those 
from an Eastern origin than among Caucasians. Socioeconomically, those in urban 
communities were more likely to fulfil the criteria for MS, particularly in developing 
countries where rural life is physically intense and nutrition more basic.  
One thing that was clear was that the prevalence of MS is increasing among 
all populations (Figure 7). The presence is higher in the older age groups but is also 
rising among the younger generations who are now becoming more obese and 
developing diseases which have previously been considered to be exclusive to adults.  
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Figure 6: Prevalence of Metabolic Syndrome Worldwide 
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1.3.4. Abnormalities associated with Obesity and Metabolic Syndrome 
 
Dyslipidaemia, hypertension, insulin resistance, and inflammatory markers 
are well-recognized predictors of CVD risk. Raised total cholesterol and LDL-
cholesterol, as well as reduced HDL-cholesterol level, are associated with the risk for 
CHD. An elevated BMI is well recognised to be linked to an increase in 
cardiovascular disease with visceral adiposity identified as a strong independent 
predictor of insulin resistance and cardiovascular risk. Visceral adiposity is 
responsible for the increased abdominal circumference and the “apple” shape which 
is linked to an enhanced cardiovascular risk34;370. The majority of these abnormalities 
are seen in overweight, insulin-resistant individuals (table 7), while some will be 
discussed in further detail. 
 
Table 7: Metabolic changes linked to the Metabolic Syndrome 
 






 Reduced HDL-cholesterol 
 Small dense LDL-cholesterol 
Insulin resistance 
 Impaired glucose tolerance 
 Impaired fasting glycaemia 




 Raised fibrinogen 
 Raised PAI-1 
 Increased platelet aggregation 
Proinflammatory state 
 Raised CRP 
 Raised inflammatory cytokines 
 Low adiponectin 
Polycystic Ovary Syndrome 
Obstructive Sleep Apnoea 
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1.4. Cardiovascular Disease 
 
In 1987, Reaven suggested that insulin resistance played a central role in the 
MS. Several studies went on to strengthen this proposition with some implying that 
although insulin resistance may be the central component, other factors (i.e. genetic 
predisposition, obesity, dyslipidaemia, hypertension and physical inactivity), 
contribute to the cluster that formulates the metabolic syndrome205. It is difficult to 
assess the degree of influence each factor plays in the cardiovascular risk associated 
with MS, although it is undeniable that their influence enhances the risk of CV disease 
by as much as two to threefold as witnessed by the presence of diabetes304(Figure 7).  
Over the past 30 years LDL-cholesterol has been targeted as an essential 
factor in CHD and numerous studies have highlighted the importance of LDL-
cholesterol reduction on cardiovascular morbidity and mortality. Statins have 
certainly proven to be effective in modifying these risks32;414;481. The rising 
prevalence of MS and its associated increase in CV risk could potentially reverse the 
benefits achieved  from LDL-cholesterol lowering and place MS on a par with 
smoking as a contributor to CHD26;98.  
Analysis of NHANES III as compared to NHANES II, demonstrated a rising 
prevalence of MS with worsening glucose tolerance with the presence among 
individuals with diabetes being very high (86%). Indeed, when the data were analysed 
for CHD, it was the presence of MS rather than diabetes that influenced CV risk 
Prevalence was highest within the group with both diabetes and MS (19.2%) or MS 
only (13.9%), while for diabetes only (7.5%), the presence of CHD was equivalent 
to, if not less than, that in the general population who had neither diabetes or MS 
(8.7%). The data did not differentiate Type 1 from Type 2 diabetes, and the authors 
concluded that it may be insulin resistance rather than hyperglycaemia which affected 
CHD risk18. In the West of Scotland Coronary Prevention Study (WOSCOPS) Sattar 
el al, defined MS by using BMI readings rather than waist measurement. Participants 
were stratified depending on the number of criteria they fulfilled for MS and followed 
through to assess for the risk of developing CHD or diabetes. Results confirmed that 
the more components for MS present, the greater was the risk for developing either 
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condition reaching 3.7 fold for CHD and 24 fold for diabetes when a full house as 
defined by NCEP ATP III was present471 (Figure 7). 
These findings were echoed in the Botnia study where 4483 Finnish and 
Swedish subjects aged 35 to 70 years were assessed. In addition to the incremental 
increase in MS prevalence with worsening glucose intolerance, its presence conferred 
a significant increase in the risk of CHD, stroke, and cardiovascular mortality304. 
Figure 7: Rising incidence of CHD and Diabetes with Metabolic Syndrome 
 
 

















Number of metabolic syndrome components
Increase in risk of CHD & Diabetes with each incremental increase in components 
of Metabolic Syndrome
Coronary Heart Disease Diabetes Mellitus
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1.5. Insulin Resistance and  Type 2 Diabetes Mellitus 
 
Insulin has pleiotropic actions including the facilitation of nutrient transport 
into cells, modification of enzymatic activity and regulation of energy homeostasis 
(Figure 8). Insulin sensitivity refers to the ability of insulin to support glucose 
homeostasis by signalling insulin-sensitive tissues or organs to absorb glucose. These 
signals include stimulating glucose utilization in both muscle and adipose tissue and 
suppressing the production of glucose by the liver. Both responses act to decrease 
plasma glucose concentration. The degree of impairment of glucose metabolism is 
influenced both by the insulin sensitivity of cells within the body and by pancreatic 
β-cell reserve capacity369.  
 
Figure 8: Link between obesity, insulin resistance and inflammation 
 
 
Adapted from de Luca110.  
 
Insulin resistance by definition is a condition in which defects in the action of 
insulin are such that normal levels of insulin do not sufficiently trigger the signal for 
glucose absorption resulting in the incomplete suppression of hepatic glucose output 
and impairment in insulin-mediated glucose uptake by peripheral organs such as 
skeletal muscle and adipose tissue, leading to hyperinsulinaemia. With time, 
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increased insulin requirements are not matched by a sufficiently increased insulin 
output leading to impaired glucose tolerance and eventually diabetes. Insulin 
resistance is associated with central obesity, hypertension, and dyslipidaemia, all well 
recognised risk factors for cardiovascular disease and components of MS273;510.  
The link between obesity and insulin resistance is strong with several studies 
indicating that obesity can account for 50% of the variance in insulin sensitivity in 
the general population. In a study of >250,000 subjects studying the relative risks for 
ischaemic heart disease and stroke mortality, a direct link relationship between fasting 
glucose levels and CV events was identified. For each 1mmol/l reduction in fasting 
glucose levels, there was a 21% coronary heart disease and 23% stroke mortality fall. 
No similar correlation was identified for prandial/random glucose levels. Other 
studies have demonstrated similar relationships, some with more modest results455;470.  
A major contributor to the development of insulin resistance is an excess of 
circulating fatty acids. These are derived mainly from adipose tissue triglyceride 
stores by the action of hormone sensitive lipase, or the lipoprotein lipase mediated 
lipolysis of triglyceride-rich lipoproteins in tissues. Insulin inhibits lipolysis within 
adipose tissue which, in the presence of insulin resistance, leads to accelerated release 
of NEFA and glycerol from adipose tissue, which further inhibits the anti-lipolytic 
effect of insulin134. The increased fatty acid load results in modifications in various 
transport signals such as impairing the activation of protein kinase C-λ and protein 
kinase C-ζ which further enhance insulin resistance134.  
Most hyperinsulinaemic states seen in MS do not convert to frank diabetes 
but once decompensation occurs and the balance is broken hyperglycaemia sets in 
along with all the associated complications known to diabetes (i.e. retinopathy, 
nephropathy, neuropathy and CVD). 
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1.6. Dyslipidaemia 
Metabolic dyslipidaemia is widely recognised to be a risk factor for CV 
disease72;73. It consists of a combination of abnormalities which include 
hypertriglyceridaemia, an increase in VLDL, an increase in small dense LDL-
cholesterol, and a reduction in HDL-cholesterol with abnormal HDL particles. 
Shortly following feeding, triglycerides and cholesterol are transported from the 
intestines to peripheral tissue in chylomicrons where triglycerides are hydrolysed via 
lipoprotein lipase (LPL) to release fatty acids which are taken up by muscle and   
oxidized for energy, or stored within adipose tissue. LPL is activated by 
apolipoprotein (apo) CII and inhibited by apoCIII. The chylomicron remnant is 
removed by the liver. 
The liver synthesises triglycerides from lipids derived from chylomicron 
remnants, excess non-esterified fatty acids derived from adipose tissue, other 
nutrients including glucose, alcohol, excess amino acids, and intermediate 
metabolites. With these triglycerides are synthesised and secreted as very low density 
lipoprotein (VLDL) containing a single copy of apoB100 acting as both a structural 
component but also a functional moiety.  VLDL particles have various other 
apolipoproteins which influence the particle metabolism. 
In a manner similar to chylomicron metabolism, LPL hydrolyses VLDL-
triglycerides for fatty acid use in peripheral tissues. Although some of the VLDL 
remnants can be removed by the liver, most are converted to low density lipoprotein 
(LDL) which delivers cholesterol to body tissues. 
LDL accounts for the majority of measured serum cholesterol. Through the 
single apo B100 an LDL particle binds to a LDL receptor and is taken up into a cell.  
Cells up or down-regulate their LDL-receptors related to cell cholesterol content. The 
liver removes circulating LDL molecules through their own LDL receptors.  
Circulating LDL particles can vary in size as well as density with evidence 
demonstrating that the smaller denser particles being more atherogenic than their 
larger more buoyant counter-parts99.   Excess circulating LDL concentrations are the 
main lipid particle responsible for cardiovascular disease risk, and many studies have 
shown that lowering serum LDL-cholesterol reduces cardiovascular events26;27. The 
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ratio of cholesterol to HDL-cholesterol is currently used (with other major 
cardiovascular risk factors) to estimate cardiovascular risk.  However apoB100 may 
be a more predictive measure as it includes VLDL and VLDL remnant particles 
which can also be atherogenic, although non-HDL-cholesterol may be a more 
practical measure of the total of these particles, calculated from current non-fasting 
measurements2;5;305;563. 
 
HDL is the smallest of lipoproteins and composed of a core of apo A-I or A-
II and phospholipids. It is synthesized by the liver and in gut, and participates in a 
reverse cholesterol transport pathway, able to accept cholesterol from cholesterol-
replete cells for recycling. HDL appears to be associated with a number of activities, 
including anti-thrombotic, anti-oxidative, anti-inflammatory roles etc. all of which 
potentially facilitate its activity in protecting against atherosclerosis 54;540. 
 
Other apolipoproteins associated with these lipoprotein particles modulate 
their metabolism.  Enzymes such as acyl-cholesterol acyl transferase (ACAT) and 
cholesterol ester transfer protein (CETP) are involved in the transfers of triglycerides, 
cholesterol and cholesterol ester between cells and lipoproteins, and between 
different lipoproteins. 
 
In normal circumstances the above interact harmoniously but can be 
dysregulated in MS and obesity producing dyslipidaemic features. Insulin resistance 
is believed to be central to this dysregulation. As an anabolic hormone insulin affects 
lipid metabolism through 
 Inhibiting hormone sensitive lipase  
 Reducing fatty acid release from adipose tissue 
 Inhibiting hepatic gluconeogenesis 
 Inhibiting hepatic glycolysis 
 Increasing VLDL production through increased fatty acid and triglyceride 
production 
 Encouraging adipose tissue fatty acid uptake through stimulating LPL activity 
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In the presence of insulin resistance there is: 
 Enhanced adipose tissue lipolysis due to a relative intracellular insulin 
deficiency and the unopposed activity of the catabolic hormones, catecholamines 
and cortisol, with an increase in circulating NEFAs and hypertriglyceridaemia 
 Enhanced production of apo B 
 An increase in triglyceride-rich VLDL 
 Inhibition of LPL activity 
 Formation of small dense LDL particles135  
 
The above metabolic effects produce a cascade which drives hepatic over-
production of triglyceride-rich VLDL. The circulating VLDL through CETP 
mediation exchanges its triglycerides for cholesterol esters from both LDL and HDL 
leading to those particles being cholesterol-deplete but triglyceride-rich260;405. These 
LDL particles are rapidly hydrolysed into a small dense atherogenic format which is 
more susceptible to oxidation, resistant to clearance via LDL receptors, and has an 
increased affinity for vascular endothelial lining42;90. The LDL particle size is linked 
to triglyceride levels with an increasing predominance of smaller denser particles as 
triglyceride levels rise. In fact some studies have suggested that atherogenic LDL 
begins appearing at triglyceride levels >1.5mmol/L197;211. A similar association was 
noted in the Framingham Offspring Study where LDL particle size appeared to be 
inversely related to the number of MS components275. Measured LDL-cholesterol 
levels in these individuals are usually normal although the number of LDL particles 
is very likely to be increased. These inconsistencies have led to a dilemma as to how 
best to measure atherogenicity, should this be by counting particle numbers and 
therefore measuring LDL apo B levels (ratio 1:1 per LDL particle) or should it be 
through measuring total apo B (non HDL-cholesterol) levels which include VLDL 
and IDL-cholesterol in addition to LDL-cholesterol198.  
As with LDL, HDL particles in insulin resistance are low in cholesterol but 
full of triglycerides and therefore a target for hydrolysis. This causes an imbalance 
within particle components, destabilization of the complex, with enhanced removal 
of apo A, the core component making up HDL. Apo A is then renally excreted 
reducing circulating numbers of HDL as well as its protective measures290.  




Hypertension is commonly seen in adult individuals and is a well-recognised risk 
factor for CVD. Usually asymptomatic, it tends to be diagnosed during routine 
medical assessments and can be poorly controlled due to a combination of patient and 
physician factors. Until 1997 blood pressure targets were 160/ 90mmHg, then 
lowered to 140/90mmHg following the publication of the Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) 
in 2003 (Table 8). These guidelines were further supported by similar 
recommendations in the UK by the British Hypertension Society (BHS IV) (Table 9), 
and then in Europe by the European Society of Hypertension guidelines194;572.  
 
Table 8: Joint National Committee blood pressure targets 
 
 Systolic Diastolic 
Normal <120 <80 
Prehypertension 121 - 140 81 -  90 
Hypertension    
Stage 1 140 - 159 90 - 99 
Stage 2 >160 >100 
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 




Table 9: British Hypertension Society Hypertension Targets 
 
 Systolic Diastolic 
   
Low Normal <120 <80 
Normal 121 - 129 80 -84 
High Normal 130 - 139 84 -89 
Hypertension    
Grade 1 140 - 159 90 -99 
Grade 2 160 -179 100 - 109 
Grade 3 >180 >110 
British Hypertension Societies (BHS) and European Hypertension Targets adapted from Williams and 
Graham194;572.  
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The prevalence of hypertension defined as a blood pressure >140/90 is 
approximately 27.5% among North Americans, and 44% in Europeans including the 
UK577. Hypertension is a multifactorial disorder with numerous aspects including 
genetics, ethnicity, weight, family history, diet, stress, activity, hormonal 
dysregulation, personality traits, and drugs playing variable roles586. Obesity and 
insulin resistance are particularly believed to be major contributors in its evolution 
with several studies describing the direct relationship between fasting glucose levels, 
insulin resistance and obesity to hypertension121;151;488;499. Controversy exists as to 
whether insulin resistance results in hypertension or vice versa. Those supporting the 
theory that insulin resistance is causal for hypertension believe this is through 
stimulating sympathetic drive, arterial wall hypertrophy and resistance, and renal 
sodium retention11;116;170.  
It is well documented that hypertension increases mortality through its effect 
on cardiac disease, stroke (both haemorrhagic and ischaemic), and renal dysfunction. 
From meta-analysis of results of randomised controlled trials each lowering of 
systolic BP by 20mmHg halves the cardiovascular risk with no identified lower limit. 
Some accept similar reductions with a 10mmHg reduction in diastolic pressure, 
although others believe that it is the systolic level which is the dominant risk431;431. 
As a component of MS, the CV risks associated with hypertension are further 
enhanced with the presence of each additional component474. In diabetes, the presence 
of hypertension is common with a prevalence of greater than 50%36. Many studies 
have identified the added benefits of treating hypertension in this group of 
individuals1;412;598.  
In the United Kingdom Prospective Diabetes Study (UKPDS) 1148 
hypertensive individuals with type 2 diabetes were found to benefit from improved 
blood pressure control on captopril or atenolol with reductions in microvascular 
outcomes of 37% for microvascular endpoints, 32% for diabetes-related deaths, and 
44% for stroke. No significant improvement in the rate of myocardial infarct event 
was demonstrated. It is worth noting that at the time the average blood pressure 
readings in the intensive group was 144/82mmHg and 154/87 for the standard making 
the reductions -10/-5mmHg20. The Hypertension Optimal Treatment (HOT) trial 
included 1501 individuals with diabetes and hypertension (diastolic 100-115mmHg) 
Page | 48 
 
who were randomised aiming to achieve diastolic blood pressure readings of <90, 
<85 and <80mmHg. CV events were reduced by 50%, CV mortality by 65% and 
although not significant, myocardial infarction by 50% in the group who achieved a 
reading of <80 compared to <90217. Following the publication of these trials blood 
pressure targets in individuals with diabetes were reduced from <140/90 to <140/80 
and to <130/80 in more recent years436;572.  
Obesity’s effect on blood pressure is multi-factorial as this may be partly 
through a direct impact or indirectly through its association with insulin resistance, 
and possible fluid retention. Certainly several trials have demonstrated a reduction in 
blood pressure with weight loss. A meta-analysis of 25 weight loss studies reported 
that an average weight loss of 5kg reduced systolic blood pressure by 6.5mmHg and 
diastolic by 5mmHg in individuals who were not on any hypertension medication. 
Bigger results were noted in those on treatment for hypertension386. In the Trials of 
Hypertension Prevention, approximately 1200 overweight adults with high normal or 
prehypertension, were randomised to weight loss, sodium intake reduction, combined 
weight loss and sodium reduction, or a control group and followed for 3 years. Blood 
pressure was documented at 6, 18 and 36 months. The target for the weight loss group 
was to lose 4.5kg at six months and maintain this throughout the trial. They achieved 
their initial weight loss and at six months the SBP/DBP readings were down by 
3.7/2.7mmHg in the weight loss arm, 2.9/1.6mmHg in the low salt arm and 
4/2.8mmHg in the combined group. The weight was gradually regained by the end of 
the study but despite this, all interventions managed to maintain meaningful 
reductions in blood pressure517.  
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1.8. Inflammatory State 
 
An inflammatory response is a series of complex pathways which are 
activated in response to an irritant, be it pathogen or foreign body, by which the body 
attempts to self-heal. The processes involved usually include the activation of the 
innate immune system with subsequent release of pro-inflammatory cytokines. In 
acute or chronic clinical inflammatory conditions (i.e. rheumatoid arthritis, 
inflammatory bowel disease) levels of circulating inflammatory markers are high and 
have been associated with an increased CV risk120. In obesity and MS, the same 
inflammatory markers have been identified as being elevated, although not as high as 
seen in well documented chronic inflammatory conditions. It is understood that these 
small elevations are sufficient to bring about changes that predispose to atherogenesis 
and CV disease over longer periods of time. 
It has been well documented that adipose tissue is not an inert storage facility 
but actually a dynamic, metabolically active organ which stores free fatty acids and 
regulates their release back into the circulation when required for energy. It also 
secretes its own biologically active molecules, known collectively as adipocytokines, 
in addition to  chemokines and inflammatory proteinoids which individually or 
collectively interact with various biological processes that suppress or enhance 
inflammation, immunity or prothrombotic tendencies342;353;491;537 (Figure 9).  
In 1840 J. Paget considered fat to have a number of functions including, “1)  
a giver of lightness, especially to bones, 2) to spread local pressure over large areas 
by using adipose tissue as an incompressible elastic substance (i.e. soles of feet, 
pressure area), 3) to serve as a passive material that fills up spaces between adjacent 
organs whose functions require them to possess peculiar forms (i.e. heart, eyeballs, 
gut), 4) a protective against the cold, 5) to give roundness of form with which (among 
other advantages) the limbs and trunk meet the least resistance when traversing the 
air or water, and 6) as a disordered secretion”408. 
Many studies have demonstrated the association between circulating 
inflammatory markers such as C-reactive protein, IL-6, resistin, PAI-1, and tumour-
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necrosis factor, with the components of MS. In addition adiponectin secretion, an 
adipocytokine, identified to enhance insulin sensitivity, and have anti-inflammatory 
properties is suppressed in the presence of obesity. How it exerts its effects is unclear, 
but its deficiency is coupled with insulin resistance, pro-thrombotic tendencies and 
inflammation. 
 




The precise mechanism by which an inflammatory response is initiated in 
obesity or MS is not defined. Abnormal visceral fat accumulation is associated with 
inflammatory changes, including recruitment of macrophages and activation of 
endothelial cells, which promote vascular disease277. Some believe that as adipose 
tissue increases in mass, it outstrips its blood supply, resulting in intracellular hypoxia 
and cell apoptosis which releases pro-inflammatory cytokines and attracts 
macrophages. Indeed, several molecules produced by adipocytes (adipocytokines) 
are associated with increased cardiovascular risk partly through increased expression 
of pro-inflammatory genes and induction of systemic inflammation110;595. A reduction 
in the secretion of inflammatory molecules can be achieved through weight loss, 
implicating adipose tissue mass as a partial regulator of inflammation.  
An alternative pathway is that the accumulation of adipose tissue leads to 
increased oxidative stress partly via the oxidant effects of fatty acids. Leukocytes 
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derived from obese individuals infused with free fatty acids suffer from increased 
oxidative stress. Oxidative stress in turn may promote metabolic complications such 
as insulin resistance and induce a pro-inflammatory state via deregulation of 
adipocytokines176. Thus, oxidative stress is both induced by and adversely impacts on 
adipose tissue function. Consequently, biomarkers for oxidative stress may play a 
role in obesity-induced CVD. Enhanced levels of oxidative stress are linked to 
smoking, hyperglycaemia, dyslipidaemia and obesity84;152;277. In animal studies a rise 
in vascular cell adhesion molecule-1 (a molecule which promotes the adhesion of 
monocytes and lymphocytes to the intimal surface of the endothelium) was noted 
following a short term atherogenic diet providing evidence that factors apart from 
traditional ones may affect atherosclerosis34;323.  
Although insulin resistance is believed to be central to the low grade 
inflammation seen in MS and obesity, a “chicken or egg” situation appears to exist. 
Insulin as an anabolic hormone regulates the uptake and storage of glucose and fatty 
acids in liver, muscle and adipose tissue. In the presence of insulin resistance, there 
is hyperglycaemia, enhanced lipolysis and an abundance of circulating NEFA. NEFA 
induce oxidative stress, an inflammatory response and through blocking various 
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1.9. Management Recommendations for Metabolic Syndrome 
 
The association between obesity and the development of MS constitutes the 
main argument justifying weight reduction programmes which, if successful, can lead 
to a substantial improvement or normalisation of the metabolic profile of the 
obese373;379;538;573. A 10kg reduction in weight equates to a 20% fall in total morbidity, 
15% fall in LDL-cholesterol (LDL-C), 30% fall in triglycerides and an 8% rise in 
HDL-cholesterol (HDL-C)479. A 15-20% weight loss in the first year after diagnosis 
of type 2 diabetes may reverse the excess mortality of being overweight and a 
deliberate weight loss of 5-9 kg is associated with up to  a 30-40% reduction in 
diabetes-related mortality39.   
Huge numbers of individuals in the developed world profess to be “on a diet” 
at any given time. In the USA alone approximately 35% of women and 45% of men 
aim to lose weight, but despite their efforts, the prevalence of obesity has doubled in 
the past 20 years164 suggesting that the given dietary advice may itself be a 
contributing factor. The conventional dietary approach to weight management 
recommended by the leading research and medical societies164 is a low fat, high 
carbohydrate, energy-deficient diet (30% energy from fat, 10-15% protein, 55-60% 
carbohydrate), but despite Americans consuming fewer fat-derived calories (42% in 
the 1960s and 33% in the 1990s338;584) the prevalence of obesity increased60. 
Consequently high carbohydrate diets, particularly those containing high glycaemic 
index foods and low fibre content, are now proving to be controversial as 
epidemiological, clinical and experimental studies312 indicate that such diets may in 
fact contribute to weight gain as they increase circulating plasma triglycerides, thus 
affecting LDL composition, reducing oxidation of body fat and reducing satiety312;486.  
There are two general approaches to address the management of MS. The first 
of these targets the root causes, ‘increased BMI and physical inactivity’, which have 
a knock on effect on the closely linked insulin resistance. Weight reduction and 
increased physical activity both lower insulin resistance and indirectly favourably 
affect the metabolic risk factors. The second approach directly treats the “metabolic” 
risk factors of atherogenic dyslipidaemia, hypertension, prothrombotic state, and 
underlying insulin resistance through the use of medications.  
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1.9.1.  Lifestyle Changes and Weight-Loss: 
 
Addressing obesity and physical inactivity will reverse the fundamental cause 
of MS and should be the first line of intervention in any cardiovascular risk reduction 
programme. Data from the NHANES II demonstrated that an elevated BMI was 
associated with elevated triglycerides and low HDL-cholesterol. NHANES III 
displayed the link between elevated arterial blood pressure and variations in body 
weight. A number of studies have shown that weight loss and increased physical 
activity will delay or prevent the onset of type 2 diabetes in individuals with the 
metabolic syndrome. The Finnish Diabetes Prevention Study randomised 522 non-
diabetic, middle-aged, over-weight individuals with impaired glucose tolerance to 
either a lifestyle intervention or a control group. The intervention goals included a 
targeted 5% weight reduction, reduced dietary fat intake, and at least 30 minutes of 
aerobic exercise daily. Subjects were followed for a mean of 3.2 years, with annual 
glucose testing.  
Figure 10: Incidence of Diabetes in Finnish Diabetes Prevention Study 
 
 
Adapted from Tuomilehto 543 
 
 
The risk of diabetes was reduced by 58% in the intervention group, with the 
reduction being directly associated with the lifestyle changes (Figure 10). The 
improvements were sustained in those who achieved their target intervention goals 
with a relative risk reduction at 7 years equivalent to 36% (incidence rate of 4.6% in 
the intervention group and 7.2% for the controls) 328;329;543. 
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The Diabetes Prevention Program Research Group randomised 3234 non-
diabetic subjects with elevated fasting and post-prandial glucose levels to placebo, 
lifestyle modification, or metformin (850 mg twice daily). Targets for the lifestyle 
group included 7% total body weight loss and two and half hours of weekly exercise. 
Individuals were followed for approximately 2.8 years. Reductions in incidence of 
diabetes were similar to the Finnish Diabetes Prevention Study with the lifestyle 
group achieving a 58% reduction in incident diabetes when compared to the placebo 
group, with a 39% reduction in the metformin group76. In the Nurse’s Health Study 
84,000 healthy females participated and were followed for more than 14 years.  Those 
following a healthy lifestyle (i.e. non-smokers, BMI < 25kg/m2, regular exercise and 
low alcohol consumption) were reported to have a relative risk of coronary events of 
0.17 as compared to all other women509. 
Thus with the evidence clearly favouring the need for lifestyle modifications, 
NCEP recommended that weight loss be the first target in those individuals with 
central adiposity and MS and set a target of 7-10% reduction in total weight within 
the first 6-12months.  To achieve these targets it was advised to reduce caloric intake, 
and increase physical activity with recommendations being a minimum of 30 minutes 
of intensive activity on most days of the week. Weight loss could be assisted with the 
use of therapeutic agents, although those available have only had modest success. For 
severe obesity bariatric surgery could be considered134. 
Once weight loss has been achieved, on-going weight maintenance is just as 
important and requires a lot of support both emotionally and physically, to encourage 
the individual to remain motivated and persist with the healthier lifestyle choices. 
From results in the Counterweight programme, although no correlation was seen 
between weight loss and regain, individuals who lost a greater percentage of their 
weight (>10%) were less likely to fully regain it2;292;314.  
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1.9.2. Physical Activity 
 
Physical activity assists weight reduction, and has favourable effects on 
cardiovascular risk factors. Several physical activity studies have demonstrated the 
improvement in a number of CV risk factors (i.e. reduction in blood pressure and 
triglycerides and increase in HDL-cholesterol), and consequent reduction in 
cardiovascular events. In addition other benefits include improvements in myocardial 
function, cardiac perfusion, and vascular tone. Some studies have reported the 
incidence of coronary disease to be 50% lower in active groups as compared to their 
sedentary counterparts529.  
The current recommendations suggest 30 minutes of moderate-intensity 
exercise on most days, with extra exercise adding to the benefits. To achieve weight 
loss activity should be increased to sixty minutes of moderate aerobic exercise, 
supplemented by additional short bouts of high intensity exercise throughout the day. 
The American Heart Association recommends that those individuals with high 
cardiovascular risk should consult a specialist for a prescribed exercise programme 
to limit the risk of harm224. Despite the documented success of physical exercise in 
improving weight, insulin resistance and CV risk, compliance in reality is a recurring 
stumbling block.  In an American health survey Kruger et al. identified that 
approximately one in three adults who participated reported successfully losing and 
maintaining their weight loss. These successful candidates were more health 
conscious, planned their meals, calculated caloric intake and engaged in regular 
exercise both aerobic and weight-bearing. On reviewing the obstacles to exercising 
regularly, these included lack of time, motivation, lack of an exercising partner, 
funding, and tiredness296.   
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1.9.3.   Dietary Modifications 
 
The current recommendations state that the diet should not only be low in 
calories but low in saturated fats, trans fats, cholesterol, sodium, and simple sugars. 
People are expected to partake of ample portions of fruits, vegetables, whole grains 
and oily fish. Controversy remains around which diet should be promoted. ATP III 
advises that a diet for those with MS should help reverse the dyslipidaemia but any 
increases or decreases in dietary components will inevitably alter the percentage of 
the others and potentially affect the absolute quantities (i.e. a fat intake of greater than 
35% potentially increases the saturated fat and caloric intake, while less than 25% 
may increase the carbohydrate portions). High carbohydrate intake, especially of 
refined carbohydrates can have a deleterious effect by encouraging 
hypertriglyceridaemia and reducing HDL-cholesterol.  
There has long been an interest in the question of whether changing the 
macronutrient content of the diet can promote weight reduction. For many years, a 
low-fat diet was advocated because the high caloric density of fat could increase the 
likelihood of obesity. More recently, interest has grown in the possibility that high-
protein, low-carbohydrate diets will enhance weight reduction. The rationale seems 
to be that fat and protein offer satiety that is absent with carbohydrates. That this 
effect of fat and protein on satiety makes the diet more effective for producing weight 
loss is a disputable hypothesis. Arguments arise that such diets lack essential 
recommended nutrients in the form of fruits, vegetables, and whole grains and cannot 
be tolerated by all individuals. In general successful weight loss requires a 
combination of caloric restriction, physical activity, and motivation; effective lifelong 
maintenance of weight loss essentially requires a balance between caloric intake and 
physical activity (Table 10)201.  
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The “eatwell plate” visually describes how much an individual should eat 
from each food group including snacks (Figure 11). The general principal behind it is 
to encourage the consumption of2: 
 plenty of fruit and vegetables 
 plenty of bread, rice, potatoes, pasta and other starchy foods – choose 
wholegrain varieties when possible 
 some milk and dairy foods 
 some meat, fish, eggs, beans and other non-dairy sources of protein 
 just a small amount of foods and drinks high in fat and/or sugar 
Figure 11: The Eatwell Plate 
 
People are advised to look at the eatwell plate and modify their food intake to 
something equivalent. They are expected to try to choose options that are lower in 
fat, salt and sugar when possible.  
                                                          
2 The information on this page has been taken from the eatwell.gov.uk website201. 
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Joint British Societies 2 Lifestyle 
Recommendations 
American Guidelines for Lifestyle 
Management of Metabolic 
Syndrome 
   
Smoking Smoking cessation Smoking cessation 
  To maintain body weight in a healthy 
range, balance calories from foods and 
beverages with calories expended 
Ideal Body 
Weight 
Aim for BMI 20 -25kg/m2  Aim to reduce body weight by 7% to 
10% during year 1 of therapy 
Then aim for BMI <25kg/m2 
Waist 
Measurement 
White Caucasians :     <102 cm in 
men and <88 cm in women 
Asians:  <90 cm in men and <80 cm 
in women 
<102 cm in men and <88 cm in women 
 
Physical Activity Regular aerobic physical activity of 
at least 30 mins per day, most days 
of the week 
To reduce CV risk:     at least 30 
minutes of moderate-intensity physical 
activity, above usual activity, at work 
or home on most days of the week. 
To sustain weight loss:    at least 60 to 
90 minutes of daily moderate-intensity 
physical activity while not exceeding 




Fruit & vegetable  Fresh fruit and vegetables to at least 
five portions per day 
Two cups of fruit and 2½ cups of 
vegetables per day 
Grains  Consume 3 or more ounce-equivalents 
of whole-grain products per day, with 
the rest of the recommended grains 
coming from enriched or whole-grain 
products 
Dairy Products  3 cups per day of fat-free or low-fat 
milk or equivalent milk products 
Fat  Aim for dietary cholesterol <300 
mg/day 
Aim for dietary cholesterol <200 
mg/dL;  
 Aim for total fat ≤30% of total 
energy intake. 
Replace saturated fats by an 
increased intake of monounsaturated 
fats 
Aim total fat intake between 20 to 35% 
of calories, with most fats coming from 
polyunsaturated and monounsaturated 
fatty acid. 
 saturated fats to ≤10% of total fat 
intake 
saturated fat <7% of total calories 
 Regular intake of fish and other 
sources of omega 3 fatty acids  
 
Alcohol Limit alcohol intake to <21 
units/week for men or <14 
units/week for women 
 
Salt Limit the intake of salt to <100 
mmol/l day (<6 g of sodium 
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1.9.4. Targeting the Metabolic Risk Factors 
 
The second approach to managing MS is to specifically target the different 
risk factors with the aid of pharmacological agents. Where a healthy lifestyle can be 
prescribed to the population in general, this alternative method is required for those 
who are at a high risk of CVD and would receive significant benefit. In the NCEP-
ATP III recommendations individuals are stratified to low, moderate or high risk 
using the Framingham cardiovascular risk model (Table 11). They were automatically 
categorised as high risk if they already had diabetes or a known CV event. 
 
Table 11: Framingham risk stratifications for establishing management targets 
 
Risk level  Hard CHD risk 
High  CHD or CHD Risk Equivalent >20% 
Moderate ≥2 Risk Factors* 10 – 20% 
Low ≤1 Risk Factors* <10% 
The risk factors used here are cigarette smoking, hypertension (BP 140/90 mmHg or on treatment), 
low HDL-cholesterol (<40 mg/dl), family history of premature CHD and age26. 
 
  




Although MS is particularly identified with an atherogenic dyslipidaemia 
consisting of low HDL-cholesterol, small dense LDL-cholesterol and elevated 
triglycerides, guidelines recommend that it is essential to first address the well-
established atherosclerotic risk presented by LDL-cholesterol. Only when treatment 
targets have been achieved and LDL-cholesterol has been reduced to 2mmol/l3 or less 
should the focus then shift to addressing the other dyslipidaemic components.  A large 
number of cardiovascular outcome studies have demonstrated the benefit of LDL-
cholesterol lowering but similar favourable outcomes are yet to be demonstrated with 
agents targeting the other components of dyslipidaemia (i.e. fibrates, cholesteryl ester 
transfer protein inhibitors, and niacin)53;100;101;115;141;189;454;478;481.  
In 2005, The Joint British Societies guidelines were published and set targets for 
cholesterol management. These are stated as:   
 
“to lower total cholesterol by 25% or LDL cholesterol by 30% or to reach< 4.0 
mmol/l or < 2.0 mmol/l respectively, whichever is the greater. 
However a total cholesterol concentration < 5.0 mmol/l or LDL cholesterol < 3.0 
mmol/l or reductions of 25% or 30%, respectively (whichever is the greater), 
provides a minimal acceptable "audit" standard. 
Also cardiovascular disease (CVD) risk replaces coronary heart disease (CHD) 
risk estimation to reflect the importance of stroke prevention as well as CHD 
prevention. 
The new CVD risk threshold of ≥ 20% is equivalent to a CHD risk of approximately 
≥15% over 10 years”579 . 
 
The National Institute for Health and Clinical Excellence (NICE) in 2010 
published its updated version of the 2008 lipid management guidelines which 
recommended initial lifestyle and other risk factor modification for primary 
prevention in those with a >20% 10 year CVD risk and statin therapy for secondary 
prevention regardless of risk factor modification. Treatment targets in secondary 
                                                          
3 Quality and Outcomes Framework (QOF) would set the target for primary prevention at <3mmol/l 
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prevention remain at <4mmol/l for total-cholesterol and <2mmol/l for LDL-
cholesterol although there are ongoing discussions to potentially reduce LDL-
cholesterol treatment targets to <1.8mmol/l particularly in high risk individuals (i.e. 
type 2 diabetes). Similar recommendations26;261  are seen in other international lipid 
guidelines (Table 12) allowing for a stepwise approach in lipid management which 
may include: 
1. Initial intervention with dietary and lifestyle changes 
2. LDL-cholesterol lowering with statins with LDL-cholesterol target <3mmol/l in 
the low risk individual and <2mmol/l in the high risk individual. Diabetes and a 
previous cardiovascular event, would automatically be included in the high risk 
category. 
3. Triglyceride lowering aiming to reduce the risk of pancreatitis in those with levels 
> 5.6mmol/L. 
4. Increasing HDL-cholesterol to >1.3mmol/L although no benchmark target level 
has yet been identified.  
 
 
Table 12: LDL Cholesterol targets for lifestyle and treatment 
 
Risk Category LDL Level at which to 
initiate lifestyle advice  
LDL Level at Which to Consider Drug 
Therapy 
High  ≥100 mg/dL (2.6mmol/L) 130 mg/dL (3.4mmol/L) 
Drug therapy can be initiated at lower targets 
depending on physician’s discretion 
 
Medium ≥130 mg/dL (3.4mmol/L) 10-year risk 10-20%: 130 mg/dL (3.4mmol/L) 




≥160 mg/dL (4.2mmol/L) 190 mg/dL (5mmol/L) 
 
Adapted from NCEP executive statement 26.  
 
  




Blood pressure targets in people with MS are generally no different from those 
set for the general population. A target of <140/90mmHg is aimed for in the majority 
with levels falling to <130/80mmHg in individuals with diabetes (Table 13).  
In those with mildly elevated readings, the importance of lifestyle changes are 
to be emphasised including dietary sodium reduction, moderation in alcohol, weight 
loss and increased activity, which are established as effective first line measures for 
blood pressure reduction. Recommendations were made to target antihypertensive 
therapy according to an individual’s needs. Thus those with cardiac disease should 
preferably be initiated on beta-blockers and/or ACE-inhibitors whilst those with 
diabetes should receive ACE-inhibitors or ARBs for renal protection. It was 
acknowledged that in most situations a combination of agents would be required in 
order to achieve targets in the more complex patients26;199;579. 
 




Joint British Societies 2 Lifestyle 
Recommendations 
American Guidelines for Lifestyle 
























<130 mm Hg 
systolic and 
<80 mm Hg 
diastolic 
<140 mm Hg 
systolic and 
<85 mm Hg 
diastolic 
<130 mm Hg 
systolic and 












and <80 mm 
Hg diastolic 
Lipids       
Total Cholesterol <4.0 mmol/l <4.0 mmol/l <4.0 mmol/l    
LDL-Cholesterol <2.0 mmol/l <2.0 mmol/l <2.0 mmol/l 4mmol/L <3.6mmol/L <2.6mmol/L 
Glucose       
Fasting Plasma 
Glucose 
≤6.0 mmol/l ≤6.0 mmol/l ≤6.0 mmol/l    










 75mg od* 
Aspirin 




75mg od * 
* Aspirin is no longer recommended as primary prevention for diabetes unless there is an increased 
cardiovascular risk. Adapted from59;200;421;579.  
  




Lifestyle interventions are important to delay the progress to frank diabetes in 
those who are glucose intolerant, and to avoid microvascular and macrovascular 
morbidities in those with established type 2 diabetes. Should these measures fail, then 
the addition of hypoglycaemic agents is recommended for type 2 diabetes. First line 
agents have included metformin and sulphonylureas. Thiazolidinediones 
theoretically help improve insulin resistance and preserve pancreatic function but 
recent evidence questioned their benefit in cardiovascular risk reduction, safety in 
cardiac dysfunction, risk of bladder neoplasm and fractures, resulting in the 
withdrawal of rosiglitazone and limited use of pioglitazone 126;140;241;390. Oral agents 
are not recommended for those without established diabetes although some tend to 
administer metformin in obese females with polycystic ovary syndrome. Targets are 
to achieve normoglycaemia in those with impaired fasting glycaemia and HbA1c of 
<6.5% in those with established diabetes on metformin (Table 13). Alternative targets 
are set for the vulnerable (at risk of hypoglycaemia particularly the elderly and those 
with disabilities), and those on insulin. 
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1.9.4.4. Hypercoaguable State 
 
MS has been well documented to be a pro-coagulant state with increases in 
the level of fibrinogen, plasminogen activator inhibitor-1, and other coagulation 
factors which potentially accelerate arterial thrombosis. Current recommendations to 
counteract the potential risk of thrombosis in both primary and secondary prevention 
has been low dose anti-platelet agents in the form of aspirin or clopidogrel where 
aspirin is not tolerated.  A recent trial has failed to demonstrate the benefit of aspirin 
for primary prevention in individuals with diabetes but highlighted the increased risk 
of bleeding. As a result recommendations have now changed and aspirin is only 
recommended in secondary prevention or in those with an increased risk of CV 
disease59;421. The ASCEND trial which is currently investigating the use of aspirin in 
diabetes for CV risk prevention has recruited 15,000 individuals with diabetes and is 
expected to report in 201735. 
 
1.9.4.5. Proinflammatory State 
 
As yet no actual drugs have been produced to target the pro-inflammatory 
state associated with MS. Weight reduction through lifestyle changes is currently the 
best recommendation. Many of the generally used cardiovascular drugs such as 
statins, ACE inhibitors, or pioglitazone have been reported to  affect beneficially 
some of the various inflammatory markers but they are not recommended to be used 
purely as an anti-inflammatory agent281;385. In fact recognised anti-inflammatory 
agents have been associated with increased cardiovascular risk. Individuals taking 
them for prolonged periods should do so under supervision74;163.  
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1.10. Drugs used in the treatment of Obesity 
 
Living organisms obey the first law of thermodynamics, and their body 
weight depends ultimately upon the balance between energy intake and output. 
Consequently, the current available agents used in achieving weight loss work along 
one of three strategies, to stimulate anorexigenic signals, oppose orexigenic signals, 
or increase energy expenditure. Up until 2009 there were three drugs available to be 
used to target weight loss. These were orlistat, sibutramine, and rimonabant. Both 
Sibutramine and Rimonabant have had to be withdrawn due to adverse side-effects 
leaving Orlistat as the only contender. Glucagon like Peptide (GLP-1) agonists, have 
recently been released on the market for the management of type 2 diabetes mellitus.  
Their potential to reduce weight has made them possible agents particularly in the 




Orlistat (Xenical) is a derivative of lipstatin which inhibits gastric and 
pancreatic lipase degradation of triglycerides within the gut, decreasing fat 
absorption, encouraging its elimination in the stool, and reducing the overall caloric 
intake. Studies have proven that it may reduce triglyceride absorption by up to 30%. 
Data from several trials have shown that regular use of this drug in its prescribed 
dosage of 120mg three times daily in the context of a low fat diet, produced an 
additional 5% weight loss above that sustained by caloric restriction. The weight loss 
was maintained for the initial two year study period498;513;534. Not only did orlistat 
help with weight loss but additional data demonstrated favourable changes in blood 
pressure, lipid profile, particularly post prandial hypertriglyceridaemia and glycaemic 
control125;244.   
In the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) 
study, the use of orlistat in 3,300 obese subjects reduced the risk of progression to 
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diabetes by 37%, when compared to placebo535. The benefits were predominantly 
observed in those with IFG and IGT. In the Orlistat and Cardiovascular risk profile 
in patients with metabolic syndrome and type 2 Diabetes (ORliCARDIA) study, 126 
individuals with type 2 diabetes on oral treatment, fulfilling the criteria for MS were 
randomised to a hypocaloric diet with orlistat or diet alone, and followed for 6 month. 
Significant favourable changes in weight, blood pressure, LDL-cholesterol, fasting 
glucose and insulin resistance were noted in the orlistat arm with the researchers 
concluding that it may have protective cardiovascular benefits125. Orlistat has also 
been shown to reduce C-reactive protein, and adipokines (interleukin-6 and a-tumour 
necrosis factor) as well as raise adiponectin levels593. The clinical impact of these 
findings is yet to be evaluated.  
Despite its benefits, orlistat’s use is limited by its side effects which are 
mainly gastrointestinal. The adverse effects, are not serious, but can be embarrassing. 
They include increased defecation, fatty/oily stools, leaking of oil from the rectum, 
faecal urgency and faecal incontinence. The symptoms can be avoided with proper 
counselling and maintaining a low fat diet, being related to higher fat meals. They 
tend to reduce with time. In addition there is a potential for a reduction in fat-soluble 
vitamins with reduced intestinal absorption leading to recommendations that 
individuals should take multi-vitamins to counteract the effect71.  
Up until now no long term cardiovascular outcome data are available for 
orlistat and this is surely required to assess its overall benefit, apart from weight loss, 
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1.10.2. Sibutramine 
Sibutramine (Reductil) is a -phenethylamine that acts centrally selectively 
inhibiting the reuptake of noradrenaline, serotonin (5-HT) and, to a lesser extent, 
dopamine. It was originally developed as an anti-depressant but during experimental 
phases, it was noted to increase thermogenesis and suppress appetite thus reducing 
caloric intake. Trials confirmed that sibutramine could reduce weight by up to 9% 
which could increase to 15% when combined with caloric restriction. In a meta-
analysis of 8 weight loss studies in type 2 diabetes sibutramine reduced weight, waist 
circumference and triglycerides, improved glycaemic control and raised HDL-
cholesterol559. The meta-analysis confirmed that sibutramine increased systolic and 
diastolic blood pressure and heart rate which restricted its initial use. Other adverse 
symptoms reported included headaches, insomnia, dry mouth and constipation. 
Unlike its predecessors, fenfluramine, and dexfenfluramine, sibutramine was not 
associated with pulmonary hypertension, or valvular dysfunction406;461.   
In January 2010, following an interim analysis from the Sibutramine 
Cardiovascular Outcomes (SCOUT) Trial, the European Medicines Evaluation 
Agency (EMEA) and the Medicines and Healthcare products Regulatory Agency 
(MHRA) produced a statement withdrawing it use from European markets. At the 
same time the Federal Drugs Agency in the USA added cardiovascular disease as a 
contraindication for sibutramine.  
SCOUT was a cardiovascular outcome trial which randomised over 10,000 
obese patients with high cardiovascular risk to sibutramine or placebo, plus lifestyle 
changes. Individuals were to be followed for up to 5 years. Primary outcomes 
included the incidence of non-fatal myocardial infarction, non-fatal stroke, and 
cardiovascular death. The interim analysis from SCOUT demonstrated that 
cardiovascular events were higher in the sibutramine arm (11.4%) as compared to 
placebo (10%). Although seemingly small, the difference was enough to pronounce 
that the risk of sibutramine far outweighed its potential benefits, especially as it had 
been linked to prolongation of the QT interval, cardiac arrhythmia and death23;461. 
Arguments arose that the individuals recruited to SCOUT would normally have been 
contra-indicated for the use of sibutramine, but with obesity being closely linked with 
cardiovascular morbidity, there was a potential for inappropriate use. 




Rimonabant (Accomplia) was a selective antagonist of the cannabinoid 
receptor CB1 exerting its effect through appetite suppression. It is an 
endocannabinoid which acts as a neuromodulator centrally and peripherally. An over-
expression of endocannabinoid receptors is seen in the obese which is believed to 
enhance stimuli for food intake. Rimonabant interferes with these signals resulting in 
appetite suppression and weight loss461. It was endorsed for restricted use in obese 
individuals by the EMEA in June 2006, following the results of four randomised 
controlled trials which studied over 6000 subjects and looked at various aspects of 
cardiovascular disease. The “Rimonabant In Obesity” (RIO) trials focused on 
overweight and obese individuals (RIO Europe and RIO North America), individuals 
with type 2 diabetes (RIO-Diabetes) and those with lipid disorders (RIO Lipids). In 
all four trials the use of rimonabant in conjunction with dietary measures 
demonstrated improvements in weight, abdominal adiposity, lipid profile, blood 
pressure, and other cardiometabolic factors. 20mg of rimonabant daily resulted in an 
average weight loss of 8kg in a year as compared to 3kg in the control group. The 
diabetes group had a weight loss of 5.3kg (5.4% of baseline body weight) as 
compared to 1.4kg in the placebo group419;473;550;551.  
Within the RIO trials, a 7% withdrawal rate on the 20mg dose due to 
psychiatric problems, mainly depression, was noted. As individuals with known 
significant depression had been excluded from the trial, this figure was considered 
excessive and the FDA investigated further. A meta-analysis looked at data from over 
4,000 individuals and concluded that patients given rimonabant were 2·5 times more 
likely to discontinue treatment because of depressive mood disorders than those on 
placebo, and that another significant proportion experienced symptoms of anxiety97. 
In October 23, 2008, the EMEA released  a statement that its Committee for Medical 
Products for Human Use (CHMP) had concluded advising that rimonabant be 
suspended from the UK market as its benefits no longer outweighed its risks22. 
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1.10.4. Glucagon Like Peptide 1  Agonists / Analogues 
A new class of agents for the management of individuals with type 2 diabetes 
are the glucagon like peptide 1 (GLP-1) mimetics, Exenatide, Liraglutide, and more 
recently Bydureon. GLP-1 is a hormone secreted from gut enteroendocrine cells 
known as an incretin. Incretins were noted in the 1970s to have insulinotropic 
properties and to regulate insulin levels546. Incretins are believed to be responsible for 
up to 70% of post-prandial insulin secretion240.The GLP-1 receptor when activated 
engages in a series of events via adenylate cyclase and exerts physiological actions 
within pancreatic islets, liver, adipose tissue and skeletal muscle, which have been 
identified to 
 stimulate insulin secretion 
 increase beta cell proliferation 
 enhance intestinal somatostatin production 
 inhibit glucagon secretion 
 promote hepatic glucose uptake and glycogenesis 
 inhibits acid secretion and delays gastric emptying127;128 
These actions appear to be glucose-mediated making incretins attractive as 
they are also less likely to promote insulin over-secretion and hypoglycaemia196. 
Human GLP-1 is rapidly degraded by dipeptidyl peptidase IV making it ineffective 
unless given as a constant infusion, and thus the search for a longer acting alternative. 
Exenatide, the first GLP-1 mimetic was released on to the market in 2005. It 
is derived from exendin-4, a naturally occurring GLP-1 receptor agonist originally 
found in the saliva of the Gila monster. It is 53% homologous with human GLP-1 but 
lacks the site recognised by dipeptidyl peptidase IV, allowing it to attach to GLP 
receptors, but avoid rapid degradation thus increasing the half-life. It is administered 
as a twice daily subcutaneous injection. Liraglutide, marketed in 2009, is an analogue 
of human GLP-1 with an amino acid substitution and the addition of a C-16 palmitic 
acid side chain which makes it resistant to degradation. It is administered as a once 
daily sub-cutaneous injection81;545. Other companies have released or are in the 
process of releasing their version of a GLP-1 mimetic, including bydureon, a one 
weekly extended-release exenatide and once daily lixisenatide. 
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GLP-1 agonists improve HbA1c, post–prandial glucose levels, and insulin 
requirements. Cardiovascular outcome trials are currently ongoing82;117;148;383. In 
randomised controlled trials these agents have resulted in 2 to 4kg weight loss in 
excess to placebo, sulphonylureas, metformin or thiazolidinediones262;439.  They have 
also been demonstrated to improve blood pressure, as well as total and LDL-
cholesterol533. The exact mechanism for weight loss is to be clearly identified but is 
currently believed to be a combination of delayed gastric emptying, premature satiety 
and a central anorectic effect from stimulation of the brain GLP-1 receptors. 
GLP-1 mimetics are currently licensed for use in type 2 diabetes, but a trial is 
currently on-going investigating the potential for use in obese, insulin resistant 
individuals. SCALE (Satiety and Clinical Adiposity – Liraglutide Evidence in Non-
Diabetic and Diabetic Subjects) is currently on-going having randomised individuals 
to placebo or liraglutide 0.6, 1.2 or 3mg394. The results may help provide further 
evidence to justify using these agents in obese insulin-resistant patients without 
diabetes306;533. 
GLP-1 agonists’ side effects are mainly gastrointestinal, but hypoglycaemia 
can occur when administered with insulin secretagogues. Liraglutide and Exenatide 
extended-release in animal studies were noted to enhance thyroid C-cell hyperplasia, 
raise calcitonin levels, and potentially promote medullary thyroid cancers. 
Consequently the FDA, placed a black box warning on both drugs, encouraging both 
physicians and patients to assess pros and cons prior to use62. 
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1.10.5. Metformin 
Metformin is a biguanide which is botanically linked to Galega qfficina 
(Goat’s rue) a herb which had in medieval times been used for the treatment of 
diabetes. Derivatives of biguanides were initially introduced in the 1920s but did not 
gain popularity due to side-effects and the discovery of insulin which was much more 
effective in controlling blood sugars. Reintroduced in the 1950s, metformin has since 
become one of the commonest used oral hypoglycaemic agents, and is first line 
therapy for individuals with type 2 diabetes in the UK21;45;46. 
The exact mechanism of action of metformin remains unclear. It is believed 
to reduce insulin resistance by enhancing glucose uptake by both peripheral muscles 
and liver and reducing gluconeogenesis. Metformin is effective at reducing blood 
glucose levels, without causing hypoglycaemia or weight gain making it a desirable 
agent compared to the sulphonylureas. Its side-effects are mainly gastro-intestinal. 
The incidence of lactic acidosis, which was the reason for the withdrawal of other 
biguanides, is low in metformin7;86.  
Metformin was the first hypoglycaemic agent to suggest a positive effect on 
cardiovascular outcomes25. Not only is it effective in improving glucose control, it 
appears to have an independent positive effect on total and LDL-cholesterol, It is 
commonly used in polycystic ovary syndrome where it appears to improve insulin 
resistance and help regulate menstrual cycles and ovulation.  
In addition to its above benefits, metformin is now being increasingly used to 
assist with weight loss. Studies in overweight or obese individuals with type 2 
diabetes have demonstrated that metformin resulted in appetite suppression and 
weight loss, an effect that was clear when compared to sulphonylureas or 
insulin85;315;344;594. In obese hyperinsulinaemic teenagers on hypocaloric diets, 
metformin achieved a greater reduction in weight (6.5% vs. 3.8%, p<0.01) and body 
fat, as well as improved insulin sensitivity276.   A systematic review of  studies looking 
at weight loss with metformin in overweight or obese individuals without type 2 
diabetes reported that although metformin might enhance weight loss in individuals 
with a BMI >35kg/m2, they were unable to conclusively confirm this 321.  
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Certainly, over the years, it has become a popular agent used in increasingly 
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2. CHAPTER 2: Adipocytokines 
 
2.1. Introduction & Definition 
 
The precise mechanisms linking obesity, insulin resistance, dyslipidaemia and 
hypertension to the development of the metabolic syndrome are ill-defined, but it is 
noted that many of these factors are associated with higher than normal circulating 
levels of inflammatory markers, “cytokines”  which are associated with 
atherogenesis63;435. Cytokines are molecular substrates secreted by a cell to alter its 
own function (autocrine activity) or that of adjacent cells (paracrine activity). They 
have a role in immunomodulation. Cytokines are elevated in both obesity and 
metabolic syndrome with the underlying cause likely to be adiposity. Adipose tissue 
develops in many sites throughout the human body aggregating in areas of loose 
connective tissue, such as the subcutaneous layer dividing muscle and skin. It may 
accumulate around internal organs particularly abdominal viscera and the heart. 
Previously adipose tissue was believed to be solely an inactive storage facility whose 
function was to provide insulation, mechanical support and storage of surplus energy.  
Studies have demonstrated it to be a metabolically active organ with its own 




Figure 12: An overview of secretion of adipocytokines in adipose tissue under normal and obesity 
conditions604. 
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Adipose tissue is classified into white and brown. White adipose tissue makes 
up the larger component and is the major site for energy storage. A white adipocyte 
is composed of a single fat droplet with a peripheral nucleus. It is regulated by a 
cascade of hormones, including glucagon and catecholamines, which activate or 
deactivate hormone sensitive lipase which in turn regulates the influx and efflux of 
free fatty acids and thus energy supplies for gluconeogenesis. White adipose tissue 
has a capacity for major expansion which is a feature unique to it allowing it to 
potentially become the largest body organ. Brown adipose tissue is linked to 
thermogenesis and preservation of body temperature and is thus seen in abundance in 
situations where heat generation is required such as in animals that hibernate or in 
neonates including humans.  
Table 14: Action of Cytokines 
 
Adipocytokine Site of production Actions 
 
Adiponectin Adipose tissue 
Skeletal muscle 
Inverse relationship with obesity 




Beneficial effect on dyslipidaemia 
Leptin Adipose tissue (subcutaneous) 
Placenta 
Ovaries 





Increases  metabolism and energy 
expenditure 
Enhances insulin sensitivity  
Inhibits lipogenesis 
Stimulates pro-inflammatory cytokines 




Augments insulin resistance 
Stimulates smooth muscle cell 
proliferation 
Pro-inflammatory 





Enhances insulin sensitivity 





Adipose tissue Augments insulin resistance 
 
Plasminogen 
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Unlike white adipocytes the brown adipocyte is made up of several small fat 
droplets, has a larger number of mitochondria, a higher capillary supply and a greater 
oxygen requirement. Cytokines secreted by adipose tissue are collectively known as 
adipocytokines (Table 14). They were first described in 1994 with the discovery of 
leptin, a satiety regulator, which demonstrated that adipose tissue was capable of 
producing signals that enabled it to regulate food intake and energy balance, and 
thereby affect the body’s nutritional status. Other largely adipose-derived factors 
soon followed: adiponectin, resistin, visfastin and plasminogen activator inhibitor 1 
(PAI-1). Adipocytokines interact with several organ systems, their systemic 
influences during times of dysregulation potentially linking them to the insulin 
resistance, metabolic dysfunction, and inflammation in MS249. 
In more recent years another category of fat has become recognised. This is 
known as ectopic fat and has been defined as the collection of fat (triglyceride) 
deposits in areas that are not commonly recognised to be associated with fat/adipose 
tissue (i.e. liver, skeletal and cardiac muscle, and pancreas). The exact mechanism 
behind the formation of ectopic fat is still poorly understood but adipose tissue 
dysfunction and the saturation of subcutaneous adipose tissue are both believed to be 
causative factors. A disproportion in the rate of accumulation of free fatty acids and 
metabolites, and their oxidation leads to a build-up in intracellular lipid which 
depending on the organ they affect, may negatively impact on its function (i.e. non-
alcoholic fatty liver, or pancreatic exocrine dysfunction)318;503. A group from 
Newcastle have recently demonstrated that a strict hypocaloric diet (<600kcal/day), 
could reduce pancreatic and hepatic triglyceride stores, and reverse the metabolic 
abnormalities associated with type 2 diabetes4.  
Ectopic fat has been divided into two types depending on its area of activity.  
There is (1) ectopic fat with systemic effects (intramuscular, fatty liver, visceral 
adipose tissue) which is believed to have a role in insulin resistance and metabolic 
dysfunction, through the release of adipocytokines and inflammatory markers; and 
(2) ectopic fat with local effects (perivascular fat, pericardial fat, myocardial 
                                                          
4 Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased 
pancreas and liver triacylglycerol, E. L. Lim & K. G. Hollingsworth & B. S. Aribisala & M. J. Chen 
& J. C. Mathers & R. Taylor. Diabetologia. DOI 10.1007/s00125-011-2204-7 
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steatosis), which directly affects the organ to which it is confined resulting in reduced 
muscle contractility or vascular hardening.  
Many include visceral adipose fat as part of ectopic fat and have thus 
associated it with an increase in metabolic and cardiovascular risk. Studies have 
demonstrated that lifestyle changes and improving insulin-sensitivity does have a 
positive effect on the quantity of ectopic fat. .Much work is still needed to fully 
appreciate and quantify the effect that the various deposits of ectopic fat contribute 
to insulin resistance and the inflammatory process75.  
  




Adiponectin is a 244–amino acid protein synthesised and secreted almost 
exclusively by white adipocytes. It circulates mainly in two forms: hexamers of 
relatively low molecular weight and larger high molecular weight, multimeric 
structures. The ratio between the two forms is believed to determine adiponectin’s 
physiological activity181. Its secretion is likely to be hormone regulated. IGF-1 
stimulates its production whereas insulin, TNF- , endothelin-1, and glucocorticoids 
appear to be suppressive188.  
Unlike the other adipose-related cytokines, adiponectin has an inverse 
relationship with obesity with levels rising during weight loss but falling with weight 
gain. It appears to have a role in metabolic dysfunction as well as anti-atherogenic 
and anti-inflammatory effects. Adiponectin has an inverse correlation to 
hyperinsulinaemia, insulin resistance, obesity, BMI, hypertension, dyslipidaemia, 
and hyperglycaemia. Its correlation to insulin resistance appears to be stronger than 
for obesity or degree of body fat. Low plasma adiponectin was an independent risk 
factor for development of type 2 diabetes (but not for obesity) 31;342;484;591. Although 
negatively associated with general adiposity, adiponectin levels differ according to 
the distribution of fat with levels being lower in visceral adiposity or high waist to 
hip ratios249;302. Females have higher adiponectin levels than males which may be a 
reflection on their fat distribution which tends to be more peripheral and 
subcutaneous. Such associations suggest that adiponectin levels may be affected by 
sex hormones in addition to the pattern of fat distribution although the evidence is 
variable236;508.   
Studies in mice have demonstrated an improvement in insulin resistance when 
adiponectin was administered to obese rodents or ones with type 2 diabetes. Other 
studies combining both adiponectin and leptin demonstrated that while both agents 
improved insulin sensitivity, the combination had additive effects with complete 
resolution of insulin resistance in some293;585.  
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Plasma concentrations of adiponectin are lower in people with CVD than in 
controls, even after matching for BMI and age. Individuals with 
hypoadiponectinaemia (<4μg/ml) are likely to have multiple metabolic risk factors 
and an increased risk of CVD300. At the same time those with higher adiponectin 
levels have reduced long term risk of myocardial infarction. These differences in risk 
persist after adjustment for family history, BMI, alcohol intake, history of diabetes 
and hypertension, haemoglobin A1c, hsCRP, and lipoprotein levels423. In obese 
individuals adiponectin levels decreased incrementally with each additional 
component of MS.  
The mechanisms by which adiponectin may influence insulin resistance is not 
fully understood. It is believed to be linked to a reduction in circulating fatty acids 
and triglyceride load through adiponectin’s ability to stimulate intra-muscular fatty 
acid oxidation585 or to activate AMP-activated protein kinase, increasing 
intramuscular and adipose tissue glucose uptake. In addition to its effects on obesity, 
insulin resistance and associated markers of CVD, adiponectin plays a potential anti-
thrombotic and anti-inflammatory role.  In human studies it is negatively correlated 
to hsCRP levels, which are associated with inflammation and atherogenesis355;403. In 
vitro adiponectin inhibits pro-inflammatory TNF-α and interleukin-8 induced 
synthesis of adhesion molecules which trigger a series of events which suppress the 
production of pro-inflammatory cytokines and enhance the secretion of the anti-
inflammatory cytokine interleukin-10299;402;520. 
Controversially, a few studies have implied that high adiponectin levels are 
not protective for secondary CVD protection and may actually be associated with an 
increased mortality. These might suggest that in time of disease, a counter-regulatory 
increase in adiponectin occurs, representing a defence mechanism against 
inflammatory conditions119;282;309. Further studies are required to elucidate 
adiponectin’s role in disease.  
 
  




Leptin, was the first adipocytokine to be discovered in 1994. It is produced by 
the leptin gene, whose name is derived from the Greek word "leptos," meaning "thin.”   
Leptin is an 167-amino acid protein, synthesised and secreted mainly from white 
adipose tissue as an afferent signal molecule that interacts with the appetite and 
satiety centres in the brain to regulate body weight, inhibit food intake and increase 
energy expenditure, enhance thermogenesis and metabolic rate12;425;490. Circulating 
leptin levels correlate with body fat stores although the mechanisms regulating its rise 
when overfeeding and fall in starvation appear to be unrelated to adiposity. Leptin 
receptors are located in the central nervous system, adipocytes and endothelial cells 
where they facilitate pathways which are essential for regulating appetite, modulating 
hepatic gluconeogenesis and gonadotrophin secretion438;600.   
Leptin deficiency or receptor dysfunction causes hyperphagia, obesity, 
hyperinsulinaemia and insulin resistance in both animal and human studies. 
Hyperleptinaemia can also be present in obesity. While inherited leptin deficiency or 
mutations occur in the morbidly obese, insulin resistant (without diabetes), and 
sexually dysmorphic, these are rare accounting for only a tiny percentage of obese 
individuals, and respond positively to recombinant leptin therapy12;147;434;438;490. Most 
obese individuals are considered leptin resistant, with bodies adapting to high 
circulating levels and failing to trigger the satiety effect. 
In addition to feeding, factors affecting leptin levels are exercise,  raised 
metabolic rate, which hypothetically should induce hypoleptinaemia (although results 
remain controversial), and exposure to the cold, a possible self-preservatory effect 
during hibernation219;289;411;415;600. In men, hyperleptinaemia may be a predictor of 
type 2 diabetes, but female studies have failed to show a similar association.  
Leptin inhibits insulin biosynthesis and secretion in pancreatic β-cells. Insulin 
stimulates leptin secretion from adipose tissue. The two are interlinked in a feedback 
mechanism that precludes leptin resistance when dysregulated and contributes to 
hyperinsulinaemia and type 2 diabetes in overweight individuals480. Leptin may 
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contribute to worsening cardiovascular risk by counteracting the antioxidative actions 
of insulin on free fatty acids. Studies have reported hyperleptinaemia to be a predictor 
for future CV events in those with a previous event or family history287;363;507. 
Controversially some studies have implied that leptin may have cardioprotective 
properties and indeed hypoleptinaemia has been linked to increased cardiovascular 
mortality420. Consequently some have wondered if leptin’s contradicting properties 
exist within a balance with anti-atherogenic and insulin-sensitising properties on one 
side and atherogenic and insulin resistance promotion on the other. Obesity and MS 
clearly tip the scales towards oxidative stress and a pro-inflammatory status 
promoting cardiovascular disease and type 2 diabetes. 
Leptin is also involved in many physiological processes. It modulates T- cell 
immune response, stimulates proliferation of T-helper cells, tumour necrosis factor, 
and production of pro-inflammatory cytokines. Leptin has also been found to up-
regulate the production of endothelin 1 (ET-1), a potent vasoconstrictor and mitogen, 
in human umbilical vein endothelial cells and this may explain the relationship 
between adipose tissue and obesity-associated hypertension and atherosclerosis434. Its 
role in atherosclerosis is still not fully determined. Hyperleptinaemia has been 
identified to be associated with increased platelet aggregation381. In in vitro or animal 
studies, different atherogenic properties, including increased oxidative stress, 
impairment of vaso-relaxation, and increased thrombosis, have been 
described505;506;562.  
The role of leptin for the future management of obesity and cardiovascular 
risk is still being considered. Treatment with recombinant human leptin reverses 
hyperphagia, obesity, hypogonadism, and T-cell immunodeficiency in those with 
congenital leptin deficiency. In addition, leptin replacement for the management of 
lipodystrophy is a promising therapeutic approach. Disappointingly, most obese 
individuals, for unknown reasons, are resistant to the satiety and weight-reducing 
effect of leptin. Studies are on-going looking at how to manipulate the neurohormonal 
pathways to make it an effective anti-obesity pharmacotherapy145;146;238. 
 
  




Resistin (for resistance to insulin) was first described in 2001, whilst 
researching rosiglitazone514. It is a 114-amino acid polypeptide hormone belonging 
to a family of cysteine-rich proteins. Human resistin is only 59% homologous to the 
mouse molecule, which may account for variability between animal and human 
studies, limiting the full understanding of its mechanism of action. Although secreted 
mainly from white adipose tissue in mice, resistin, in humans, is primarily secreted 
from macrophages, then bone marrow, lungs and at a low level, adipocytes249;592. 
Resistin is implicated as a link between obesity and diabetes through the 
augmentation of insulin resistance. In mice, resistin antagonizes insulin-mediated 
glucose uptake within peripheral cells and enhances hepatic gluconeogenesis. 
Treatment with recombinant resistin resulted in insulin resistance, whereas 
administration of an anti-resistin antibody enhanced insulin sensitivity in obese and 
insulin-resistant animals514. It is supposedly regulated by nutritional status with levels 
rising in response to feeding and acute hyperglycaemia and falling in fasting and 
hyperinsulinaemia 226;365;514;515.  
Some animal studies have demonstrated that resistin levels are elevated in 
ob/ob, db/db and diet-induced obesity model rodents while others failed to 
demonstrate similar findings. In some human studies, resistin mRNA levels in 
adipocytes were increased in morbidly obese subjects when compared to lean controls 
with levels correlating positively with BMI and visceral fat area but not waist-hip 
ratio109;118;472. In contrast, other studies have shown no correlation between resistin 
levels and body fat, visceral adiposity or BMI230;496. In children serum resistin levels 
were similar in the obese and nonobese and did not change with body mass index 
over time187;443.  
As resistin is expressed in only small amounts in human adipose tissue, its 
role in obesity and insulin resistance remains unclear. Some have reported that 
resistin is secreted mainly from visceral adipose tissue, particularly “omentum” and 
highly correlates to insulin resistance, arguing that this relationship links it to 
obesity364;365. In addition weight loss studies, have reported reductions in resistin with 
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moderate weight loss and in those treated with gastric banding548;555. At the same time 
others have reported that resistin is not preferentially secreted from visceral tissue but 
is equally present in gluteo-femoral fat and failed to show any correlations to markers 
of obesity301;316;496. Resistin has been positively correlated to insulin resistance with 
levels reported to be 20% higher in those with type 2 diabetes by some human studies 
while others have failed to show any association with markers of insulin resistance 
adding to the confusion of resistin’s role171;257;316;590. Even the effect of insulin 
sensitizers on resistin was variable with rosiglitazone and troglitazone both showing 
signs of down regulation, and metformin and pioglitazone enhancing resistin 
expression172;175;301;374. 
As an inflammatory agent, resistin activates vascular endothelial cells and 
stimulates smooth muscle cell proliferation resulting in atherosclerosis247. Studies 
have confirmed resistin levels to be increased in inflammatory conditions such as 
rheumatoid arthritis and atherosclerosis, and reported that  inflammatory markers 
such as TNF-α, CRP and interleukin-6, were regulated by resistin implying that 
hyperresistinaemia may be a mediator of inflammation rather than a by product442. 
Cardiovascular studies  have identified it as a risk factor for females with coronary 
heart disease and a predictor of future myocardial infarction but not ischaemic 
stroke422;566. Interestingly the studies have shown a positive correlation among 
females but not in males suggesting a possible gender effect112;392.    
 
  
Page | 83 
 
2.5. Visfatin  
 
 Initially believed to be preferentially expressed in visceral fat, visfatin was 
first described by Fukuhara in 2005 who considered it to have insulin-mimetic 
functions173;442;442. After sequence analysis, visfatin was found to correspond to the 
pre-B cell colony-enhancing factor 1 (PBEF1) previously described by Samal468, 
which was responsible for lymphocyte maturation and inflammatory regulation. 
Since, it has been identified as nicotinamide phosphoribosyl transferase, an enzyme 
responsible for nicotinamide adenine dinucleotide (NAD) biosynthesis186. In addition 
to adipocytes, visfatin is expressed in skeletal muscle, liver, bone marrow and 
lymphocytes where it has been linked to inflammatory responses, inhibition of 
apoptosis, and maturation of vascular smooth muscle cells599. Visfatin levels are 
elevated in individuals with type 2 diabetes, glucose intolerance, gestational diabetes 
and severe obesity (BMI >40). It is also noted to be elevated in sepsis, established 
coronary artery disease, and unstable angina with levels appearing to be higher among 
those with established evidence of atherosclerosis or MS334;601.  
Visfatin’s role in insulin regulation and insulin resistance is controversial. It 
was first reported to exert insulin-like activity in a number of cells, and to upregulate 
insulin secretion by 46%. In mice, an injection of visfatin lowered blood glucose, 
while mutations within the visfatin gene can cause glucose intolerance mainly 
through insulin deficiency and a reduction in glucose uptake 
intracellularly33;93;173;248;447. Further studies failed to show similar findings casting 
doubt over visfatin’s role and ending with Fukuhara retracting their original 
findings77;174;447. While supposedly regulating glucose and insulin secretion visfatin 
appears to be regulated by the same, with glucose infusions increasing visfatin levels 
and insulin or somatostatin suppressing it207.   
In patients with type 1 or type 2 diabetes, visfatin levels were significantly 
elevated in those with a longer duration of disease. In those with type 2 diabetes, there 
even appeared to be a positive correlation with glycated haemoglobin levels 
(HbA1C)
336, although other studies seemed to indicate the inverse particularly in    
type 1 diabetes536.   
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In some human studies, visfatin expression within visceral adipose tissue 
appeared to positively correlate with BMI, while subcutaneous fat visfatin negatively 
correlated with BMI implying a link between visfatin, visceral adiposity and thus 
insulin resistance. Others studies have failed to demonstrate the same differences 
reporting that visfatin expression was equal in all fat tissue, while some failed to 
establish any relation to other anthropometric measures or insulin 
resistance61;92;407;599. Visfatin plasma levels increase in response to a high-fat intake, 
indicating that it may play a significant role in diet- or obesity-induced insulin 
resistance206;210;214;554. Responses to weight loss studies have been variable with some 
reporting visfatin levels falling and others rising in response to weight loss through 
dieting or bariatric surgery66;93;182;210.   
As a pre-B cell colony-enhancing factor 1, visfatin is believed to be an 
inflammatory mediator. It has been shown to positively correlate to interleukin-6, 
CRP and TNF-α, and has been reported to be elevated in inflammatory conditions 
(i.e. rheumatoid arthritis, acute lung injury, inflammatory bowel disease and 
myocardial stress). In rodent studies it was implied that an acute infusion of visfatin 
at the time of myocardial injury may be protective but this is yet to be described in 
human studies303;327;399.  
There are a number of inconsistencies among the different studies of visfatin, 
and the role of this adipokine in obesity, insulin resistance and inflammation is yet to 
be clearly defined.  
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2.6. Retinol Binding Protein 4 (RBP4) 
 
Retinol binding protein 4 (RBP4) is a 21 kDa protein which acts as a specific 
carrier for retinol in blood. It is one of the proteins that solubilize and stabilize the 
hydrophobic and labile metabolites of retinoids in aqueous spaces within extra- and 
intra-cellular spaces. Its physiological function appears to be binding to retinol and 
preventing its loss via kidneys. It was first reported as an adipocytokine in 2005 
during investigations of muscle-related insulin resistance in mice devoid of the 
glucose-transporting protein (GLUT) 4. Although mainly produced in liver, it is also 
known to be secreted by adipocytes with enhanced production in obesity, causing 
speculation of another link for impaired insulin sensitivity589. In rodent studies, RBP-
4 levels were inversely proportional to the amount of GLUT4 expressed in mice 
adipose tissue. Insulin sensitivity is improved and GLUT4 restored when circulating 
RBP4 levels fall, by natural measures or  through the administration of a synthetic 
retinoid, and insulin resistance is induced when recombinant RBP4 
administered195;522.   
Cho et al. reported that plasma concentrations of RBP4 were higher in 
individuals with impaired glucose tolerance or type 2 diabetes than in normal glucose 
tolerance. No difference in RBP4 levels were noted between those with glucose 
intolerance and severe diabetes94. A different study demonstrated RBP4 to correlate 
with severity of insulin resistance in obese subjects with impaired glucose tolerance 
or type 2 diabetes, as well as in non-obese, non-diabetic persons with a strong family 
history of type 2 diabetes195. RBP4 levels rise with increasing numbers of MS 
components and correlated strongly to BMI, blood pressure, serum triglyceride and 
HDL-cholesterol levels195. RBP4 was reported to be more highly correlated with 
waist-to-hip ratio and visceral fat than with BMI.  However, Janke et al. reported that, 
RBP4 mRNA is down-regulated in the abdominal subcutaneous adipose tissue of 
obese women, although circulating RBP4 levels were similar in lean, overweight, and 
obese females. Exercise may reduce RBP4 levels but only in the presence of 
improved insulin resistance. 
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Despite several studies identifying close associations between RBP4 and 
insulin resistance, a number of others were unable to demonstrate similar findings. In 
healthy insulin resistant individuals plasma RBP-4 levels failed to correlate with 
insulin levels or measures of insulin resistance. Another group failed to show changes 
in circulating RBP4 levels despite a 5% body weight loss although there was positive 
correlation to GLUT4 expression with down regulation in those losing weight. In a 
Japanese study Takashima et al could find no correlations of RBP4 levels to fasting 
blood glucose, waist-to-hip ratio, BMI, systolic blood pressure, or fasting insulin, in 
their study group, regardless of a family history of diabetes521. It remains uncertain 
as to why the differences exist among similarly conducted human studies.  
Of interest is a German study investigating 220 individuals with and without 
type 2 diabetes, RBP4 levels appeared to correlate with the degree of renal function 
rather than diabetes, implying that renal function not insulin resistance might affect 
RBP4 levels. Similar results were reproduced by a different group who reported 
RBP4 to be affected by renal but not hepatic dysfunction168;234. Another study 
correlated high circulating RBP4 levels with elevated intrahepatic fat deposits and 
presumed the changes were related to hepatic insulin resistance511.  Certainly, future 
studies are needed to clarify how RBP4 affects insulin resistance in rodents, whether 
it does in man, and if so to define the role it may play in the development of MS, type 
2 diabetes, and even CVD. 
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2.7. Plasminogen Activating Inhibitor type 1 (PAI-1) 
 
Plasminogen activating inhibitor type 1 (PAI-1), a linear glycoprotein with a 
molecular weight of 48,000, is an inhibitor of plasminogen activators and inhibits 
fibrinolytic activity288;490. Initially believed that  PAI-1 was solely synthesised by 
endothelial cells and the liver, it is now known to be produced in smooth muscle cells, 
fibroblasts, monocytes/macrophages, endometrium, peritoneum, liver cells, 
mesothelial cells, cardiac myocytes and adipose tissue (especially intra-abdominal 
visceral fat which is a major source)357;465;490. Its production within adipose tissue is 
mainly in the stromal compartment and is modulated by macrophages responding to 
oxidative stress, TNFα, loss of circadian rhythm and metabolic markers such as 
hyperinsulinaemia, hyperglycaemia, and hypertriglyceridaemia. PAI-1 is mainly 
stored within platelets from which the active form is released when platelets are 
stimulated by thrombin.  Active PAI-1 is unstable, with a half-life of 30 minutes. For 
transportation it is usually stabilized by binding to vitronectin.  
Elevated plasma PAI-1 levels are associated with the destabilization of 
coronary disease and development of acute coronary syndromes and myocardial 
infarction. Raised plasma PAI-1 concentrations are positively associated with 
myocardial infarction in individuals with stable angina and angiographic evidence of 
progressive CAD in young men with a history of myocardial infarction. Despite 
raised plasma PAI-1 levels being identified as a predictor of myocardial infarction, 
its predictive ability resolves once adjustment for components of MS are considered, 
implying that MS may be a prerequisite for elevated PAI-1 in individuals prone to 
atherothrombosis56.  
PAI-1 levels are reported to be lower during the day than at night, an 
observation which may explain the higher incidence of myocardial infarction in the 
early morning hours, as  PAI-1 activity favours fibrin production by disturbing 
equilibrium between fibrin generation and fibrinolysis 19.  In addition, PAI-1 has an 
effect on many other systems including ovarian function, cancer progression and 
insulin resistance298;531.  
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In rodent models, PAI-1 prevented fat accumulation in PAI-1 deficient mice 
through dietary modification or genetic manipulation and PAI-1 inhibition appeared 
to improve insulin sensitivity by enhancing intracellular glucose uptake340. The lack 
of increased adiposity was reported to be due to an increase in metabolic rate, total 
energy expenditure and thermogenesis implicating that PAI-1 may be involved in 
controlling fat accumulation through a central effect on the hypothalamic 
paraventricular nucleus which controls satiety523. 
The plasma concentration of PAI-1 is elevated in obese subjects with insulin 
resistance, type 2 diabetes, or MS, with levels increasing with each increase in 
components of MS or presence of microalbuminuria375.  PAI-1 levels also fell with 
improvement in insulin resistance, reduction in insulin and weight loss28.  Population 
studies have shown that raised PAI-1 levels are a predictor for the development of 
diabetes154.  In humans, a direct correlation between visceral fat and PAI-1 levels 
exists, independent of insulin sensitivity, insulin or triglyceride levels490. Exogenous 
insulin was noted to reduce plasma PAI-1 activity in type 2 diabetes without 
improvement in glycaemic control and suppresses the secretion of both insulin and 
insulin precursor molecules, such as proinsulin and split proinsulin which have also 
been noted to affect PAI-1 expression254;288. Genetic polymorphisms in PAI-1 have 
been linked with obesity, insulin resistance, and increased triglycerides in some 
studies but not in others377. 
Inhibition of PAI-1 is associated with enhanced cardiac recovery following 
myocardial infarction and reduced aortic wall thickening as promoted by angiotensin 
II and a high-salt diet in mice. Paradoxically, PAI-1 inhibition was also associated 
with increased growth of atherosclerotic plaques in mice predisposed to 
atherosclerosis. In some studies, PAI-1 increased the risk of recurrent myocardial 
infarction, atrial fibrillation, and progression of coronary atherosclerosis following 
myocardial infarction while in other studies no association to subsequent coronary 
events was noted215. Some believe that the enhanced expression and release of       
PAI-1 from visceral adipose tissue is the link between this adipocytokine and 
cardiovascular disease especially as it is highly associated with adverse metabolic 
risk factors16.  
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PAI-1, the main inhibitor of the fibrinolytic system, could be a component of 
the MS. The mechanisms linking the two are complex and probably interrelated, with 
several inducers possibly acting at several sites of synthesis. Studies have indicated 
that PAI-1 might be involved in the development of obesity, insulin resistance and 
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2.8. C-Reactive Protein 
 
 C-reactive protein (CRP) is an acute-phase reactant that is produced in 
response to acute injury, infection or other inflammatory stimuli. CRP has been 
shown in numerous cohort and case–control studies to be a measure of underlying 
systemic inflammation and a strong associate of future cardiovascular events 
particularly myocardial infarction, ischaemic stroke and peripheral vascular disease, 
stimulating interest in a possible role for CRP measurement in CVD risk assessment 
in clinical practice448;449;451.  
Acute inflammation triggers the release of cytokines which in turn stimulate 
the substantial production of CRP largely through interleukin-6. Once the 
inflammatory stimulus has passed, CRP levels return to baseline. Many conditions 
cause mild elevation in CRP such as low grade inflammation, smoking, pollution, 
hormone replacement therapy and atherosclerosis which are not picked up by 
standard CRP assays430.  Newer assays are up to one hundred times more sensitive 
and capable of measuring these smaller changes. To distinguish it from standard CRP 
these assays are known as high-sensitivity CRP (hsCRP). CRP has been demonstrated 
to be a good predictor for CVD risk, and the development of type 2 diabetes430. In the 
Physicians’ Health Study men in the highest CRP quartile had an increased risk of 
MI (3x), and ischaemic stroke (2x), as those in the lowest quartile450. Similar results 
were seen in the Reykjavik Study where over 6000 subjects were studied106. The 
Atherosclerosis Risk in Communities (ARIC) study demonstrated that the risk of 
CHD incrementally increased depending on the baseline hsCRP with it being 2.5 
times higher in those with a baseline level of >3mg/L as compared to <1mg/L. Risk 
changes were independent of  age, gender, and ethnicity48.  
In MS, many studies have confirmed that CRP levels were strongly associated 
with insulin resistance, blood pressure, plasma glucose, low HDL-cholesterol, and 
triglycerides. A linear relationship was established between the increasing number of 
components of MS and rising CRP levels153;160;596. The strongest associations were 
observed between CRP levels, central adiposity, and insulin resistance. The link 
between MS and CRP was so strong that at one point there had been considerations 
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to add it as a component of MS. Controversy remains on where best to incorporate it 
as some studies have failed to show that its addition to current criteria (IDF) would 
be of benefit. In fact in a Finnish study the addition of hsCRP was potentially an 
inferior identifier in males239.    
CRP is believed to play a role in facilitating the activation of endothelial cells 
and promoting progression of atherosclerosis by impairing endothelial vasoreactivity 
and reducing endothelial nitric oxide synthase activity155;156;524;524. In rodent studies, 
the injection of CRP maintained sustained hepatic CRP expression and increased 
systolic and mean arterial blood pressures. Previous experiments had confirmed that 
CRP reduced prostacyclin levels, a known vasodilator, leading to observations that 
CRP may be a cause of hypertension202;557. CRP has been shown to increase 
circulating levels of PAI-1 contributing to increased thrombin formation. In a study 
of 1001 males with angiographically proven atherosclerosis, plasma CRP levels were 
negatively correlated to adiponectin levels confirming results seen in wild-type 
mice403.  
CRP exerts a proinflammatory effect on monocyte–macrophages activating 
proinflammatory cytokines, enhancing oxidized LDL uptake as well as inhibiting 
cholesterol efflux, and activating transcription factors which are pivotal in the 
activation of proinflammatory genes. 
Certainly the evidence supporting CRP as an important marker for enhanced 
cardiovascular risk among individuals with obesity, MS, or type 2 diabetes is 
overwhelming but, would targeting CRP help protect against CVD? This is yet to be 
formally investigated. 
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3. CHAPTER 3: Dietary Interventions 
 
3.1. Introduction – NCEP recommendations 
 
As the prevalence of obesity increased over the past 20 years, the difficulties 
faced by overweight patients and their health care practitioners have become 
apparent. Less than 25% of those attempting to lose weight actually reduce their 
caloric intake or increase exercise as currently recommended. Those who 
successfully lose weight have difficulty maintaining the weight loss and will usually 
re-accumulate the shed weight within two years. Consequently, an industry has 
opened providing all sorts of weight loss products and services complicating and 
confusing the choices. Most diets are poorly researched with scanty evidence for their 
effectiveness. Those which are well researched are hindered by compliance and 
concordance issues thus limiting an individual’s ability to make an informed and safe 
choice568. Diets are an integral part of life with some of the first appearing as part of 
religious instructions such as the Jewish Kashrut by the prophet Moses, 
recommending, ‘bread, wine, milk, honey; quadrupeds with cloven hooves that 
ruminate, non-preying birds, and fish with scales, and prophet Mohammed (peace be 
upon him) in the description of halal food which excludes pork and its by-products, 
alcohol and non-slaughtered meat225;384.  
The first commercially produced diet was by William Banting (1797-1878) 
the undertaker who made the Duke of Wellington's coffin. Banting was known to be 
so obese as to be almost spherical. He had tried numerous diets and treatments 
including exercise, starvation and purging in order to off-load his terrible weight with 
no success. Finally, believing he was becoming deaf, Banting presented to William 
Harvey, an ENT surgeon, who diagnosed his problem to be excessive fat compressing 
his airways and prescribed a low ‘farinaceous’ diet (Table 15). Within a year he had 
lost 50 pounds and 12.5 inches of his waist. The diet Banting was instructed to follow 
formed the basis of his book, “Letter on Corpulence”.  which he published for the 
general public, and is the forerunner to the Atkins diet225. In his own words he 
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mentioned "I can now confidently say that QUANTITY of diet may be safely left to 
the natural appetite; and that it is the QUALITY only which is essential to abate and 
cure corpulence”.  
Table 15: William Banting's diet 
 
William Banting's Diet (1864)  
(Losing 46lb ) 
Breakfast: Four or five ounces of beef, mutton, kidneys, broiled fish, bacon or cold meat of 
any kind except pork. One small biscuit or one ounce of dry toast. A large cup 
of tea without milk or Sugar. 
 
Lunch: Five or six ounces of any fish except salmon, any meat except pork, any 
vegetable except potato. Any kind of poultry or game. One ounce of dry toast. 
Fruit. Two or three glasses of good claret, sherry or Madeira. (Champagne, port 
and beer were forbidden.)  
 
Tea: Two or three ounces of fruit. A rusk or two. A cup of tea without milk or sugar. 
Supper: Three or four ounces of meat or fish as for lunch. A glass of claret, or two. Night-
cap (if required): A tumbler of grog (gin, whisky or brandy with water but 
without sugar) or a glass or two of claret or sherry. 
Adapted from “Eat Fat and Grow Slim”341.  
His book became a best seller with the “Banting” being the most popular 
method for weight loss. Unfortunately his diet was never fully understood by the 
medical profession and not until the twentieth century was further interest cast in such 
a direction50.  
Obesity can develop when an imbalance exists between energy intake and 
energy expenditure, a simple equation that appears to be poorly understood or 
interpreted. Total energy expenditure can be divided into the following components: 
1. Resting metabolic rate, the largest single component of energy 
expenditure. Approximately 60% to 80% of the variation in resting 
metabolic rate can be explained by fat-free body mass; 
2. The thermic effect of food, or the increase in energy expenditure that 
occurs after eating; and 
3. The energy expended in physical activity which varies due to differences 
in body mass. The energy expended in physical activity is an important 
component in understanding both. 
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Over the centuries, obesity has always been considered to be due to overeating 
and individual behaviour. Management plans focused on behavioural changes and 
limiting caloric intake with limited or no success. Individuals continued to increase 
in weight and researchers focused on looking at modifiable external factors as well 
as quantity and quality of caloric intake. Epidemiological studies investigating the 
cause of increasing obesity have identified a number of factors attributed to 
urbanisation, including industrialisation which promoted the use of automobiles for 
transport and reduced physical activity, increasing dependency on prepared food, 
with the availability of reasonably priced, fast, energy-dense food83. Where obesity 
was previously seen in higher socioeconomic groups, more recent trends identify the 
majority of obese or overweight individuals to be among the lower socioeconomic 
classes in developed countries, with developing countries still following old trends 
with the higher socioeconomic groups sporting larger BMIs504. These trends appear 
to be more prominent among the female population, although the difference is less 
marked in more recent years360.  
Table 16: American Heart Association 2006 Diet and Lifestyle goals 
 
 
 Balance calorie intake and physical activity to achieve or maintain a 
healthy body weight. 
 Consume a diet rich in vegetables and fruits. 
 Choose whole-grain, high-fibre foods. 
 Consume fish, especially oily fish, at least twice a week. 
 Limit  intake of saturated fat to <7% of energy, trans fat to <1% of energy, 
and  cholesterol to <300 mg per day by 
• choosing lean meats and vegetable alternatives; 
• selecting fat-free (skim), 1%-fat, and low-fat dairy products; and 
• minimizing intake of partially hydrogenated fats. 
 Minimize intake of beverages and foods with added sugars. 
 Choose and prepare foods with little or no salt. 
 If you consume alcohol, do so in moderation. 
 When eating food that is prepared outside of the home, follow the AHA 
Diet and Lifestyle Recommendations. 
 
 
American Heart Association 2006 Diet & Lifestyle Goals for Cardiovascular Risk Reduction – 
adapted from324.  
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Consequently strategies to limit the rise in obesity and its associated 
cardiovascular consequences required revision, targeting causative factors. Although 
MS is a complicated multifactorial entity, it is clear that dietary and lifestyle changes 
are central to its management. A number of recommendations have been set based on 
what is attributed to be a healthy lifestyle, but there is no clear consensus to what “an 
ideal diet” is.  The American Heart Association published non-specific goals aimed 
at the general population, including children, which encouraged consuming an overall 
healthy non-atherogenic diet, aiming to achieve the recommended lipid and blood 
pressure targets, stop smoking and maintain activity (Table 16). Recommendations by 
the IDF were equally as vague, including energy restriction, increased physical 
activity, reduction in fat intake, increased fibre intake, and salt restriction. 
The ATP III dietary recommendation for therapeutic lifestyle changes stated 
that an individual’s daily caloric intake be divided as below:- 
 Carbohydrate intake:   50-60% of total energy  
 Total fat intake    25-35% of total energy 
o Saturated fat    <7% of total energy 
o Polyunsaturated fat  <10% of total energy 
o Monounsaturated fats  <20% of total energy 
o Cholesterol    <200mg/day not <300mg 
 Protein intake    15% of total energy 
ATP III recommended that any carbohydrate intake should be complex 
carbohydrates including whole grains, fruits and vegetables and daily exercise should 
be enough to consume 200Kcal per day. Such recommendations are reasonable but 
focus mainly on reducing LDL-cholesterol and possibly adversely affect other 
parameters, triglycerides and HDL-cholesterol, which are the abnormalities seen in 
MS. It is thus appropriate to assume that alternative dietary recommendations may be 
more suitable in MS. Physicians, dieticians and others working within the health 
industry should look at alternative methods that may be more rewarding. The 
population, in general, are disenchanted with current dietary recommendations which 
they find slow and unrewarding. As a result more and more have turned to alternative 
regimens which promise a quick fix. The evidence behind these diets is small and it 
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is therefore difficult to assess which is helpful long term.  Of the diets which have 
particularly gained in popularity, are the low carbohydrate, high fat diets such as the 
Atkins’ diet which has been around since the 1970’s and the South Beach diet. In the 
dietary world interest has particularly turned to the Mediterranean life-style which 
consists of a diet that contains complex carbohydrates, monounsaturated fats and at 
least the recommended five portions of fruit and vegetables per day. 
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3.2. The Effect of Diet on Parameters of the Metabolic Syndrome 
 
Weight loss has a profound effect on a number of cardiovascular risk markers 
and consequently on MS. A 10kg reduction in weight can potentially reduce total 
morbidity by 20% in addition to reductions in LDL-cholesterol (15%), triglycerides 
(30%) and a rise in HDL-cholesterol (8%) 479. A 5% weight reduction theoretically 
reduces the age-adjusted overall mortality by 12%. Weight loss of 1kg is professed 
to reduce systolic blood pressure by 1mmHg with reductions sustained for up to 3 
years 41;191;387.  In a study of 41 individuals with MS placed on dietary regimens as 
per NCEP-ATP III guidelines, two thirds (10 out of 15) of those who achieved >10% 
weight loss no longer fitted the criteria for MS despite maintaining a BMI that was 
still considered obese compared to only 20% (5 out of 26) in those who lost <10% 
total body weight378. Another study  demonstrated that a 6.5kg weight loss through  a 
very low calorie diet for only 4 weeks could reduce systolic blood pressure 
(11mmHg), fasting glucose (1mmol/l), triglycerides (1.06mmol/l), and total-
cholesterol (0.96mmol/l)41;88. In glucose intolerant individuals a combination of diet 
(low-fat, high-carbohydrate) and exercise achieving 5% weight loss reversed 
progression to type 2 diabetes with a 39% reduction in incidence of diabetes39;409.  In 
the Diabetes Prevention Program, every 1kg weight reduction was associated with a 
16% relative risk reduction in diabetes incidence 213. In the Nurses’ Health Study 
lifestyle changes including lack of smoking, regular exercise, healthy eating and 
moderation in alcohol intake reduced the risk of diabetes, CVD and CHD by 91, 74 
and 82% respectively245. Weight loss with the aid of medication has similarly reduced 
the incidence of diabetes. The “xenical in the prevention of diabetes in obese subjects 
(XENDOS) study” randomized 3,300 obese individuals without diabetes to treatment 
with orlistat or placebo. After a 4 year follow-up orlistat reduced the incidence of 
diabetes by 37%. Twenty-one percent of the participants had impaired glucose 
tolerance and it was among this group that the effect was best noted535.   
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3.3. The Effect of Diet on the Lipid Profile in Metabolic Syndrome 
 
 
The National Obesity Forum has published on its website the improvements 
expected from a 10% total body weight loss. For lipids the expected changes are:-  
  10% decrease in total cholesterol  
 15% decrease in LDL cholesterol  
 30% decrease in triglycerides  
 8% increase in HDL cholesterol 5 
 
In the UKPDS 2,906 patients had lipid profiles measured at diagnosis of 
diabetes and at 3 months following diet therapy. Average weight loss was 4.5kg, with 
a subsequent 3mmol/l reduction in plasma glucose, and 2% in HbA1c. Changes in 
total cholesterol, LDL-cholesterol,  HDL-cholesterol and triglycerides were -5%, -
6.4%, +2% and -23% in men and -2%, -2.3%, +1% and -13% in women. Greatest 
changes were noted among those with highest initial values for total cholesterol, 
LDL-cholesterol and triglycerides and lowest values of HDL-cholesterol. Of note, 
less than 2% of subjects in the UKPDS were on lipid lowering therapy346;544. In a 
systematic analysis of trials investigating lipid outcomes in weight loss, every 10 kg 
weight reduction lowered total cholesterol by 0.23mmol/l. Similar changes were seen 
for LDL-cholesterol and triglycerides but no correlation was noted for changes in 
HDL-cholesterol. Once more, results were more favourable in those achieving the 
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3.4. The Effect of Weight Loss on Inflammatory Markers 
 
Weight loss not only improves classical cardiovascular markers, but helps 
reverse some of the inflammatory changes seen in obesity. Studies have demonstrated 
that higher concentrations of inflammatory markers (interleukin 6, TNFα) in obese 
individuals, positively correlated to visceral obesity, and improved with weight 
reduction programmes388;487;603.  An Italian study of premenopausal obese sedentary 
females placed on a year’s programme of diet, exercise and counselling demonstrated 
reductions in TNFα (-31%), interleukin-6 (-47%), P-selectin (-30%), intercellular 
adhesion molecule 1 (-26%) and vascular cell adhesion molecule (17%) in addition 
to improvements in all parameters including insulin and glucose with a total body 
weight loss of 10% 603. Another study comparing diet-induced weight loss, exercise, 
or diet with exercise over 18 months in 300 elderly individuals reported reductions in 
hsCRP, interleukin-6 and TNFα in all three groups although the reductions were not 
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3.5. Standard Dietary Recommendations  
 
"A patient can be treated successfully even though he does not know what a 
calorie is, what a gram represents or the meaning of the words carbohydrate, protein 
and fat. Indeed, many of my patients cannot read or write. But I think if one has a 
disease, it is more fun to know something about it."  —E.P. Joslin, MD, 1934270;351 
Recommendations for weight loss and particularly MS have traditionally 
focused on low fat intake with overall fat intake making up 15-20% and 
carbohydrates 65% of the total daily caloric intake. Dietary fat is the most energy-
dense macronutrient in the diet, providing 9 calories per gram, as opposed to 4 
calories per gram for carbohydrate or protein.  Fat is considered to add flavour and 
palatability to food encouraging a greater level of consumption. Additionally, 
mechanisms behind fat absorption and metabolism are more efficient than those for 
carbohydrate and protein requiring less caloric expenditure and thus providing more 
for storage. In a meta-analysis of studies focusing on weight loss and dietary 
composition Bray and Popkin concluded that high fat diets encouraged obesity by 
enhancing passive over-consumption of energy and increasing the energy density of 
the diet70.  They felt that low fat isocaloric diets were likely to be as effective if not 
more so than their counter-parts on a high fat diet partly through enhanced satiety as 
low fat diets tended to contain more complex carbohydrates. Astrup et al, in an 
analysis of 16 trials, reported similar results, claiming that a reduction in fat intake, 
without calorie adjustment, did result in greater weight loss than isocaloric higher fat 
diets37;38;149.  
In the Women's Health Initiative of approximately 49,000 females, half were 
placed on dietary intervention including a reduction in fat intake from 30 to 20% of 
total daily calories, increased fruit and vegetable consumption to five or more daily 
servings, and increasing grains to six or more daily servings, while half had no dietary 
change. Women in the intervention group lost on average 2.2kg weight in the first 
year (p<0.001) and maintained the weight for the 7.5 years of follow-up242. Fat 
analysis from the self-completed food frequency questionnaires confirmed that a 5% 
increase in saturated fat increased the risk of CHD by 15%, as compared to the 
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equivalent carbohydrate intake in calories thus strengthening the argument for low 
fat diets or substituting unhydrogenated unsaturated fats for saturated fats246;413.  
One disadvantage of carbohydrate-loaded diets is that they contribute to 
increasing serum triglycerides and reducing HDL-cholesterol levels. Forty-six 
subjects with MS, randomised to a low-fat, complex-carbohydrate or low fat simple 
carbohydrate diet for six months, lost  more weight on complex carbohydrates with 
no change in LDL-cholesterol, an increase in triglycerides (higher with simple 
carbohydrates), and a fall in HDL-cholesterol429. Reaven and colleagues studied low-
fat, high-carbohydrate diets and reported increases in post-prandial glucose, insulin, 
triglycerides and VLDL-cholesterol and reductions in HDL-cholesterol. They felt 
that the national dietary recommendations were potentially harmful to individuals 
with diabetes or insulin resistance and could enhance cardiovascular risk104;105;330;333. 
A review of carbohydrate-induced dyslipidaemia confirmed that 
hypertriglyceridaemia did sequentially increase with incremental increase in dietary 
carbohydrate content. Although reductions in total and LDL-cholesterol levels were 
demonstrated, there was an increase in the small dense atherogenic LDL subtypes. 
Regular moderately intense exercise could negate these changes with evidence 
attained from studying athletes who consumed copious amounts of carbohydrate  
while training and middle aged men who regularly endurance-trained232;580;581. 
Refined high carbohydrate intake, has been shown to be associated with elevated 
blood pressure and MS43;602. Dietary analysis from the Nurses’ Health Study 
associated a high glycaemic load intake with a greater prevalence of cardiovascular 
risk factors 333. 
Although a reduction in fat intake with enhanced carbohydrate intake may 
promote weight loss and reductions in LDL-cholesterol, there is risk for substituting 
refined sugars which even when isocaloric may promote hyperinsulinaemia, 
dyslipidaemia and a worsened metabolic picture.  
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3.6. Low Glycaemic Index/Load Diets 
 
3.6.1. Definition of Glycaemic Index and Glycaemic Load 
 
The Glycaemic Index (GI) is expressed as a percentage, but it really represents 
the relative rate of entry of glucose from the gut into the bloodstream compared with 
the rate of entry when the glucose is derived from digestion of a reference 
carbohydrate. The GI is defined as the ratio of: 
 
Integrated increase in blood glucose in a 2h 
period after ingestion of known quantity of a 
test food x100  
Integrated increase in blood glucose level in a 
2h period after ingestion of known quantity of 
a *reference food5 
 
Carbohydrates are scored as high GI if they score >70, moderate if between 
40 and 70, and low if <40. As the glycaemic index is a marker of the speed glucose 
is absorbed into the body, foods with a low GI e.g. beans, grains and most vegetables, 
which are absorbed slowly over a prolonged period, are meant to be better for weight 
management and cardiovascular risk. Foods high in the glycaemic index e.g., white 
bread, most cereals and sweets are rapidly absorbed and may result in fluctuations in 
blood glucose levels that could potentially be diabetogenic or inflammatory. The 
definition was introduced in the 1980s as a means for predicting post-prandial glucose 
levels and combating glucose intolerance. It built on Burkitt and Trowell’s dietary 
fibre hypothesis which stated that foods that are more slowly absorbed (low GI) may 
have metabolic benefits in relation to diabetes and to the reduction of CHD 
risk79;263;264. The GI is good for qualifying a type of food, but even low GI foods can 
promote weight gain and dysmetabolism if eaten in large quantities (i.e. low GI 
spreads are glucose-deficient but fat rich), and weight reflects calories.  
                                                          
5 The initial reference food used was  glucose, but has now been changed to white bread                                                                                                
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Therefore the Glycaemic Load (GL) is a better predictor of the impact of 
carbohydrate-containing food on post prandial insulin levels as it is a measure of both 
quality (GI) and quantity of carbohydrate ingested.  
Glycaemic load (g) = (Glycaemic index of food (%) X Carbohydrate (g) of that food) / 100% 
The increased glycaemic load seen in today’s diets is partly due to the 
increased consumption of refined carbohydrates. Although GI is a tool which alerts 
health-conscious individuals to alternative beneficial carbohydrates, it has been 
criticised in causing more confusion and dietary restriction, encouraging failure and 
defeatism. The use of GI in mixed meals is limited as the differences in glycaemic 
indices between foods is lost when combined185. High GI carbohydrates will dilute 
the effect of the lower GL components. Fat within a meal can is believed to alter 
glycaemic response although some studies in which 8–24g fat was fed in mixed meals 
containing 38–104 g carbohydrate, reported minimal effects on the predicted 
glycaemic response264;575.  
 
3.6.2. Benefits of Low Glycaemic Load 
 
The GL of a meal influences appetite through its effect on hormonal 
regulation. Many studies have confirmed that ingestion of meals containing 
carbohydrates low in GL reduced the average caloric intake by 20% in comparison 
to the high GL diets. 
In randomised crossover studies subjects placed on low GL diets experienced 
less hunger, reduced their total caloric intake by 25% and improved their basal energy 
expenditure. In addition, serum triglyceride levels dropped by 35%, while these 
increased by 28% in the high GL groups60;129. Other studies have proven that low GL 
diets were more effective at weight loss, improved cardiovascular risk and reduced 
the hyperinsulinaemia associated with insulin resistance, a key factor in MS. There 
are knock-on favourable changes in other parameters of MS including blood pressure, 
dyslipidaemia and markers of inflammation67;317;333;339;571. Data from NHANES III 
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demonstrated an inverse relationship between GL & HDL cholesterol, and GI & 
HDL-Cholesterol161. A cross-sectional analysis of people without diabetes taking part 
in the Health Worker Cohort Study, described the improvement in lipid profiles by 
being on low GI or GL diets in  5,000 plus participants122. Similar results reported in 
the Nurses’ Health Study where higher GL diets were associated with increased risk 
of CHD. Interestingly the relationship was more obvious in those with higher BMIs 
despite adjustments being made for other risk factors333.  
Two systematic Cochrane reviews by Thomas and Elliott assessing the effect 
of low GI and GL diets on obesity, the overweight and diabetes concluded that obese 
individuals following low GL diets experienced more weight loss and improvements 
in lipid profiles, glycaemic control, and total fat mass, than those on low-fat, high-
carbohydrate diets, regardless of whether the intake being hypocaloric or ad 
libitum527;528.  
In a randomised controlled trial comparing the effects of a low GL diet to a 
low fat diet, individuals with glucose intolerance were more responsive to a low GL 
regimen while no similar advantage was seen in those with normal glucose tolerance, 
suggesting that low GL intake may be better suited for those with hyperinsulinaemia 
or glucose intolerance132. In a meta-analysis of 14 randomised controlled trials the 
positive effect of low GI intake for individuals with diabetes was equal to the benefits 
provided by additional post-prandial hypoglycaemic agents reducing glycated 
haemoglobin by an additional 0.5% as compared to standard diets67;132.  
In the Zutphen study, the group implied that the benefits of GL are only seen 
among females when failing to demonstrate and an association between low GI intake 
and lipid profile, hyperinsulinaemia or glucose levels in men aged 64-84years549. The 
EPICOR study, a cohort of the European Prospective Investigation into Cancer and 
Nutrition study, reported that Italian women with high GI intake had a higher risk for 
CHD, but similar findings were not demonstrated for men494. Reports from the 
National Diet and Nutritional Survey suggested that the lack of association may be 
age related as the group failed to display any benefits of a low GI diet on weight loss 
or cardiovascular risk reduction among those aged 65 or over368.  
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By reducing GI and GL within dietary components, there is a natural tendency 
to increase protein and fat intake which can be beneficial, depending on the type. 
Diets rich in protein improve HDL-cholesterol to triglyceride ratios and promote 
satiety312. Monounsaturated fatty acids (MUFA), which are typically seen in 
Mediterranean diets, are useful in lowering LDL-cholesterol without deleterious 
effects on HDL-cholesterol184. In addition the lower carbohydrate content decreases 
the post-prandial glucose surge and insulin response maintaining euglycaemic levels 
and reducing the risk of progression to insulin resistance and type 2 diabetes144;313. 
These observations are additional to improvements in insulin resistance due to weight 
loss311.   
Low GI and GL intake has been implicated to be protective in chronic 
diseases, but a meta-analysis of 37 prospective cohort studies concluded that the 
protection against heart disease or diabetes, attributed to such diets, was similar to 
that seen by increasing whole grain or high fibre intake and that the effect was not 
diet specific but as a result of the reduced surge in post-prandial glucose51. Another 
meta-analysis of 39 cohort or case-control studies examining the association of GL, 
GI and glucose loading to various neoplastic conditions, reported a protective benefit 
of these diets for colorectal and endometrial carcinomas, but not breast or  pancreatic 
cancer190. Others have reported a risk reduction of up to 53% in breast cancer with 
low GL and GI diets308;495. Furthermore evidence suggests that the inclusion of 2 oily 
fish meals each week can help prevent cardiovascular disease through the effects of 
omega-3 polyunsaturated fatty acids222, and inclusion of at least 5 servings of fruit 
and vegetables a day has been a widely accepted recommendation for cardiovascular 
disease  and cancer prevention. 
 
Low GL and GI diets have been reported to have favourable effects on 
cytokines and markers of sub-clinical inflammation seen in MS and obesity. The 
majority of studies available are either observational or cohort. In a cohort of 244 
healthy females, dietary glycaemic load was significantly and positively associated 
with plasma hsCRP independent of all other conventional risk factors for ischaemic 
heart disease331. In the Health Professionals’ Follow-up Study, adiponectin was 
identified to be low in individuals with high GL and low dietary fibre intake and 
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increased by up to 19% in those on high fibre, low GL diets432. Other studies have 
suggested that by reducing plasma free fatty acids, low GL diets  may suppress the 
release of signalling inflammatory cytokines such as TNF-α and IL-6 from adipose 
tissue.  
Indeed if low GL/GI diets prove to be effective in reducing markers of 
inflammation in addition to their benefit in weight loss, insulin resistance and 
dyslipidaemia, then it would be reasonable to use it for standard dietary 
recommendation instead of current advice. 
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3.7. The Mediterranean Diet 
 
The Mediterranean diet is considered to be closely linked or even synonymous 
with low GL or GI diets. Its benefits were first highlighted by A Keys, when reporting 
on the Seven Countries Study, possibly the first to examine systematically the relation 
among lifestyle, diet, and the rates of heart attack and stroke in contrasting 
populations. Over 12,000 healthy men from different countries were studied. It was 
identified that the Greeks, despite a diet which consisted of 40% fat intake, had the 
lowest cholesterol levels and least reported cardiovascular events. Studying their diet 
further it was noted that most of the fat intake was derived from olive oil and olives. 
The remaining caloric intake came from cereals, vegetables and generally “blue 
fish”6, with something of meat and derivatives, as well as a modest amount of wine. 
As most Mediterranean countries appeared to share similar dietary habits, the name 
“Mediterranean Diet” evolved (Table 17)30;280.  
An important part of the Mediterranean diet is the quality, not quantity, of fat 
intake. It encourages the ingestion of monounsaturated fats, found in seafood, olive 
oil and poultry, in preference to animal fats which are rich in the saturated form. 
Whether qualifying the type of fat within a diet has any benefits is yet to be fully 
proven. In one 28-day study individuals were randomised to diets high in fat intake, 
one arm using monounsaturated fats and the other saturated fats. Both groups lost 
equal weight, with triglycerides falling in both, but only significantly in the 
monounsaturated fat arm89.  
The benefits of the Mediterranean diet are very similar to those of a low GL 
diet, and for this thesis the two will be considered as one. 
  
                                                          
6 Blue fish refers to sardines and anchovies 




Table 17: Characteristics of the Mediterranean Diet 
 
1. High consumption of virgin olive oil. 
2. High intake of vegetables and fruits and legumes. 
3. Use of non-refined carbohydrates (portions to be adjusted to physical 
activity). 
4. Consumption of fish, specially oily (or “bluish”*) three or four times a 
week 
5. Consumption of milk and derivatives, cheese and yogurt (the original 
cheese was fresh goat cheese). Keep an eye on the saturated fats of the 
dairy products. Not too much! 
6. Three or four eggs per week. 
7. Moderate consumption of meat and saturated fats. 
8. One or two small glasses of wine a day, preferably red and at the main 
meals. White wine and beer are alternatives. 
9. Nuts as snacks 
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3.8. High Protein, High Fat, Low Carbohydrate 
 
High-protein, high-fat, low-carbohydrate diets were the recommended 
therapy in the pre-insulin era. Towards the end of the twentieth century, the 
"popularity" of high-protein diets re-emerged but individuals received all sorts of 
messages about protein: when to eat it, how much to eat, what it will or won't do to 
blood glucose, and whether high intakes will or won't hasten the development of renal 
disease.  
John Rollo was a Scottish Surgeon in the Royal Artillery who first 
recommended the use of a high-protein, low-fat diet for the treatment of diabetes in 
the pre-insulin era (1797) which he published in his “An account of two cases of the 
diabetes mellitus”. 
"Noon meal: Plain blood pudding, blood and suet only. Dinner meal: Game 
or old meats, fat and rancid old meats as fat as the stomach may bear." 
—John Rollo's diet for Captain David Meredith, 1797457 
The controversies which are associated with the benefits or hazards of a high 
protein intake have been documented as far back as 1929 when the Arctic explorer 
Vilhjalmur Stefansson who existed for seven years on a diet of only meat and fish 
(80% caloric intake from fat) was studied. Prior to this, a belief existed that a group 
of serious diseases were either caused directly by meat or prevented only by 
vegetables and therefore man was unable to exist on meat only. Stefansson’s good 
health and tolerance of such a high protein and fat intake were suggested to be due to 
vigorous exercise and acclimatization to the extreme cold weather. Consequently, 
both Stefansson and Anderson (who had been in the Arctic with him) were placed on 
a 12 month meat diet while living within an urban environment. At the end of the 
trial, physical and metabolic assessments reported that neither suffered any ill effects 
in physical stamina, mental alertness, deterioration of renal function or 
hypocalcaemia283;325;512.  
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With the rising problem of obesity low carbohydrate diets have increased in 
popularity with the most popular being the Atkins’ Diet which was advocated by Dr 
R. C. Atkins, a cardiologist who himself lost weight following a low-starch diet 
studied by Alfred W. Pennington. He then successfully applied the same diet on a 
number of his overweight patients, and finally published it in his book “Dr Atkins’ 
Diet Revolution” in 1972 where it rapidly became a bestseller. Dr Atkins followed 
his own dietary recommendations and it is of interest to know that when he underwent 
angiography in 2000 following a diagnosis of viral cardiomyopathy, his treating 
cardiologist reported that his coronary arteries were remarkably disease free despite 
other expectations from his dietary habits. Dr Atkins died in 2003 having sustained a 
head injury due to a fall. Many rumours have prevailed as to the cause of the fall with 
a cardiac arrest being implicated although never confirmed.  
Atkins’ diet is essentially based on the consumption of ≤50grams 
carbohydrate per day and involves several stages.  It begins with a 2-week 'ketogenic 
induction' period, during which dieters consume less than 20grams of carbohydrate 
per day. Protein intake particularly in the form of red or white meats and eggs are 
encouraged with an unlimited allowance of fat. Within the induction phase not only 
are refined carbohydrates prohibited, but also fruits, bread, grains, starchy vegetables 
or dairy products other than cheese, cream or butter. Once the ketogenic induction 
stage is completed individuals will gradually increase their carbohydrate intake but 
should aim to maintain it at a level that promotes weight loss and borders on 
ketogenesis40. Such levels of carbohydrate restriction could vary between 25-
100grams per day. The rationale behind ketogenic diets is that a reduced carbohydrate 
intake encourages the body to use alternative methods to produce energy (Figure 46, 
page265). Once running out of glycogen stores, insulin levels fall and the body turns 
to its fat stores in order to produce energy. Fatty acid oxidation produces ketones 
(acetone, acetoacetate, and β-hydroxybutyric acid) as its catabolic products which is 
the basis of the ketosis in these diets485;486. Following the success of the Atkins’ diet 
several low carbohydrate diets were published including the “Carbohydrate Addict’s 
Diet231, the South Beach Diet9 & the Protein Power Diet131” 
The initial rapid weight loss seen with low carbohydrate diets is believed to 
be due to reduced caloric intake from appetite suppression secondary to the ketosis366 
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and the enhanced satiety from the increased protein intake312. Despite the ad libitum 
recommendation with Atkins’ Diet, it is noted that the greatest weight loss is seen in 
those with the lowest caloric intake and the highest initial body weight40. A third 
cause for the initial weight loss is similar to most diets which is depletion of glycogen 
stores. Each gram of glycogen requires 3 grams of water for storage. This is 
consequently lost in the first weeks of dieting as glycogen is consumed in 
gluconeogenesis. Naturally once this process is complete, the rate of weight loss 
declines sharply69. Critics of such diets are quick to point out that this is weight that 
is rapidly replenished once dieting is over and carbohydrate intake is sufficient to 
replenish glycogen stores.  
Speculation abounds with regards to the safety of ketotic diets. Many trials 
have been performed to try and assess their benefits and hazards. The general belief 
is that low carbohydrate diets are potentially nutritionally deficient lacking dietary 
fibre, vitamins, calcium, potassium, magnesium and iron due to the restrictions in 
food choices. Of note is that compliance with such diets is low and the drop-out rate 
much higher than for those diets with higher carbohydrate intake367. Reasons for 
dropping out tend to be for symptoms such as dehydration, headache, constipation 
and hypoglycaemia. 
 
3.8.1. Benefits of Low Carbohydrate Diets 
 
Weight loss attributed to low carbohydrate diets is reported to be greater than 
with other programmes. This appears to be true for the initial phase, but studies have 
suggested that at 12 months, the degree of weight loss achieved by individuals on a 
high or low carbohydrate regimen was similar164;516. In 2003 a systematic review of 
the safety of low carbohydrate diets from studies published between 1966 and 2003 
concluded that among all published studies, participant weight loss while using low-
CHO diets was principally associated with decreased caloric intake and increased diet 
duration but not with reduced carbohydrate content. They concluded that the evidence 
was scarce, and the duration of available trials was too short to make conclusive 
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recommendations68. Some observations have implied that weight loss with low 
carbohydrate, high protein diets was through reductions in body fat, whilst the higher 
protein intake, particularly the amino acid leucine, encouraged muscle protein 
synthesis311.   
Low carbohydrate diets are reported to positively improve many features of 
MS. In two randomised controlled trials, low carbohydrate diets compared to 
conventional low-fat, calorie-restricted diet, were superior in weight loss at 3 (6.8 vs. 
2.7% of body weight) and 6 (7 vs. 3.2%) months. The significance was lost at 12 (4.4 
vs. 2.5%) months. Improvements were noted in other markers of cardiovascular risk 
including reductions in triglycerides, increased HDL-cholesterol and improvements 
in insulin sensitivity164;221;466. Similar results were noted from a meta-analysis of 5 
trials, including 447 individuals, comparing ad libitum low carbohydrate diets to low 
fat diets.  Total and LDL-cholesterol were better improved by low fat diets and thus 
questions were raised querying which cardiovascular risk marker was most important 
to be targeted in individuals with MS393. Some have implied that the LDL particle 
size increases in low carbohydrate diets becoming less atherogenic486. A group 
studying ketogenesis for the treatment of epilepsy in 20 healthy individuals  reported 
that polyunsaturated fatty acids exerted a more pronounced ketosis with less adverse 
effect on total or LDL-cholesterol as compared to saturated fat intake169.  
In studies looking at the effect of low carbohydrate intake on glucose levels, 
many have demonstrated reductions in post-prandial insulin response and 
stabilization of blood glucose levels. Some have implied that improvements in 
glycaemia is possibly linked to amino acid intake, particularly leucine, which plays a 
regulatory role in modulating skeletal muscle glucose oxidation and maintaining 
muscle mass in periods of energy restriction. This may contribute to the stabilization 
of glucose levels311-313. A study of 28 subjects with type 2 diabetes placed on a low 
carbohydrate diet for 16 weeks demonstrated that HbA1c improved from 7.5% to 
6.3%. Only 21 individuals completed the study, but seven discontinued diabetes 
medications, and ten had dose reductions in hypoglycaemic drugs. The study was too 
short a duration to accurately reflect long term glycaemic control, but these results 
are promising and have been reflected in other trials73;587.  
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Low carbohydrate diets positively affect blood pressure as reported in a study 
of 185 overweight individuals placed on a very low carbohydrate diet. A 15% 
decrease in weight reduced systolic (11.8mmHg) and diastolic (5.3mmHg) blood 
pressure over a period of approximately 17 weeks88.   
The evidence for the effect low carbohydrate diets have on markers of 
inflammation and cytokines is scanty. It seems that they may have beneficial effects 
reducing such markers as hsCRP, TNFα, interleukin-6, and intercellular adhesion 
molecule -1, as has been seen with other diets and weight loss. The effect seems to 
be a result of weight reduction and specific to the low carbohydrate intake487.  
One of the controversial health arguments raised against high-protein diets is 
their potential to cause renal dysfunction.  Dietary recommendations for individuals 
with declining renal function are to reduce protein intake, so as to preserve eGFR. 
Even then the benefits of protein restriction on renal function have been unclear. 
Andrew Levey, reviewed data from the Modifications of Diet in Renal Disease 
(MDRD) trial and reported that the evidence was controversial and as a result felt it 
was difficult to supply any specific dietary recommendation320. In a study looking at 
protein intake with declining renal function Knight et al concluded that a high protein 
intake affected individuals with compromised renal function but certainly did not 
have an effect in those with normal kidneys285. Athletes have been recognised to 
partake of large amounts of protein for muscle building and certainly have not 
experienced secondary renal deficits428.  
In general studies suggest that low carbohydrate diets may be useful for 
cardiovascular risk protection. They reduce fasting insulin and glucose levels, 
improve blood pressure, and reverse atherogenic dyslipidaemia by increasing HDL-
cholesterol, decreasing plasma triglycerides and possibly increasing LDL particle 
size. The mechanisms by which these effects occur are unclear but it is believed to be 
linked to the increased satiety from high protein intake, increased thermogenesis and 
more efficient energy expenditure410.  
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3.9. Comparative Studies 
 
3.9.1. Comparative Studies of the Effect of the Three Diets on Weight 
 
The majority of studies comparing the superiority of the variable dietary 
interventions are of short duration, the longest being 3 years. Studies comparing an 
ad libitum low carbohydrate diet to a calorie restricted low fat diet, have demonstrated 
that weight loss is greater in the low carbohydrate groups by up to 50% or 
more164;466;482;516;588.  Those studies which were of 12 month duration reported the 
changes to be sustained with additional benefits noted in lipid profile, and insulin 
resistance favouring the low carbohydrate group. One study did report that the weight 
loss was not sustained and after an initial reduction at 6 months of -7% in the low 
carbohydrate arm (low fat, -2.5%), weight was only -4.4% at 12 months (the low fat 
group remaining at -2.5%) 164. A systematic review of 13 randomised controlled trials 
comparing low carbohydrate to standard recommendations reported the low 
carbohydrate groups to be superior in weight reduction at 6 and 12 months, although 
at 12 months the differences were small237. The superior weight reduction in addition 
to the cardiometabolic improvement implies that low carbohydrate diets may be 
better for cardiovascular risk reduction. 
In a two year randomised controlled trial (DIRECT - Dietary Intervention 
Randomized Controlled Trial), 322 individuals were assigned to one of three diets, 
ad libitum low- carbohydrate, calorie restricted Mediterranean or calorie restricted, 
low-fat diet. Mean weight loss was greatest in the low carbohydrate and 
Mediterranean arms compared to the calorie-restricted low-fat arm, (4.7kg, 4.4kg and 
2.9kg respectively). Changes in lipid profiles were similar to other trials with 
significant improvements in triglycerides, HDL-cholesterol and total 
cholesterol/HDL-cholesterol ratio seen in the low carbohydrate group. Changes in 
LDL-cholesterol were minimal and not significant in any of the groups. 
Improvements in glycaemic control were noted among those with diabetes in the 
Mediterranean arm but numbers (36) were too small to draw any conclusive results. 
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All three groups sustained reductions in blood pressure and waist measurements, but 
differences were not significant suggesting that these improvements might primarily 
be weight rather than diet related483.  
 
3.9.2. Comparative Studies on the Effect of the Three Diets on Insulin 
Resistance 
 
Glycaemic control tends to improve with weight loss as insulin resistance 
improves. Although theoretically it seems reasonable to believe that low carbohydrate 
diets will be most effective at improving glycaemic control, evidence does not appear 
supportive. Suggestions were made that high protein intake could affect glucose 
tolerance based on Sweeney’s observations when he demonstrated that individuals 
fed a high protein diet appeared to have an impaired  response to an oral dextrose load 
as compared to those on a high carbohydrate diet519. Many other studies seemed to 
imply similar results suggesting that certain proteins may play an inhibitory role on 
glucose regulation459;477. However, it seems that this effect occurs with intravenous 
amino acid administration and has not been easily replicated with oral protein 
intake179;311;395;396.  
In a meta-analysis published in 1998 comparing the effects of high 
monounsaturated fat diets to high carbohydrate diets in subjects with type 2 diabetes, 
Garg et al was able to identify that the monounsaturated fat diet reduced insulin 
requirements, and stabilized fasting and post prandial glucose levels. No significant 
improvement in insulin sensitivity was established. The benefits could only be 
attributed to the reduced carbohydrate load184. More recent studies have more 
successfully demonstrated improvements in insulin sensitivity. In a crossover study 
59 healthy individuals were placed on a saturated fat diet for 28 days then switched 
to either a low fat high carbohydrate regimen, or Mediterranean diet, for a further 28 
days. Significant improvements in fasting insulin (32.2, 13.8 & 14.7IU/l 
respectively), overall glucose disposal (8.06, 6.61 & 6.25mmol/L respectively) and 
free fatty acids levels (0.52, 0.37 & 0.37mmol/L respectively) were seen in favour of 
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the Mediterranean and low fat diets417. In the KANWU study, 162 volunteers were 
assigned to an isocaloric high saturated or monounsaturated fat intake and followed 
for 3 months. At the end of the trial, insulin sensitivity was significantly impaired 
among the high saturated fat group (-12.5% vs. 8.8%). Changes in the lipid profile 
confirmed increases in Apo B, total-cholesterol and LDL-cholesterol (+2.1%, +2.5% 
& +4.1%respectively) among the saturated fat arm with reductions (-4.3%, -2.7%, & 
-5.2% respectively) in the monounsaturated group. Reductions in triglycerides and a 
rise in HDL-cholesterol were noted in both558. 
 
3.9.3. Comparative Studies on the Effect of the Three Diets on Lipid 
Profile 
 
In the 1998 meta-analysis by Garg et al the superiority of a monounsaturated 
fat diet in improving lipid profile was demonstrated. Monounsaturated fat diets were 
accompanied by a significant lowering of serum triglycerides, total cholesterol, and 
VLDL-cholesterol levels, with increases in HDL-cholesterol. Although there was no 
improvement in LDL-cholesterol there were no evident deleterious changes184. A 
randomised controlled trial of 83 individuals assigned to a low fat, high 
monounsaturated fat or low carbohydrate diet confirmed similar results to most other 
trials. The low carbohydrate diet was more effective at reducing triglycerides and 
improving HDL-cholesterol. The authors concluded that there may be a role to use 
such diets in the short term to improve lipid profiles in individuals with 
dyslipidaemia391.  A study of 53 overweight or obese healthy men and women 
randomised to a low-fat or moderate-fat diet for 10 weeks identified the moderate-fat 
diet to be superior by reducing triglycerides and the total cholesterol/HDL-cholesterol 
ratio. HDL-cholesterol remained unchanged. Despite similar weight loss in the low 
fat group, triglyceride levels increased, HDL-cholesterol decreased, and total 
cholesterol/HDL-cholesterol ratio remained static416.   
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3.9.4. Comparative Studies on the Effect of the Three Diets on 
Inflammatory Markers 
 
A randomised controlled trial of 40 overweight men and women with MS and 
atherogenic dyslipidaemia placed on either a low fat or low carbohydrate diet for 12 
weeks, demonstrated  similar reductions for hsCRP (-23%), vascular endothelial 
growth factor (-21%), vascular cell adhesion molecule 1 (-6%) and P-selectin (-11%) 
for both interventions. The low carbohydrate group was superior showing additional 
positive anti-inflammatory changes in TNF-α (−32 vs. −12%), the chemokines IL-8 
(−33 vs. +4%) and monocyte chemo-attractant protein-1 (−24 vs. −5%), and the 
adhesion molecules E-selectin (−34 vs. −14%) and intercellular adhesion molecule 1 
(−17 vs. −3%). PAI-1 levels reduced more in the low carbohydrate group (−34 vs. 
−8%) 162. An analysis of 1,922 healthy females in the Nurses’ Health Study noted that 
those adhering to a healthy dietary programme as assessed by the Alternate Healthy 
Eating Index had higher adiponectin levels (+24%), particularly of the active high 
molecular weight form and lower resistin levels (-16%)  as compared to those with 
poor compliance. Additionally hsCRP (-41%), ferritin (-24%) and E-selectin (-19%) 
were lower in the same group of individuals, all results being adjusted for 
anthropometric measures and lifestyle factors143.  
In the DIRECT study, there were significant reductions in hsCRP among the 
Mediterranean-diet group (-21%) and low-carbohydrate group (-29%), during both 
weight-loss and weight-maintenance phases. High molecular weight adiponectin 
levels increased and serum leptin levels decreased with all forms of intervention 
without any inter-group differences, leading to the conclusion that these effects are 
particularly weight related and not an attribute of one particular diet483.  
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4. CHAPTER 4: The Battle of the Bulge:-   
A randomised study comparing the effect of three dietary approaches on 
cardiovascular risk in subjects with the metabolic syndrome -  
 
4.1.  Introduction & Rationale 
 
The epidemics of obesity and metabolic syndrome are increasing with 
substantial CVD risk.  That insulin resistance, hyperinsulinaemia, dyslipidaemia, and 
obesity collectively form the metabolic syndrome has been discussed extensively in 
the previous chapters273;510. Obesity particularly appears to play a significant role and 
is a major factor in the development of the others373;379.  
Obesity, insulin resistance, dyslipidaemia and hypertension have all been 
linked to elevated levels of cytokines that are associated with atherogenesis 63;435.  The 
raised inflammatory cytokines associated with diabetes, metabolic syndrome and 
obesity are very similar suggesting that they have one and the same cause, a surfeit 
of fat. These include TNF-α, adiponectin, leptin, resistin, PAI-1, and angiotensin 
which are thought to be partially responsible for the development of insulin resistance 
by inhibiting insulin action 342;490;491.  
Adiponectin is produced exclusively by white adipose tissue and appears to 
have a central role in the metabolic syndrome, in addition to anti-atherogenic and 
anti-inflammatory effects 484.  Plasma adiponectin levels are reduced in obesity and 
type 2 diabetes 342;484, hypertension, dyslipidaemia  or hyperglycaemia all of which 
are components of the metabolic syndrome 484. Studies have demonstrated an inverse 
correlation between plasma adiponectin concentrations and the severity of insulin 
resistance 342. 
Leptin, synthesised and secreted mainly from adipose tissue, is an afferent 
signal molecule that interacts with the appetite and satiety centres in the brain to 
regulate body weight 490.  This hormone contributes to the regulation of both food 
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intake and energy expenditure 12, by enhancing thermogenesis and metabolic rate 490. 
Animals that are defective in either leptin synthesis or leptin receptor function 
become obese and develop hyperinsulinaemia and insulin resistance 490.   
Resistin, has been found to impair glucose tolerance and insulin action when 
administered to obese mice 342;490. Human studies correlate it with other inflammatory 
markers, insulin resistance and increasing adiposity suggesting that resistin may serve 
as a link between obesity and insulin resistance 171;342;376. 
PAI-1 is an inhibitor of plasminogen activators and inhibits fibrinolytic 
activity 490. It is mainly synthesised by endothelial cells, liver and recently adipose 
tissue490.  Plasma concentration of PAI-1 is elevated in subjects with type 2 diabetes 
and in humans there is a direct correlation between the amount of visceral fat and 
plasma levels of PAI-1 490 although the mechanisms linking these together remain 
unclear. 
It is this association between obesity and metabolic complications that 
constitutes the main argument justifying weight reduction programmes which, if 
successful, can lead to a substantial improvement in the metabolic profile of the 
obese573 or even normalisation538. Despite 35% of woman and 45% of men in the 
USA, at any given time professing to be “on a diet”, the prevalence of obesity has 
doubled in the past 20 years suggesting that inadequate dietary advice may be a 
contributing factor164. 
The conventional recommended dietary approach to weight management, is a 
low-fat, high-carbohydrate, energy-deficient diet (30% energy from fat, 10-15% 
protein, 55-60% carbohydrate) 60;164;338. Its suitability is being challenged with 
increasing evidence stating that conventional diets may promote weight gain, raise 
plasma triacylglycerols, affect LDL-cholesterol, reduce body fat oxidation and 
satiety312;486. Consequently, low-carbohydrate, high-protein, high-fat diets, such as 
the Atkins diet, have become increasingly popular with results comparing them  
favourably to conventional diets,  particularly for weight loss, at least in the short 
term164;466. 
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The quality of carbohydrate consumed is believed to be an important factor in 
the success of low carbohydrate diets as individuals are encouraged to choose options 
low in glycaemic load.  Carbohydrate replacement in low fat diets is typically of a 
high glycaemic index which increases inflammatory markers that promote 
atherothrombosis and hyperinsulinaemia 165;331.   
In contrast low GL diets are beneficial in improving lipid profiles and 
glycaemic control, and reducing cardiovascular risk. A higher protein intake has been 
demonstrated to improve HDL-cholesterol to triglyceride ratios and promote satiety. 
Diets rich in monounsaturated fatty acids, are proven to reduce LDL-cholesterol, 
without negatively affecting HDL-cholesterol67;184;312;332. Evidence available 
supports the  inclusion of 2 oily fish meals each week as a source of omega-3 
polyunsaturated fatty acids, and the  inclusion of at least 5 servings of fruit and 
vegetables a day as a means of cardiovascular disease  and cancer prevention222. 
Despite dietary intervention being a well-established primary management 
plan for obesity and MS, the evidence about which diets may beneficially modify 
classical and contemporary CVD risk factors is limited.  The work to be described 
examines the effects of three different dietary approaches on weight loss achieved 
and possible changes, potentially beneficial or otherwise, of certain CVD risk factors. 
This information may potentially help to clarify some of the mysteries surrounding 
the metabolic syndrome, and help reduce its progression to type 2 diabetes. 
The first of the diets used in the study is based on the conventional high 
carbohydrate, low fat, calorie-restricted diet currently advised to most individuals.  
This will be compared with a second diet of low carbohydrate, high fat, high protein 
ad libitum diet (like Atkins) and with a third diet based on the Mediterranean diet. 
Details of the diets are in Table 18. 
 It is expected that the metabolic diet will have a clinical desirable effect on 
key risk factors for cardiovascular disease including insulin resistance, plasma lipid 
profile and inflammatory markers. 
 
  





Table 18 : The three proposed dietary plans and expected metabolic effects 
 
 
 High carbohydrate, Low 
fat (Conventional) 
Low carbohydrate, high 
fat/protein (Atkins) 
Proposed dietary 















15-20% sat fat 
15-20% mono fat 
15-20% poly/mono 
 





10% poly – 5% omega 3. 
5 servings of fruit and 
vegetables a day and 2 































Insulin sensitivity greater 
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4.2. Inclusion and exclusion criteria 
The study aimed to recruit 120 medically fit subjects, aged between 18–70 
years, who fulfilled the NCEP-ATP III criteria for MS to take part in a 12 month 
dietary intervention randomized controlled trial. To reduce the potential for external 
influences to produce any significant effect, individuals with uncontrolled diabetes, 
or were on insulin, weight modifying agents, or lipid-modifying drugs were excluded. 
In view of the concerns of the effect of high protein diets on renal function those with 
renal impairment or long term chronic medical problems that may affect renal 
function or restrict their diet were excluded.  
A comprehensive list of inclusion and exclusion criteria is given below. 
Inclusion criteria 
 Males or non-pregnant females fulfilling the criteria for the metabolic 
syndrome. Criteria for metabolic syndrome used for recruitment included the 
presence of 3 or more of the following criteria - 
1. Abdominal obesity (waist circumference >102 cm in men and >88cm 
in women). As all those recruited were Caucasian no modifications 
were necessary  
2. Triglyceride level >150mg/dL (1.7mmol/l) 
3. HDL-cholesterol <40mg/dL (1.03mmol/l) for men and <50mg/dL 
(1.3mmol/l) for women 
4. Blood pressure >130mmHg systolic or >85mmHg diastolic 
5. Fasting plasma glucose > 110mg/dL (6.1mmol/dL)*7 
 Age 18 – 70 years 
 If on treatment for hypertension, must be stable on hypertensive therapy for 
past 3 months 
 Type 2 diabetes on diet, metformin or sulphonylureas, must be stable on 
diabetes medication for past 3 months and have HbA1c <10%  
 Willing to be randomised to any of three diets 
                                                          
7 If the subject had type 2 diabetes, they were considered to fulfil the fasting glucose criteria 
regardless of their fasting glucose level. 
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Exclusion criteria 
 Recent cardiovascular or thromboembolic event (i.e. stroke, myocardial 
infarction, or pulmonary embolism) within past 4 months 
 On-going chronic inflammatory condition – vasculitis,  chronic ulcers (feet, 
skin), inflammatory bowel disease, malignant disorder  
 HbA1c ≥ 10% 
 Renal impairment  (Creatinine > 135umol/l) 
 Hepatic impairment.  (ALT or AST > 4 times upper limit of normal) 
 On lipid-modifying therapy 
 Poorly controlled diabetes (requiring regular and recent changes to diabetes 
medication within the past 3 months) 
 Type 1 or Type 2 diabetes on insulin 
 Type 2 diabetes on a thiazolidinedione (rosiglitazone*8/pioglitazone). 
 Untreated thyroid disorders – should be stable on thyroid modifying 
medication for at least 3 months 
 Known Cushing’s disease/syndrome 
 On an anorectic agent (i.e. orlistat, sibutramine*) – can be given a 4 week 
washout period. 
 Food allergies/intolerance 
 Vegetarian 
 Unwilling to be randomised to one of three diets 
  
                                                          
8 Rosiglitazone and sibutramine had been available at the inception of the protocol although they 
were later withdrawn from use. 
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5. CHAPTER 5: Study Methodology  
 
5.1. Ethical Consideration: 
 
Ethical approval was obtained from the Bath Local Research Ethics 
Committee which was in partnership with the Bristol Local Research Ethics 
Committee and therefore granted approval for individuals to be approached in both 
localities as an overlap existed. The main ethical issues included: informed consent, 
autonomy to participate in or withdraw from the study, causing no harm to the 
participants, anonymity and data confidentiality. All participants gave informed 
verbal assent and written consent to participation in the study prior to any form of 
testing. Participants were verbally informed of the nature and reason for each 
procedure, and were given an opportunity to ask questions. Participants were also 
reassured that they did not have to give any reason for withholding from participating 
in the testing procedures or withdrawing from the study. 
 
5.2. Recruitment Procedure: 
 
Letters were sent out to GP practices requesting permission to run a search 
looking for suitable subjects (Figure 42: GP Invitation Letter, page252). Once approval was 
given by the practices, subjects fulfilling the criteria for metabolic syndrome were 
identified from the Department of Diabetes & Endocrinology diabetes database 
(DIAMOND, Hicom, Surrey) at the Royal United Hospital, and GP database 
searches. Database interrogation involved running several searches looking for all 
patients with type 2 diabetes or fasting glucose greater than 6.1mmol, hypertension 
or systolic blood pressure greater than 140mmHg, HDL-cholesterol less 1mmol/l and 
triglycerides greater than 1.8mmol/l. The search was asked to exclude patients with a 
BMI less than 24kg/m2, an HbA1c greater than 10%, and individuals on statins, or 
insulin.   
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Once the initial list was generated, the search was then modified to exclude 
all individuals who did not have at least two of the criteria for metabolic syndrome. 
The list generated for the second search was then individually reviewed going through 
blood results available on the Royal United Hospital’s WebIce (Intercontinental 
Exchange, Inc) programme. All with fluctuating readings for HbA1c or thyroid 
function, biochemical evidence of renal or hepatic dysfunction were then omitted 
from a final list of potential candidates. 
A letter of invitation explaining the study was sent out to the potential 
participants (Figure 43: Patient Invitation Letter, page254). Enclosed was a form which 
volunteers completed indicating their interest, or lack of, in the study (Figure 44: Initial 
details form, page255). If they wished to be considered for the study, if eligible, then they 
would complete the details form including the section for contact details, known 
medical history, and a list of current medications and return it in the stamped envelope 
which was provided.  
The patients who did not fulfil study criteria due to medical or drug history 
were written to with an apology, explaining the reason for their unsuitability. Those 
whom on paper appeared to potentially fulfill the basic requirements were invited to 
the Wolfson Centre, Royal United Hospital, Bath, for an initial screening visit. Before 
attending they were asked to complete a baseline food questionnaire which they 
brought to the interview (Table 53: Baseline Dietary Questionnaire 42: Baseline Dietary 
Questionnaire, page257). 
 
5.2.1. The Screening Visit: 
 
At the screening visit, interested participants were invited to attend the 
research centre, fasting (12 hours) where the study was discussed in detail. If still 
willing to proceed they were then asked to sign a consent form (Figure 45: Consent Form, 
page256), prior to further interventions.  Waist and weight measurements, blood 
pressure and baseline fasting bloods were taken to ensure they fulfilled the 
biochemical criteria for the study, followed a physical examination. If blood pressure 
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was high recommendations for antihypertensive therapy adjustments were made and 
only when readings were stable for more than three months were they re-screened*9. 
Each qualifying subject was given a set of weighing scales and asked to carry out 
seven consecutive days of a weighed food diary.  
Qualifying subjects were booked to return in a fortnight for the randomization 
visit. During this time they were to continue with their normal dietary habits and make 
no modifications. Those who failed to meet the criteria for MS were informed of the 
reasons and provided with dietary and lifestyle advice as a thank you 
 
5.2.2. The Randomization Visit: 
 
Subjects would attend having fasted for twelve hours. They would have 
measurements taken including weight, height, waist circumference, blood pressure 
and baseline bloods for measurement of renal function, fasting lipid profile, fasting 
glucose, and other analytes as indicated below. They were then given a 75gram 
glucose load to drink followed by a 2 hour glucose sample to complete a glucose 
tolerance test.  
A diet was then allocated by the patient choosing a number from a spreadsheet 
ranged from 1 to 120. Each number had been randomly allocated to one of the three 
dietary categories by an independent third party who held the allocation coding. Once 
randomized the subject would be counseled by the investigator or a trained research 
dietician. The research dietician was available for five sessions per week. She would 
see subjects on a regular basis alternating the sessions with the researcher if possible 
providing dietary advice, and counseling for those who were particularly struggling 
with lack of weight loss or dietary compliance issues. All subjects would be seen by 
the medical researcher for their initial visit, randomization and each visit where blood 
taking or an examination was required. 
                                                          
9 *Two candidates who were persistently keen in taking part insisted on being re-screened once their 
blood pressure had been stabilized by their doctor. 
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Those allocated to Low-Fat Diet were counselled to consume low-fat grains, 
vegetables, fruits, and legumes and to limit intake of added fats, sweets, and high-fat 
snacks. The target macronutrient composition was 55% of energy from carbohydrate, 
25% from fat, and 15% from protein. The intervention was not designed to reduce 
dietary glycaemic index and glycaemic load; rather, the aim was to prescribe a diet 
consistent with the current high carbohydrate, low-fat guidelines. The individuals 
were given a calorie allocation according to their weight, and level of physical activity 
with a calculated 500kcal deficit which is compatible with an average 0.5kg weekly 
weight loss Table 55: Table of Prescribed Energy Intake, page263). They were supplied with a 
portion conversion guide (Figure 48: Copy of the eating plan given to those on a HC diet, p276) 
and a seven day food menu to help facilitate caloric estimation for most general foods. 
The subjects who were placed on the Metabolic Plan (Low–Glycaemic 
Load) Diet were counselled to consume low–glycaemic load foods (particularly non-
starchy vegetables, legumes, and fruits) and to limit intake of high–glycaemic load 
foods (such as refined grains, starchy vegetables, fruit juices, and sweets). Attention 
also was directed toward consuming “healthy fat” high in mono-unsaturated fatty 
acids, such as those particularly found in shellfish, oily fish, nuts, seeds, and rapeseed 
or olive oils. The target macronutrient composition was 40% of energy from 
carbohydrate, emphasizing low-glycaemic index sources, 35% from fat, and 25% 
from protein. Participants were equipped with food-choice lists that delineated 
products into low- or high-glycaemic load. Again subjects were given a diet 
calculated to provide a daily 500kcal deficit, and provided with food charts (Figure 47: 
Copy of the eating plan given to those on the LGL Diet, page270) and sample menus to aid them 
in their daily allocations. 
Subjects allocated to the Atkins’ Diet were counselled to a high fat, high 
protein diet with an initial carbohydrate restriction of 20grams per day. They were 
also supplied with the Atkins’ diet revolution book and asked to follow its 
instructions.  The 20gm carbohydrate restriction was to be maintained for the first 
two weeks followed by a gradual increase in carbohydrate intake as per 
recommendations (Figure 46:  The four phases of Atkins, page265).  The carbohydrate 
introduced was encouraged to be of a low glycaemic load in the form of non-starchy 
vegetables and fruits (Table 56: List of allowed foods in Atkins adapted from 40). As there had 
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been substantial speculation on possible mineral and vitamin deficiency associated 
with Atkins’ diet, all were supplied with a daily calcium and vitamin D tablet and a 
daily multivitamin/mineral tablet. 
 
5.2.3. The Follow-up Visits: - 
 
Once randomised subjects were given an initial two weeks trial run, to see if 
they were able to maintain the restrictions placed on them by their dietary allocation 
and to ensure that they did not suffer any adverse effects. If they were able to complete 
the two weeks they would then be considered to be in the study and their progress 
monitored on a regular basis. 
Having completed the run in period and consented to continue on the trial, 
subjects were seen fortnightly for the first twelve weeks. At each visit they had their 
weight and waist circumference measured, and received dietary counselling.  
At week six in addition to anthropometric measures, individuals were given a 
four day weighed food diary to complete and visits continued on a fortnightly basis. 
At the next major visit (week 12) participants attended fasting. Blood was 
taken for renal function, lipid profile, glucose, glycosylated haemoglobin (if they had 
type 2 diabetes) and other analytes. This is the stage where subjects were assumed to 
move from a fast weight loss phase to a slower but steady rate prior to moving into a 
maintenance phase. Weight, waist and blood pressure measurements were taken and 
calorie requirements readjusted according to an individual’s weight and energy 
requirements. At the visit, subjects were given forms to complete another three day 
weighed food diary. One of the days was to include a weekend day, to give a general 
overall picture. 
From this point visits were changed to a 4 weekly basis with subjects calling 
in the interim should they have any queries or require extra advice. Visits at week 16, 
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and 20 were similar to the initial fortnightly visits with weight and waist 
measurements and dietary counselling. 
The next full visit was at week 24 where subjects were re-measured for 
weight, waist and blood pressure, again provided fasting blood samples and a repeat 
glucose tolerance test, and caloric requirements were readjusted as required. Most of 
those on the Atkins’ diet had by now reached a maintenance phase with an intake of 
approximately 50-70grams of carbohydrate. Individuals were counselled and 
encouraged to maintain carbohydrate of a low glycaemic load quality, and asked to 
complete another three day weighed food diary. At this stage, subjects were believed 
to be entering into a phase where weight loss would be slow or there would be weight-
loss maintenance. This was discussed with each individual to avoid disappointment 
and encourage compliance. Calorie changes according to weight and activity 
requirements were made, and individuals re-educated on their specific diet plan.  
Follow-up visits continued on a 4 weekly basis with weight and waist 
measurements taken at each visit, and dietary counselling provided for those who 
required it.  
The penultimate visit was at week 48. Participants attended fasting overnight. 
Bloods were taken as on previous visits and a glucose tolerance test performed. 
Weight, waist and blood pressure measurements were recorded, and a physical 
examination was performed. Individuals were given a final four day weighed food 
diary to complete.  
They returned for their final visit a fortnight later. At this visit they handed in 
their scales and final food diaries. The results of their weight, blood pressure and 
general laboratory bloods were discussed. Changes were made to the diet to help each 
individual to continue on a regimen most suited to that person and to encourage 
weight-loss maintenance.  
At all stages of the study, a healthy life-style was encouraged, but at no point 
was an exercise regimen ever prescribed. 
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5.3. Data Collection 
 
 
5.3.1. Anthropometric variables 
 
Height was measured at the start of the study, while weight and waist 
measurements took place at each visit. Measurements for height were taken with 
candidates standing straight, heels placed together using a wall mounted stadiometer. 
Subjects were asked to gaze straight ahead with the back flat against the wall as the 
headboard was lowered to the most superior point of the head with enough pressure 
to compress the hair. Measurements were taken to the nearest .01m.  
Weight measurements were collected with candidates dressed in light day 
clothes to the nearest 0.1kg using calibrated electronic scales (Tanita Corp, Tokyo, 
Japan).  
Waist circumference was assessed at the mid-point between the lowest rib and 
the iliac crest and at the iliac crest as recommended by the IDF13.Waist 
circumferences are reported to the nearest 0.1cm using an inflexible tape measure. 
BMI was calculated as body mass/ height2, where body mass is expressed in 
kilograms (kg) and height in metres (m).  
 
5.3.2. Blood pressure 
Blood pressure was measured using a digital OMRON (Omron HEM-
773AC, UK) blood pressure machine. 3 readings were taken after the subject had 
been sitting quietly for 5 minutes and the average of the last two was used as the 
blood pressure reading. The appropriate cuff size was used in all measurements and 
readings were taken either by the researcher or a dedicated research nurse. Blood 
pressure measurements were completed before blood sampling.  
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Processing of blood samples 
 
When subjects attended on their fasting visits (12 – 13 hours), 75mls of blood 
was drawn into appropriate BD Vacutainer™ tubes by venepuncture using  Butterfly 
needles “21g” (BD Vacutainer® Safety-Lok™ Blood Collection Set ™) aided by the 
use of a tourniquet. Blood withdrawal was undertaken by the researcher or a dedicated 
research nurse who were experienced at phlebotomy. 
Sample collections were 10mls for:- 
 A serum separation tube:    urea and electrolytes, liver functions, and          
fasting lipid profile 
 A 2-ethylenediaminetetraacetic acid (EDTA)  tube: full blood count and 
glycosylated haemoglobin if the subject had diabetes 
 An heparinised tube: coagulation screen and fibrinogen 
 A fluoride oxalate tube:  fasting glucose 
 
These were analysed at the Central Laboratories, Pathology Department, at 
the Royal United Hospital as part of routine clinical samples. Results for lipids and 
glucose were incorporated into the data. The remaining 60mls was taken as 40mls in 
four serum separation tubes and 25mls in three EDTA tubes. All tubes were inverted 
8 - 10 times to ensure proper mixing. EDTA tubes were immediately spun at 4◦C for 
20mins at 1000g in the centrifuge. Serum separation tubes were placed in a 4◦C fridge 
for 20 minutes to allow for clotting and then spun down at 4◦C at 1000g for 20mins.  
Serum and EDTA tubes were aliquotted into individual safe lock tubes and 
stored in a -70°C freezer until study end. The samples were thawed in batches to run 
enzyme-linked immunosorbent assays (ELISA) under similar circumstances and 
reduce the margin for error.  
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The aliquots were divided as such: 
The EDTA samples were intended to be used for: - 
 5ml for lipoprotein subfractions 
 1ml for HDL-cholesterol 
 4 x 500ul samples for  endothelin, CRP, visfatin  and RBP-4 
 4 x 50ul samples  for PAI-1, hsCRP and measuring oxidative stress 
 2 x 40ul samples for electrophoresis 
 
The serum samples were intended to be used for:-  
 8 x 500ul samples for RBP-4, visfatin, TNFα, IL-1β, oxidised LDL,  
and MCP-1 
 4 x 300ul samples for IL-6 and IL-8 
 6 x 150ul samples for leptin, resistin, and adiponectin 
 4 x 60ul samples for insulin 
 5 x 50ul samples for leptin, resistin, and adiponectin 
 4 x 10ul samples for leptin, resistin, and adiponectin 
 
As at the start of the study it had not yet been identified which ELISA kits 
would be used it was felt best to divide the serum and plasma into numerous safe lock 
tubes allowing for plenty of spares and to avoid repetitive defrosting and sample 
degradation.   
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5.3.3. Biochemical analyses 
 
Insulin, hsCRP, and the adipocytokines were run in batches using ELISAs. 
Sets were chosen depending on the assay sensitivities, company support, and 
reliability from previous experience. 
Consequently ELISA kits were sourced from three different companies. 
 AdipoGen Inc., Adipogen Institute for Life Science, Seoul, Korea: for  
RBP-4 and visfatin kits  
 DRG Instruments GmbH, Marburg, Germany:   for insulin and leptin 
 R&D Systems, Inc., Minneapolis, USA:  for PAI-1, adiponectin, hsCRP, 
and resistin.  
 
The ELISAs were run by Dr Julia Reid, clinical research scientist at the 
Wolfson Centre, Royal United Hospital 
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Serum insulin analysis was performed using a DRG Insulin Enzyme 
Immunoassay Kit. This is a solid phase enzyme-linked immunosorbent assay 
(ELISA) which utilises chemiluminescent technology and is based on the sandwich 
principle which utilises two antibodies (capture antibody and detection antibody) to 
provide the “sandwich”.  
The ELISA kits contained:   
1. The Microtitre wells (96 as 8 x 12) which were already pre-coated 
with anti-Insulin monoclonal antibody (capture) 
2. Zero Standard solution 
3. Standard (Standard 1-5) solution 
4. Enzyme Conjugate :  mouse monoclonal anti-Insulin antibody 
conjugated to biotin 
5. Enzyme Complex (detection) :  Streptavidin HRP Complex 
6. Substrate Solution:    Tetramethylbenzidine (TMB) 
7. Stop Solution:     0.5M H2SO4, 
8. Wash Solution 
 
Serum samples (60ųl aliquots) were retrieved from the -70°C freezer and 
allowed to thaw to room temperature prior to use.  
25 µl of standard solution or serum sample were aliquotted into the wells with 
the standard ones identified to be used as a reference point. 25 µl of enzyme conjugate 
(mouse monoclonal anti-Insulin antibody conjugated to biotin) was then added and 
mixed thoroughly allowing for the two to react and bind. The mixture was incubated 
for 30 minutes at room temperature and then excess contents were removed prior to 
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washing.  Each well was washed three times with 400ul wash solution supplied in the 
kit to remove any unbound conjugate.  
Fifty microliters of enzyme complex (Streptavidin HRP Complex) was added 
to each well and incubated at room temperature for a further 30 minutes allowing it 
to bind to the biotin-anti-Insulin antibody. The degree of binding should be directly 
proportional to the sample’s insulin concentration. The wells are then once more 
washed three times with 400ul of wash solution followed by the addition of 50µl of 
substrate solution and a further 15 minute incubation at room temperature during 
which each well should have fully developed.  To stop the reaction 50µl of Stop 
Solution was added to each well. Depending on the underlying insulin concentration 
each well will have developed to produce an equivalent degree of colour intensity 
which was then quantified by the use of microtitre plate reader.   
All the ELISAs used facilitated the sandwich method for substrate extraction 
and analysis. The length of incubation periods and substrates differed and are 
recorded in the table below (Table 19& Table 20). For all protocols plates would be 
carefully and thoroughly washed with the washer solution between incubation 
periods. Samples were completed in duplicate and readings were taken as the average 
of the two. Any outlying results would be repeated to ensure accuracy. All readings 
were taken with the use of a microtitre reader able to read at 450nm. 
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Table 19: A list of ELISA protocols undertaken 
 First Incubation Second Incubation Third Incubation Fourth Incubation Sensitivity 
DRG Instruments 
GmbH 
     
Insulin  Wells pre-coated with anti-Insulin 
monoclonal antibody.  
25µl substrate + 25µl mouse 
monoclonal anti-insulin antibody 
conjugated to biotin  
Incubate for 30 minutes 
50µl Streptavidin HRP 
Complex 
Incubate for 30 
50µl of TMB 
Incubate for 15 
minutes 
 analytical sensitivity 1.76IU/mL  
intra-assay variability 2.6%. 
inter-assay variability 2.9% 
Leptin Wells pre-coated with monoclonal 
anti-Leptin antibody 
15µl substrate + 100µl Assay buffer 
Incubate for 120 minutes 
100µl polyclonal Leptin 
antiserum 




Incubate for 30 
minutes  
100 µl of TMB 
Incubate for 15 
minutes 
analytical sensitivity 1.0 ng/ml. 
intra-assay variability 5.9%. 
inter-assay variability 11.55% 
AdipoGen Inc      
Retinol Binding 
Protein 4 
Wells pre-coated with recombinant 
human RBP4 
50μl  substrate + 50 µl polyclonal 
antibody against human RBP4 
Incubate for 60 minutes 
 
100µl HRP conjugated 
anti-rabbit IgG 
Incubate for 60 minutes 
100 µl of Substrate 
Solution (chromogenic 
reagents) 
Incubate for 20 
minutes 
 analytical sensitivity 1.0 ng/ml. 
intra-assay variability 2.6%. 
inter-assay variability 3.5% 
Visfatin Wells pre-coated with monoclonal 
antibody against  human visfatin 
Add 100μl  substrate  
Incubate for 180 minutes 
 
100µl polyclonal Ab 
against human visfatin 
Incubate for 60 minutes 
100µl HRP conjugated 
anti-rabbit IgG 
Incubate for 60 
minutes 
100 µl of Substrate 
(chromogenic 
reagents) 
Incubate for 10 
minutes 
analytical sensitivity 30pg/ml. 
intra-assay variability 3.8%. 
inter-assay variability 8.2% 
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Table 20: A list of ELISA protocols undertaken, continued 
 
 First Incubation Second Incubation Third Incubation Fourth Incubation Sensitivity 
R&D Systems      
Adiponectin Wells pre-coated with a mouse 
monoclonal antibody against HMW 
Adiponectin 
100 μL of Assay Diluent + 50µl of 
substrate  
Incubate for 180 minutes 
200μl of HMW 
Adiponectin Conjugate 
Incubate for 60 minutes 
200 μL of Substrate 
Solution (TMB + 
H2O2) 
Incubate for 30 
minutes 
 analytical sensitivity 0.195 ng/mL 
intra-assay variability 2.6%. 
inter-assay variability 8.6% 
PAI -1 Wells pre-coated with a mouse 
monoclonal antibody against  
PAI-1 
50μl  substrate + 50 µl assay diluent 
Incubate for 120 minutes 
200 µl of Serpin 
E1/PAI-1 Conjugate 
Incubate for 120 
minutes 
200 μL of Substrate 
Solution (TMB + 
H2O2) 
Incubate for 30 
minutes 
 analytical sensitivity 0.026 ng/mL 
intra-assay variability 4.4%. 
inter-assay variability 9.5% 
Resistin Wells pre-coated with a mouse 
monoclonal antibody against Resistin 
100 μL of Assay Diluent + 100µl of 
substrate 
Incubate for 120 minutes 
200µl of  
Resistin conjugate 
Incubate for 120 
minutes 
200 μL of Substrate 
Solution (TMB + 
H2O2) 
Incubate for 30 
minutes 
 analytical sensitivity 0.059 ng/mL. 
intra-assay variability 5%. 
inter-assay variability 8.2% 
Hs CRP Wells pre-coated with 
a mouse monoclonal antibody 
against CRP. 
100 μL of Assay Diluent + 50µl of 
substrate 
Incubate for 120 minutes 
200 μL of CRP 
Conjugate 
Incubate for 120 
minutes 
200 μL of Substrate 
Solution (TMB + 
H2O2) 
Incubate for 30 
minutes 
 analytical sensitivity 0.010 ng/mL. 
intra-assay variability 4.4%. 
inter-assay variability 6% 
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5.3.4. Calculating Non-HDL-Cholesterol 
 
Non-HDL-Cholesterol was calculated by subtracting HDL-cholesterol from 
total-cholesterol measurements. Measurements were recorded in mmol/l. 
 
 
5.3.5. Cardiovascular Risk Calculation 
 
10 year predictions of CVD and CHD risks were calculated using the 
University of Edinburgh Cardiovascular Risk Calculator which is based on the Joint 
British Societies’ (JBS2) Cardiovascular Disease Risk Prediction charts (Figure 49, 
page282). This is an on-line calculator into which the individual’s age, sex, smoking 
status, systolic blood pressure, total and HDL-cholesterol values can be entered to 
give a prediction of their risk for experiencing a cardiac or cardiovascular event 
within the following 10 years. Individuals who have a greater than 20% risk for 
developing CV disease should be initiated onto statin therapy according to the current 




5.3.6. Calculation of Insulin Resistance 
 
Insulin resistance and sensitivity were calculated using the Homeostasis 
Model Assessment (HOMA) calculator downloaded from the University of Oxford 
website (http://www.dtu.ox.ac.uk/homacalculator/index.php). The HOMA calculator 
provides an estimate of beta cell function (%B) and insulin sensitivity (%S) through 
a mathematical equation that is based on a theory that fasting plasma insulin and 
glucose are regulated by a hepatic-beta cell feedback loop  and accounts for variation 
in insulin and glucose secretion124;356. Insulin resistance (HOMA IR), is provided 
through calculating the reciprocal of insulin sensitivity (100/%S). The gold standard 
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for measuring insulin resistance is considered to be through the use of insulin clamps, 
but these studies are lengthy and would have been difficult to perform on the number 
of individuals who took part in this study. 
The HOMA calculator at the time would only accept insulin levels in SI units 
(pmol/L) and all insulin levels needed to be converted from µIU/ml to pmol/L by 
multiplying by 6.945460. Plasma glucose (mmol/l) and insulin levels were inputted 
into the calculator and the results for insulin resistance and sensitivity were tabulated. 
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5.4. Statistical Analysis 
 
Data were tabulated and stored on a Microsoft Access database, copied to 
Microsoft Excel for graphs and basic calculations and to IBM’s Statistical Product 
and Service Solutions (SPSS version 14 and then 18) programme for statistical 
analysis.  
Subjects included in the final analysis were those who had completed to the 
end of the 12 month study period although an intention to treat analysis for weight 
loss was run to compare differences in outcomes. 
Sample size was calculated using IBM SPSS SamplePower 3 Programme. 
Initial calculations were based on the differences expected between the High 
Carbohydrate, Low Fat (control) and the High Fat Low Carbohydrate (Atkins’) 
group. In order to achieve a power of 95%, it was expected that 33 individuals be 
recruited in to each arm. The calculations took into account that there would be a 25% 
drop-out rate with average weight loss in the control group being 4kg while that in 
the other group 8kg. The alpha was set to be two-tailed at 0.01.  
Power calculation of the study was 0.99. This was based on 40 subjects per 
category and the effect size (f) calculated to be 0.5 on the basis of the mean expected 
weight loss for each category. 
Analysis of variance (ANOVA) was used to compare the differences in results 
between the three groups at each of the study time intervals.  Post hoc multiple 
pairwise comparisons among the three diet groups were performed with both 
Bonferroni and Dunnett testing. Differences were only considered significant should 
p-values for both be p <0.05.  
Within group changes comparing mean differences at baseline to each study 
interval point was by means of the paired student t-test, which tested for parametric 
data. Correlations between the continuous data variables was assessed using Pearson 
correlation coefficients. 
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Results were taken to be statistically significant for p-value of <0.05 (two-
tailed), corrected for multiple comparisons. 
From here on while presenting and discussing the results, the three dietary 
groups will be mentioned as follows- 
 
 High Fat Low Carbohydrate (Atkins’) as Low Carbohydrate  or LCD  
 High Carbohydrate, Low Fat (Control) as Low Fat or LFD  
 Low Glycaemic Load (Mediterranean) as Low Glycaemic Load or LGL 
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6. CHAPTER 6:  The Effects of the Three Dietary Interventions 




850 subjects were identified as being potentially suitable to take part and were 
invited, by letter with a questionnaire attached, to take part in the study (Figure 43). 
Over 400 responded and sent in the completed questionnaire. 184 individuals 
attended for initial screening and of these 121 fulfilled the study criteria and were 
randomised to a dietary intervention. 11 withdrew within the first two weeks citing 
disappointment with dietary allocation, inability to maintain diet due to financial or 
disciplinary restraints or other unspecified reasons. Two more dropped out prior to 
completing 6 weeks.  Only individuals who completed the study period (86) were 
included in the final study analysis which was 71% of the total participants. At the 6 
week point, 7 (17%) had discontinued high fat, low carbohydrate (LCD), 3 (8%) 
dropped out of the high carbohydrate, low fat (LFD) group and 3 (7%) from the low 
glycaemic load (LGL) group. The highest drop-out figures were among LCD group 
with one unable to tolerate the strict carbohydrate restriction, another claiming to be 
physically unwell and a  third individual unable to cope with the financial expense 
such a diet demanded. Unfortunately funds were not available to provide diet 
expenses reimbursement. Two subjects discontinued due to unhappiness with the 
degree of weight loss. The highest retention rate was among the LFD group (79%), 
but those who discontinued did so out of disappointment with weight loss or dietary 
allocation as the participants felt that this was the standard and therefore did not 
perceive that they were receiving any form of intervention (Table 21). In this study 
retention rates were significantly better than those usually seen in weight loss diet 
studies.   At six months 67%, 82%, and 81% of volunteers (patients) continued in the 
LCD, LFD, and LGL groups respectively, while at twelve months the figures were 
59%, 79% and 76% respectively.  
  




























(1 unable to 

































IHD – statin 
started) 
0 30 91 








2 35 86 
Total  
Dropouts 








Page | 144 
 
Figure 13: CONSORT Diagram of Study Recruitment 
Identified as possibly eligible candidates (n= 850)
Excluded for not meeting inclusion criteria from 
recruitment questionnaire  (n= 409)
Assessed for eligibility (n=441)
Randomised (n= 121 )
Allocated Low Carbohydrate Group (n= 41 )
Withdrew at 2 weeks (costs, unable to maintain) (n= 6)
Withdrew before 6 weeks (unsatisfied) (n=1)
Withdrew before 3 months (lost to follow up) (n= 4 )
Withdrew before 6 months (moved away, lost to follow up) (n=4)
Withdrew before 12 months (time restaints) (n=2)
Total analyzed as intention to treat (n=34)
Excluded from intention to treat analysis (no data other than 
baseline) (n=7)
Total analysed as completers  (n= 24 )
Excluded from completers analysis (n=17)
Allocated to  Low Fat Group (n= 38 )
Withdrew at 2 weeks (unhappy with diet) (n= 2)
Withdrew before 6 weeks (unsatisfied) (n=1)
Withdrew before 3 months (unsatisfied, lost to follow up) (n= 2)
Withdrew before 6 months (CVD event on statin) (n=2)
Withdrew before 12 months (Ca pancreas) (n=1)
Total analyzed as intention to treat (n=35)
Excluded from intention to treat analysis (no data other than 
baseline) (n=3)
Total analysed as completers  (n= 30)
Excluded from completers analysis (n=8)
Allocated to Low Glycaemic Load Group (n= 42)
Withdrew at 2 weeks (unhappy with diet) (n= 3)
Withdrew before 3 months (TIA on statin, lost to follow up) (n= 5)
Withdrew before 12 months (lost to follow up) (n=2)
Total analyzed as intention to treat (n=39)
Excluded from intention to treat analysis (no data other than 
baseline) (n=3)
Total analysed as completers  (n= 32)
Excluded from completers analysis (n=10)
Excluded (n=320 )
Not meeting inclusion criteria (n= 252)
Declined to Participate (n= 21)
Unable to  committ to visiits, study duration,  or randomised 
diet (n= 47)
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6.1.1. Baseline Characteristics 
 
The baseline characteristics for subjects participating in the study are shown 
in (Table 22 - Table 24). A comparison of baseline characteristics of the whole study 
cohort (n=121) and those completing the entire 12 months (n= 86) demonstrated no 
difference between the two study cohorts (Table 23). There were no significant 
baseline demographic differences between the three groups at baseline. The average 
age was 56 years. Females (n=66, 55%) outnumbered the participating males (n=55, 
45 %) at the start of the study and remained so till the end with proportions maintained 
(n=48, 56% females, n=38, 44% males). The numbers of individuals with diabetes 
among the groups was small but equally distributed with no statistical difference in 
the starting HbA1c.  
 
Table 22: Baseline characteristics of all study cohort and completers 
 Full Study Cohort Completed Study 
Number of subjects 121 86 
Age 56 ± 10.8 57 ± 10.1 
Female 66 44 
Male 55 42 
Diabetes 22 19 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 
Weight (kg) 98.4± 18.7 97.6 ± 17.3 
BMI (kg/m2) 34.4 ± 5.6 34.4 ± 5.4 
Waist circumference 108.0 ± 12.1 108.1 ± 11.1 
Total cholesterol (mmol/dl) 5.7 ± 1.0 5.7 ±  0.9 
HDL-cholesterol (mmol/dl) 1.4 ± 0.4 1.4 ± 0.4 
LDL-cholesterol (mmol/dl) 3.4 ± 0.8 3.5 ± 0.8 
Total cholesterol/HDL ratio 4.4 ±1.2 4.1 ± 121 
Fasting Triglycerides 2.0 ± 1.0 2.0 ± 0.9 
Fasting glucose (mmol/dl) 5.9 ± 1.8 5.8 ± 1.6 
HbA1c (%) 6.7 ±1.0 (n=22) 6.7 ± 1.0 (n=7) 
Systolic BP (mmHg) 140.8 ± 15.5 139.7 ± 15.3 
Diastolic BP (mmHg) 85.6 ± 10.2 84.7 ± 9.1 
3 Components of MS n(%) 84(69) 63(73) 
4 Components of MS n(%) 28(23) 16(19) 
5 Components of MS n(%) 9(7) 7(8) 
Cardiovascular Risk Score (%) 18.7 ± 11.9 18.9 ± 12.0 
Coronary Heart Disease Risk (%) 12.0 ± 8.0 12.2 ± 8.3 
   
 














Table 23: Baseline Characteristics of Subjects in Study (all subjects recruited) 
       
 
Low Carbohydrate Low fat 
Low Glycaemic 
Load 
Number of subjects 41 38 42 
Age 51± 12.3 59 ± 10.1 56 ±  8.9 
Female 24 21 21 
Male 17 17 21 
Diabetes 6 7 9 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 
Weight (kg) 102.9± 19.0 93.9 ± 16.5 99.4 ± 19.8 
BMI (kg/m2) 35.3 ± 6.1 33.5 ± 5.2 34.3 ± 5.3 
Waist circumference 108.4 ± 11.6 106.5 ± 9.7 109.1 ± 14.0 
Total cholesterol (mmol/dl) 5.6 ± 1.0 5.7 ±  1.1 5.8 ± 0.8 
HDL-cholesterol (mmol/dl) 1.4 ± 0.5 1.4 ± 0.4 1.3 ± 0.4 
LDL-cholesterol (mmol/dl) 3.3 ± 0.8 3.5 ± 1.0 3.4 ± 0.7 
Total cholesterol/HDL ratio 4.4 ±1.2 4.5 ± 1.1 4.5 ± 1.2 
Fasting Triglycerides 1.9 ± 1.0 2.1± 0.8 2.1 ± 1.1 
Fasting glucose (mmol/dl) 5.77 ± 1.74 5.83 ± 1.49 6.18 ± 1.98 
HbA1c (%) 6.7 ±1.4 (n=6) 7.0 ± 0.9 (n=7) 6.6 ± 0.8 (n=9) 
Systolic BP (mmHg) 139.1± 18.3 141.6 ± 12.7 142.0 ± 14.6 
Diastolic BP (mmHg) 84.9 ± 9.5 85.3 ± 10.50 86.5 ± 10.5 
3 Components of MS n(%) 31(76) 26(68) 27(664) 
4 Components of MS n(%) 7(17) 10(26) 11(26) 
5 Components of MS n(%) 3(7) 2(5) 4(10) 
Cardiovascular Risk Score (%) 15.0 ± 10.7 20.8 ± 12.0 20.1 ± 11.9 
Coronary Heart Disease Risk (%) 9.1 ±6.4 13.5 ± 8.7 13.1 ±8.1 
    
























Table 24: Baseline Characteristics of Subjects in Study (subjects who completed and included in 
per protocol analysis) 
 
 
Low Carbohydrate Low fat 
Low Glycaemic 
Load 
Number of subjects 24 30 32 
Age 54.5± 11.7 59.6 ± 10.2 56 ±  8.9 
Female 15 15 14 
Male 9 15 18 
Diabetes 4 6 9 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.70 ± 0.10 
Weight (kg) 101.5± 19.5 93.4 ± 17.0 99.4 ± 19.8 
BMI (kg/m2) 35.8 ± 6.7 33.4 ± 5.0 34.3 ± 5.3 
Waist circumference 109.2 ± 11.7 106.8 ± 10.2 109.1 ± 14.0 
Total cholesterol (mmol/dl) 5.6 ± 1.0 5.7 ±  1.1 5.78 ± 0.84 
HDL-cholesterol (mmol/dl) 1.4 ± 0.5 1.3 ± 0.4 1.34 ± 0.40 
LDL-cholesterol (mmol/dl) 3.4 ± 0.8 3.5 ± 1.0 3.47 ± 0.72 
Total cholesterol/HDL ratio 4.3 ±1.1 4.5 ± 1.1 4.52 ± 1.24 
Fasting Triglycerides 1.8 ± 1.0 2.1± 0.8 2.11 ± 1.07 
Fasting glucose (mmol/dl) 5.7 ± 1.9 5.9 ± 1.6 6.18 ± 1.98 
HbA1c (%) 6.5 ±1.4 (n=4) 7.1 ± 1.0 (n=6) 6.57 ± 0.79 (n=9) 
Systolic BP (mmHg) 136.5± 17.7 142.6 ± 14.0 142.0 ± 14.6 
Diastolic BP (mmHg) 82.3 ± 8.2 86.2 ± 8.8 86.5 ± 10.5 
3 Components of MS n(%) 20(83) 20(67) 23(72) 
4 Components of MS n(%) 2(8) 8(27) 6(19) 
5 Components of MS n(%) 2(8) 2(8) 3(9) 
Cardiovascular Risk Score (%) 14.4 ± 9.8 21.9 ± 12.3 20.11 ± 11.9 
Coronary Heart Disease Risk (%) 8.9 ±6.0 14.3 ± 8.0 12.8 ±8.6 




Page | 148 
 
6.2. Changes in Weight and Waist  
Weight and waist measurements were evenly distributed amongst the three 
groups. Individuals in the LFD group were collectively lighter in weight compared to 
the other two groups but the difference was not statistically significant (p=0.12 for 
LFD vs. LCD; p=0.20 for LFD vs. LGL; p=0.78 for LGL vs. LCD in between group 
ANOVA). 
All three groups lost weight with the average overall weight loss being 6.50kg 
(6.6 %). The highest individual weight loss was 31.5kg (24.3% of total body weight) 
and the least was a gain of 4.80kg (+4.7 %). Total average weight loss was least in 
the LFD group, corresponding to suggestions from previous studies that a high 
carbohydrate intake may encourage weight gain.  
When looking at the twelve best and worst weight loss results, the LCD group 
appeared more frequently in the best losers’ category with six of the subjects, while 
the LFD group was more prominent in the least losers group (Table 25). The LGL 
group was evenly distributed among the two categories. Similar results were 
confirmed on the histograms of percentage weight loss at the end of the study period 
(Figure 14). 
Table 25: The twelve best and worst weight changes among the entire group. 
 
 Best Weight Losers  Least Weight Losers* 
Diet 
Weight loss at 12 month 
(kg) 
Diet 
Weight loss at 12 month 
(kg) 
Low Carbohydrate 31.5 Low Glycaemic Load -4.8 
Low Carbohydrate 26.9 Low Fat -4.1 
Low Glycaemic Load 25.1 Low Carbohydrate -3.8 
Low Fat 24.1 Low Glycaemic Load -3.6 
Low Carbohydrate 17.4 Low Fat -1.9 
Low Glycaemic Load 15.8 Low Fat -1.8 
Low Carbohydrate 15.6 Low Glycaemic Load -1.8 
Low Glycaemic Load 15.1 Low Fat -1.7 
Low Carbohydrate 14.9 Low Fat -1.7 
Low Fat 14.8 Low Fat -1.5 
Low Carbohydrate 13.2 Low Glycaemic Load -1.5 
Low Glycaemic Load 13.2 Low Carbohydrate -1.3 
*Least weight losers were actually the most weight gainers. 
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Figure 14: Distribution of percentage weight loss at the end of the study among the three groups 
 
 Low Carbohydrate            Low Fat     Low Glycaemic Load   
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6.2.1. Changes in Weight and Waist as Intention to Treat analysis 
 
All three groups demonstrated reductions in weight, BMI and waist 
measurements (Table 26). Reductions among the LCD group were greatest (7.8% of 
total body weight), and least among the LFD group (4.7% of total body weight). 
Despite these apparent differences there was no statistical difference between the 
groups in any of the anthropometric measurements at any stage of the study 
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Table 27: Changes in anthropometric measures (intention to treat) 
 Randomised Diet 
 Low Carbohydrate Low Fat  Low Glycaemic Load 
          
 Mean Max Min Mean Max Min Mean Max Min 
Weight (kg)          
Baseline 103.0±20.1 152.9 64.6 93.4±16.1 132.0 70.6 101.6±20.43 186.3 71.5 
3 months 95.8±19.2♥ 148.1 58.3 89.5±15.2♥ 129.5 70.1 96.1±21.0♥ 186.4 65.7 
6 months 95.0±20.0♥ 148.0 57.4 88.9±15.4♥ 130.8 68.5 94.8±21.4♥ 186.4 63.1 
12 months 95.6±20.1♥ 148.0 57.8 89.1±14.9♥ 132.3 68.7 95.8±21.9♥ 186.4 61.7 
          
BMI (kg/m2)  
 
        
Baseline 35.5±6.4 55.1 26.3 33.4±5.0 47.1 27.2 35.0±5.6 52.7 27.6 
3 months 33.0±6.7♥ 51.2 24.5 32.0±4.8 ♥ 45.7 25.6 33.1±5.4♥ 52.7 25.4 
6 months 32.7±6.1♥ 49.7 25.2 31.8±5.0♥ 46.8 25.6 32.6±4.9♥ 52.7 24.3 
12 months 32.9±6.2♥ 49.8 24.4 31.9±4.9♥ 45.6 24.6 33.0±6.4♥ 52.7 23.8 
          
Waist Circumference (cm)          
Baseline 109.1±12.1 141.0 89.5 106.6±9.6 129.0 88.0 110.5±14.4 167.0 86.0 
3 months 102.4±12.3♥ 139.0 83.0 101.7±9.7♥ 121.5 85.0 105.2±15.0♥ 166.0 80.5 
6 months 100.5±12.9♥ 137.0 76.5 100.0±9.7♥ 121.5 81.5 101.9±15.6♥ 166.0 77.5 
12 months 100.0±13.6♥ 137.0 75.5 98.8±9.5♥ 122.0 81.5 101.2±16.1♥ 166.0 74.0 
♥ p <0.001 (p-values are for within group comparisons back to baseline) 
Differences between LCD and LFD were significant for weight and BMI at 3 months (p=0.001)  
Differences between LCD and LGL were not significant at all stages. 
Differences between LFD and LGL were not significant at all stage
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6.2.2. Changes in Weight and Waist for Completers  
At 3 and 6 months there were significant differences in weight loss between the LCD 
and LFD groups (p<.0.001).   No difference was noted between the LCD and LGL 
groups or the LFD and LGL group at any point of the study (Figure 15 & Table 28). 
 
 
Figure 15: Changes in weight among the three groups (completers) 
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Table 28: Changes in anthropometric measures (completers) 
 
 Randomised Diet 
 Low Carbohydrate Low Fat  Low Glycaemic Load 
          
 Mean Max Min Mean Max Min Mean Max Min 
Weight (kg)          
Baseline 101.5±19.5 146.3 64.6 93.4±17.1 132.00 70.60 98.7±15.3 133.4 71.5 
3 months 93.1±18.0♥ 136.5 58.3 89.4±15.6♥ 129.50 70.10 92.4±14.7♥ 118.5 65.7 
6 months 91.8±18.9♥ 143.7 57.4 88.7±16.1♥ 130.80 68.50 90.9±15.3♥ 125.1 63.1 
12 months 92.6±19.1♥ 141.4 57.8 89.0±15.7♥ 132.30 68.70 92.1±16.2♥ 134.7 61.7 
          
BMI (kg/m2)          
Baseline 35.7±6.7 55.1 26.3 33.4±5.0 47.1 27.2 35.0±5.6 47.8 27.6 
3 months 32.8±6.3♥ 51.2 24.5 32.0±5.0♥ 45.7 25.59 32.1±4.3♥ 42.3 25.4 
6 months 32.3±6.5♥ 49.7 25.2 31.8±5.0♥ 46.8 25.6 31.6±4.7♥ 44.9 24.3 
12 months 32.6±6.6♥ 49.8 24.4 31.9±4.9♥ 45.6 24.6 32.1±5.3♥ 48.3 23.8 
          
Waist Circumference (cm)          
Baseline 109.2±11.7 135.0 89.5 106.8±9.6 129.0 88.0 110.5±14.4 136.0 86.0 
3 months 101.3±11.4♥ 123.0 83.0 101.8±9.8♥ 121.5 85.0 101.5±11.2♥ 124.0 80.5 
6 months 98.6±12.4♥ 126.0 76.5 99.8±9.7♥ 121.5 81.5 98.9±11.5♥ 125.5 77.5 
12 months 97.8±13.3♥ 123.5 75.5 98.4±10.0♥ 122.0 81.5 97.8±12.0♥ 128.0 74.0 
♥ p <0.001 (p-values are for within group comparisons back to baseline) 
Differences between LCD and LFD were significant for weight and BMI at 3 & 6 months (p<0.001) and waist (p<0.001) at 3 & 6 months.  
Differences between LCD and LGL were not significant at all stages. 
Differences between LFD and LGL were not significant at all stages.
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Graph demonstrates the percentage weight loss of each group at each study interval with standard error 
 
Changes in BMI (Table 28 & Figure 17) followed a similar pattern as weight with 
measurements falling maximally at 6 months, 33.3, 31.8 and 31.6kg/m2 for LCD, 
LFD and LGL respectively, rising somewhat at 12 months (32.6, 31.9 and 32.1kg/m2 
respectively). Between group changes were significant between LCD and LFD at all 
study intervals (p<0.05), and LCD and LGL at 3 months only.  
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Reductions in waist measurement (Figure 18 & Table 28) occurred within all three 
groups and persisted at all stages of the study interval despite weight measurements 
beginning to rise at 6 months. The combined mean waist measurement for the groups 
at the start was 108cm and 98cm at finish, an average loss of 8.7%. Although no 
statistical difference existed between the groups at all study intervals the percentage 
of waist circumference reduction was significant for LCD (6.7 % 9.1%) vs. LFD 4.5 




Figure 18: Changes in waist circumference measurements 
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6.3. Changes in Components of the Metabolic Syndrome 
All subjects taking part in the study fulfilled the NCEP-ATP criteria for 
metabolic syndrome at the start of the study (i.e. displayed at least three of the five 
criterion which define the syndrome) (Table 1, Figure 19). The exception was those 
individuals who were already on medication for diabetes or hypertension as baseline 
bloods were potentially normal due to the effect of medication.  Analysis of the 
number of individuals with metabolic syndrome at start and end of study included 
those individuals who were already on anti-hypertensive medication regardless of 
baseline blood pressure readings (Table 31-Table 33). 
 
Most individuals displayed 3 to 4 criteria of the metabolic syndrome (average 
=3.3) at the start of the study with equal distribution among the three groups, (average 
for LCD= 3.3, LFD= 3.4, LGL= 3.4) at the start (Table 31).  
 
Reductions in the number of individuals fulfilling the criteria for metabolic 
syndrome were noted across the three groups with the greatest of these reductions 
noted among the LCD group where there was an 83% reduction in the number of 
individuals who had 3 or more components to fulfil the diagnostic criteria for MS. 
The fall among the other two groups was 50% for LFD and 62% for LGL.  
 
Overall in combination, approximately 60% of the completers no longer had 
the features that would make them eligible for the diagnosis of metabolic syndrome 
by the end of the study (Table 34).  
 
Whereas at the start of the study only two individuals had controlled blood 
pressure on antihypertensive therapy, the numbers increased to 18 at the end of the 
study with only 62 individuals classified as hypertensive (i.e. systolic blood pressure 
>130mmmHg). Reductions and changes in blood pressure medication are discussed 
in the following section. 
  






















 M F All M F All M F All M F All 
3 Components 10 21 31 9 17 26 13 14 27 32 52 84 
4 Components 5 2 7 6 4 10 6 5 11 17 11 28 












Table 30: Prevalence of 3 or more abnormalities of Metabolic Syndrome at baseline for the study 



















 M F All M F All M F All M F All 
3 Components 67 93 83 47 87 67 64 78 72 58 85 73 
4 Components 22 0 8 40 13 27 29 11 19 32 8 19 
5 Components 11 7 8 13 0 7 7 11 9 10 6 8 
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Number of Characteristics of Metabolic Syndrome0 1 2 3 4 5



















 M F TOTAL M F TOTAL M F TOTAL M F TOTAL 
Waist Measurement 15 22 37 14 21 35 21 17 38 50 66 116 
Fasting Glucose (Diabetes) 7 (1) 5 (1) 12 (2) 7 3 10 8 (1) 9 (1) 17 (2) 22 (2) 17 (2) 39 (4) 
Triglycerides 11 7 18 14 8 22 17 9 26 42 24 66 
HDL-cholesterol 6 7 11 5 5 10 7 4 11 18 16 34 
Systolic Blood pressure 17 21 38 17(1) 20(1) 37(2) 21 21 42 55 62 117(2) 
Diastolic Blood pressure 11 14 25 13 14 27 18 11 29 42 39 81 
Figures in parentheses () indicate number of individuals with diabetes or on anti-hypertensive therapy with normal blood pressure reading. 
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 M F TOTAL M F TOTAL M F TOTAL M F TOTAL 
Waist Measurement 8 14 22 13 15 28 12 17 29 33 46 79 
Fasting Glucose (Diabetes) 4 (3) 4 (1) 8 (4) 7 2 9 6 (1) 7 (1) 13 (2) 17 (4) 13 (3) 30 
Triglycerides 6 5 11 13 6 19 10 7 17 29 18 47 
HDL-cholesterol 3 4 7 5 5 10 4 3 7 12 12 24 
Systolic Blood pressure 9 12 21 15 (1) 15 (1) 30 (2) 14 18 32 38 45 83(2) 
Diastolic Blood pressure 7 10 17 12 10 22 12 8 20 31 28 59 
Figures in parentheses () indicate number of individuals with diabetes or on anti-hypertensive therapy with normal blood pressure reading. 
 
 












 M F TOTAL M F TOTAL M F TOTAL M F TOTAL 
Waist Measurement 6 10 16 8 11 19 6 11 17 20 32 52 
Fasting Glucose (Diabetes) 3  2 5 7 (1) 2 9 5 (2) 5 (2) 10 (4) 15 (3) 9 (2) 24 (5) 
Triglycerides 2 4 6 5 4 9 7 6 13 14 14 28 
HDL-cholesterol 1 0 1 3 4 7 1 3 4 5 7 12 
Systolic Blood pressure 6 (2) 9 (2) 15 (4) 15 (5) 12 (3) 27 (8) 11 (3) 9 (3) 20 (6) 32 (10) 30 (8) 62 (18)  
Diastolic Blood pressure 1 2 3 6 4 10 5 4 9 12 10 22 
Figures in parentheses () indicate number of individuals with diabetes or on anti-hypertensive therapy with normal blood pressure reading. 


































Waist Measurement 25 29 27 39 27 32 50 35 41 39 30 34 
Fasting Glucose (Diabetes) 25 50 38 0 0 0 17 29 23 12 31 20 
Triglycerides 67 20 46 62 33 53 30 14 24 52 22 40 
HDL-cholesterol 
 
67 100 86 40 20 30 75 0 43 58 42 50 
Systolic Blood pressure 33 25 29 0 20 10 21 50 38 16 33 26 
Diastolic Blood pressure 86 80 82 50 60 55 58 50 55 62 64 63 
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6.4. Changes in Blood Pressure 
 
Changes in blood pressure readings were generally small (Table 35). 
Reductions in systolic blood pressure were 2.7, 4.8, & 5.7% in the LCD group at 3, 6 
and 12 months (p<0.01 at 6 & 12 months), 2.3, 2.3 & 1.7% for LFD (p=NS), and 1.6, 
5.0 & 5.5% for LGL (p<0.01 at 6 and 12 months) No differences were demonstrated 
in between group analysis. 
Reductions in diastolic blood pressure were +1.3, -3.0 & -4.0% in the LCD 
group at 3, 6 and 12 months respectively (p<0.05 at 12 months), 1.2, 2.7 and 3.9% 
in LFD (p<0.05 at 12 months), and 1.6, 5 and 5.5% in the LGL group (p<0.01 at 6 
& 12 months) for the same time intervals. (Figure 21 & Table 36). 
Changes in blood pressure did not correlate to changes in weight in the whole 
cohort nor for LCD or LFD. Diastolic blood pressure changes in the LGL group 
positively correlated to weight at 3, 6 & 12 months (r =0.41, 0.43, & 0.47, p<0.05 for 
all). 
Table 35: Blood pressure at each of the study intervals 
 




Low Carbohydrate Low Fat 
Low Glycaemic 
Load 
Systolic BP (mmHg)    
Baseline 138.5±17.9 141.7±13.4 141.2±15.2 
3 months 133.7±17.3 138.21±15.5 137.2±14.9 
6 months 129.8♥±14.6 138.5±18.1 132.8♦±17.7 
12 months 127.8♦±14.2 140.1±18.3 130.7*±13.2 
    
Diastolic BP (mmHg)    
Baseline 84.6±9.7 85.20±10.9 86.41±10.8 
3 months 84.8±8.7 84.42±9.5 84.44±7.9 
6 months 79.7±7.6 82.77±9.3 80.38♥±7.9 
12 months 78.7♦±7.4 82.60♦±8.9 80.41*±7.1 
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Table 36: Mean blood pressure changes across the groups 
 
 ♦ p< 0.05, * p <0.01 (p-values are for within group comparisons back to baseline) 
 
 
As individuals who were known to be hypertensive had not been excluded 
from the study the number of antihypertensive agents individuals were taking were 
documented. Sixty-two patients were taking some form of antihypertensive agents at 
the start of the study and only 53 at the end. The average number of agents used at 
the start of study was 2.0 per individual, and 2.1 at the end. Thirteen people 
discontinued all antihypertensive medication, three started new antihypertensive 
therapy, six had dose reductions and seven had dose increases. Table 37 outlines those 
who had alterations in blood pressure medication throughout the study. 
Table 37: Changes in the number of antihypertensive agents used 
 
 Low Carbohydrate Low Fat Low Glycaemic 
Load 
Systolic BP (mmHg) Mean Mean Mean 
3 months -4.6±15.3 -3.8±14.6 -3.3±16.9 
6 months -7.2±12.8* -3.6±14.9 -7.6±17.4* 
12 months -8.8±15.8* -6.5±25.2 -8.6±16.3* 
    
Diastolic BP (mmHg)    
3 months +0.7±7.03 -0.1±11.1 -1.7±8.6 
6 months -2.8±7.7 -2.5±8.7 -5.8±8.5* 











Low Fat Low Glycaemic 
Load 
Total 
 Start End Start End Start End Start End 
On 5 agents 0 1 2 1 0 0 2 2 
On 4 agents 2 0 2 3 0 0 4 3 
On 3 agents 3 1 3 7 2 2 8 10 
On 2 agents 5 6 13 9 9 7 27 22 
On 1 agent 8 5 7 6 6 5 21 16 
On no agents 1 6 1 2 1 4 3 12 
Total on 
antihypertensive 
18 13 27 26 17 14 62 53 




Figure 21: Percentage reductions in systolic and diastolic blood pressure readings 
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 Changes in Lipid Profile 
 
The changes in total cholesterol, HDL-cholesterol, LDL-cholesterol, non-
HDL-cholesterol and triglycerides for the three groups are tabulated in Table 38 & 39 
and Figure 22.  
Total cholesterol levels remained stable in the LFD group (5.76, 5.75, 5.63, 
5.75mmol/l) at 0, 3, 6 & 12 months respectively In the LCD group there was a non-
significant trend to higher total cholesterol levels (5.51, 5.56, 5.85, 5.77mmol/l), 
while in the LGL group (5.77, 5.46, 5.56, 5.59mmol/l) the trend appeared to be 
downward (p<0.01 at 3 months). The percentage changes in total cholesterol between 
LCD (+2.0 & +5.6%)   and LGL (-6.4 and -4.6% -) were significant at 3 and 6 months 
(p<0.05 for both). 
Changes in LDL-cholesterol followed a similar pattern to total cholesterol. 
LDL-cholesterol in LFD remained stable (2.6, -0.6, & 2.4%) at 3, 6 & 12 months; 
(p=NS) In the LCD group, LDL-cholesterol trended up (3.8, 8.3 & 5.7% (p=NS), and 
On the LGL diet, LDL-cholesterol fell at 3 months (p<0.05), significance not being 
maintained at 6 and 12 months (-5.3, -2.5 & -4.8%). Between group changes were 
statistically relevant at three months for LGL vs. LCD (p<0.05).  
HDL-cholesterol rose in all three groups with levels rising the most 17.5, 17.7 
& 18.6%; (all p<0.01) in the LCD group at 3, 6 and 12 months,  the least 0.6, 5.1 & 
8%; (p=NS) in the LFD group and moderately 2.0, 7.0% & 14.7%; (p <0.05 at 6 & 
12 months) in the LGL group for the same time intervals. These changes were 
statistically significant between the groups at 3 and 6 months for LCD vs. LFD (both 
p<0.01), and LCD vs. LGL (both p<0.05). LGL vs. LFD was significant at 3 months 
(p<0.01).   
Changes seen in Non HDL-cholesterol were similar to that noted for total and 
LDL-cholesterol. Non HDL-cholesterol fell by 8.9, 7.7 and 8.6% in the LGL group, 
0.1, 3.3, and 0.4% for LFD at 3, 6 and 12 months. In the LCD group levels fell at 3 
months (-2.7%), rose at 6 months (+2.2%) and returned to baseline at the end (-0.2%). 
The changes were not significant within or between the groups at any stage.   
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With the rise in HDL-cholesterol levels total cholesterol to HDL-cholesterol 
ratios fell in all three interventions by 11.8, 4.7, 9.7% at 3, 6 and 12 months, (p<0.01 
at 6 & 12 months) in LCD, 5.7, 6.5 and 9.1% (all p<0.01) in LGL, and +0.1, 5.2, and 
5.9% in the LFD group (p<0.05 at 12 months) at the same time intervals. Differences 
in the change in total cholesterol to HDL-cholesterol ratios between groups was 
significant at 3 months for LCD vs. LFD (p<0.01). 
A reduction in triglyceride levels was noted among all three groups.  Greatest 
reductions were within the first six months, the period considered to be the active 
phase of the dietary interventions.   Reductions were 22.6, 10.2 and 14.3% (all 
p<0.05) for LCD at 3, 6 and 12 months, 11.7, 14.1, and 8.4% (p<0.05 at 3 & 6 months) 
for LFD, and 15.9, 23.2 and 11.8% (all p<0.01) for LGL. At no stage in the study 
were between group differences noted. 
HDL-cholesterol levels negatively correlated with weight (r= -0.24, -0.23, -
0.26 & -0.25; all p<0.05) at 0, 3, 6 and 12 months when the three groups were 
analysed as a cohort. These changes were not noted when the groups were analysed 
individually. None of the other lipid parameters demonstrated any form of correlation 
to weight, despite the reduction in triglycerides. 
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Table 38: Changes in lipid profile over the 12 month study period 
 
 Dietary Intervention 
 Low Carbohydrate Low Fat Low Glycaemic Load 
 Mean Max Min Mean Max Min Mean Max Min 
Total cholesterol (mmol/dl)          
Baseline 5.51±1.09 8.6 3.6 5.76±1.10 8.2 5.8 5.77±0.84 7.7 4.1 
3 months 5.56±0.94 7.7 4.1 5.75±1.35 9.1 3.0 5.46±0.82* 7.6 3.5 
6 months 5.85±0.99 7.7 4.2 5.63±1.27 8.2 2.4 5.56±0.97 7.8 3.3 
12 months 5.77±1.01 7.5 3.7 5.75±1.20 7.8 2.8 5.59±0.82 7.2 4 
LDL-cholesterol (mmol/l)          
Baseline 3.24±0.78 4.9 1.9 3.51±0.99 5.8 1.0 3.59±0.71 5.0 2.1 
3 months 3.38±0.92 5.8 1.8 3.62±1.21 6.5 1.0 3.33±0.77♦ 5.3 1.3 
6 months 3.59±0.98 5.3 1.9 3.50±1.07 5.8 0.8 3.45±0.92 5.8 1.0 
12 months 3.47±0.95 5.4 1.9 3.52±0.99 5.6 1.0 3.33±0.79 4.9 1.6 
HDL-cholesterol (mmol/l)          
Baseline 1.34±0.43 3.2 0.7 1.36±0.35 2.1 0.8 1.35±0.42 2.4 0.8 
3 months 1.59±0.47♥ 0.8 3.4 1.34±0.34 2.1 0.8 1.42±0.44 2.5 0.9 
6 months 1.63±0.57* 0.8 3.4 1.41±0.40 2.2 0.8 1.48±0.40* 2.6 0.8 
12 months 1.66±0.66* 1.0 4.0 1.44±0.39♦ 2.2 0.9 1.58±0.50* 2.8 0.9 
Non HDL-cholesterol (mmol/l)          
Baseline 4.18±1.09 7.5 2.6 4.40±1.03 6.8 2.2 4.42±0.84 6.7 2.9 
3 months 3.97±1.00 6.3 2.1 4.41±1.27 7.5 2.0 4.04±0.91 6.4 1.7 
6 months 4.22±1.17 6.4 2.1 4.22±1.15 6.8 1.6 4.09±1.02 6.5 1.4 
12 months 4.11±1.09 6.1 2.2 4.31±1.07 6.4 1.9 4.02±0.94 6.1 2.2 





Table 39: Changes in lipid profiles cont... 
 
 Dietary Intervention 
 Low Carbohydrate Low Fat Low Glycaemic Load 
          
Triglycerides (mmol/l)          
Baseline 1.9±0.9 4.8 0.8 2.1±0.8 4.0 1.0 2.0±0.9 4.0 0.6 
3 months 1.3±0.5* 2.7 0.6 1.8±0.7* 3.9 0.5 1.6±0.8♥ 3.8 0.5 
6 months 1.4±0.7♦ 2.8 0.6 1.7±0.83♦ 4.7 0.5 1.4±0.7♥ 3.1 0.5 
12 months 1.4±0.7♦ 2.9 0.5 1.76±0.83 4.0 0.5 1.5±0.8* 3.9 0.5 
Cholesterol/HDL-chol. Ratio          
Baseline 4.4±1.20 7.8 1.9 4.5±1.1 6.9 2.7 4.5±1.2 7.7 2.5 
3 months 3.7±1.0♥ 6.3 1.6 4.5±1.3 7.9 2.6 4.2±1.3* 7.2 1.9 
6 months 3.9±1.5 9.0 1.6 4.2±1.1♦ 6.3 2.3 4.0±1.2♥ 6.8 1.7 
12 months 3.8±1.1* 6.1 1.6 4.2±1.0♦ 6.8 2.7 3.9±1.2* 6.5 1.9 
          
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values are for within group comparisons back to baseline) 
 
Differences in changes in total cholesterol between LCD & LGL were significant at 3 & 6 months (p<0.05)  
Differences in changes in HDL- cholesterol  between LCD and LGL  were significant at 3  months  and  between LCD and LFD at 3 & 6 months (p<0.01)  
Differences in changes in LDL-cholesterol between LGL and LFD were significant at 3 months (p<0.05) 
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Percentage changes in lipid profiles at 3, 6 and 12 months 
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6.5. Changes in Cardiovascular risk  
 
Reductions in CVD risk (Table 40) were 16.9, 15.6, and 15.8% (all p<0.01) for 
LCD, 6.6, 8.9, and 3.5% (p<0.05 at 3months) for LFD and 3.9, 18 and 15.4% (all 
p<0.05)) for LGL at 3, 6 and 12 months (Figure 24) Between group differences were 
significant for the LCD vs. LFD at 3, 6 and 12 months (all p<0.01) but not LFD vs. 
LGL or LCD vs. LGL. 
CHD risk reductions were similar in pattern to the CVD reductions. Within 
group changes in LCD and LGL were statistically significant at all study intervals 
and only at 6 months for LFD (p<0.05). Between group differences were significant 
for the LCD vs. LFD at 3, 6 and 12 months (all p<0.01) but not LFD vs. LGL or LCD 
vs. LGL. 
 





Low Fat Low Glycaemic 
Load 
 Mean ± SD Mean ± SD Mean ± SD 
Cardiovascular risk (%)    
Baseline 15 ±1 21 ± 1 20 ± 1 
3 months 12 ± 9* 22 ± 11 18 ± 11♦ 
6 months 12 ± 9♦ 20 ± 12 15 ± 11* 
12 months 12 ± 8* 21 ±12 16 ± 12* 
Coronary Heart Disease risk (%)    
Baseline 9 ± 6 14 ± 9 13 ± 8 
3 months 7 ± 5* 13 ± 7 11 ± 7* 
6 months 7 ± 6   12 ± 8♦ 10 ± 7* 
12 months 7 ± 5* 13 ± 8 11 ± 8♦ 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values are for within group comparisons back to baseline) 
 
 













3 months 6 months 12 months 3 months 6 months 12 months
CVD Risk
CHD Risk








-16.9 -15.6 -15.8 -20.6
-15.1 -17.3
Percentage change in CVD and CHD risk
Low Fat Low Glycaemic Load Low Carbohydrate
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7. CHAPTER 7: Results from Dietary Analysis  
 
7.1. Introduction & methodology 
 
When starting this study it was the intention to perform a comprehensive 
dietary analysis looking at the subjects’ weighed food and oral intake prior to entering 
the study and then at various intervals throughout the study. The intention was to look 
at the participants’ dietary changes, and concordance with the prescribed dietary 
regimen. Participants were supplied with weighing scales (Salter aquatronic 
electronic kitchen scales, Salter Housewares HoMedics House, Tonbridge, Kent) and 
asked to complete weighed food diaries at various intervals and for the following 
lengths of time – 
1. Prior to starting study   7 day food diary 
2. 6 weeks     4 day food diary 
3. 3 months    3 day food diary 
4. 6 months    3 day food diary 
5. End of study     3 day food diary 
Data from the completed food diaries were entered into a dietary analysis 
programme. The programme used was DietPlan6 version 6.15 supplied by 
Forestfield Software Ltd, Horsham, United Kingdom. 
The data from the consequent analysis were downloaded onto an Excel 
spreadsheet and contained such details as caloric intake, and a breakdown of 
carbohydrate, protein, fat and its subgroups intake as well as some of the minerals.  
Sixty subjects were randomly chosen by an independent party for dietary 
analysis. Of the chosen food diary sets, 7 were excluded as they were considered to 
be substantially incomplete leaving 53 to be included in the analysis (Table 41). 
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7.2. Results 
There was a slightly higher number of female diaries in total which was in 
proportion to the ratio of males to female recruited to the study (Table 41). Analysis 
for the LCD and LGL groups contained almost double the number of females as men 
while the reverse is true in the LFD group. The disparity could be accounted for 
within the LCD group which did have a larger proportion of females from the start. 
Table 41: Number of food diaries analyzed at each study interval 
 






Male : Female 6:11 11:6 7:11 24:28 
Pre study 17 17 18 52 
6 weeks 17 16 17 50 
3 months 17 16 17 50 
6 months 16 14 18 48 
End of study 13 17 16 46 
 
7.3. Compliance to diet 
 
The food diaries were collected to assess concordance with the diet and 
whether individuals were meeting the recommended targets. The LCD group just 
about achieved the minimum expected level of protein intake, kept to target on fat 
intake and overshot the carbohydrate intake by the end of the study (Table 42). The 
LFD group increased protein intake by up to 25% throughout the study. Interestingly 
protein intake in this group rose rather than decreased with randomisation despite the 
restrictions. Their carbohydrate intake was equal to what would be expected at that 
time period. They were within their fat recommendations managing to reduce 
saturated fat to comply. The LGL group were compliant with protein and 
carbohydrate intake and most of the fat intake apart from saturated fat which was 20 
-30% higher than recommended.  Of note the changes made to the diets were enough 
to make the groups different for all the parameters at 6 weeks (p<0.01).  
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Table 42: Confirmation of compliance to diet 
 
 Low Carbohydrate 
 
Low Fat Low Glycaemic Load 
 Target Achieved Target Achieve
d 
Target Achieve
d Protein % % % % % % 
Baseline 30-40 20 10-15 18 25 19 
6 weeks  30  19  25 
3 months  30  19  25 
6 months  28  20  24 
12 months  28  22  23 
Carbohydrate  gms gms % % % % 
Baseline 10-12 220 50-60 41 40 44 
6 weeks 40 40  47  34 
3 months 40-80 42  47  36 
6 months 40-100 62  47  37 
12 months 40-100 114  43  38 
Fat % % % % % % 
Baseline 50-60 33 <30 32 35 33 
6 weeks  57  28  38 
3 months  56  26  34 
6 months  52  27  35 
12 months  44  29  35 
Saturated Fat (gms) % % % % % % 
Baseline NS 12 <10 12 <10 12 
6 weeks  22  9  13 
3 months  22  9  12 
6 months  20  9  11 
12 months  16  10  12 
Monounsaturated Fats 
(gms) 
% % % % % % 
Baseline NS 12 NS 12 <15 11 
6 weeks  2  10  14 
3 months  21  9  13 
6 months  18  10  13 
12 months  16  10  13 
Polyunsaturated Fats (gms) % % % % % % 
Baseline NS 6 <20 5 <10 6 
6 weeks  8  6  7 
3 months  8  5  6 
6 months  8  5  7 
12 months  7  6  7 
Measurements reported as percentage of daily calorie intake. NS=Not specified 
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7.4. Caloric Intake 
 
At start the average calorie intake was approximately 2000Kcal per day across 
the study population. Reductions  in caloric intake was seen across the three groups 
with reductions of 21.6, 19.2, 18.2, and 12.2% (P< 0.01 at 6 weeks, 3 and 6 months ) 
in LCD, 23.5, 24.9, 21.5, & 21.7% (p< 0.05 at 6 weeks, 3, 6 & 12 months ) in LFD, 
and 9.6, 16.4, 16.5, & 7.2% (p<  0.05 at 6 weeks, 3 and 6 months) in LGL at 6 weeks, 
3, 6 and 12 months respectively (Table 43, Figure 24). Changes in caloric intake were 




Protein intake increased in the LCD (98.8, 111.5, 109.4, 110.2 & 110gms/day 
baseline, 6weeks, 3, 6 & 12 months respectively) and LGL (96.6, 107.9, 106.6, 98.1, 
& 102.2gms/day) groups (Table 44). These rises were expected and in concordance 
with the recommended dietary requirements (Table 18) reaching 30% for LCD and 
25% for LGL (p <0.001 for both) of the total energy intake. Total protein levels fell 
in the LFD group (96.1, 74.1, 71, 82.8 & 81.8gms/day at the same study intervals. 
Although these reductions were up to 22% of initial protein intake, the overall 
proportion of calories from protein remained stable (18-20%) and above the 
recommended dietary target of 10-15%.  
The changes in protein intake was adequate to maintain a significant 
difference throughout the study intervals between LCD and LFD (all p<0.05), LGL 
and LFD at 6 weeks and 3 months (p<0.05), but no difference was noted for LCD and 
LGL at any stage. 
  




The average carbohydrate intake at the start was 225gms/day (Table 44) and 
approximately 40% of total daily calories. At baseline refined sugars made up 
approximately 40% (84.2, 95.7, 100.7gms/day for LCD, LFD & LGL respectively), 
of the carbohydrate load. The LCD group reduced its carbohydrate intake by up to 
80% as recommended in the dietary advice and maintained the reductions for 3 
months after which incremental increases were made (220.4, 40.2, 42.5, 61.7, & 
114.0gms/day at baseline, 6weeks, 3, 6 & 12 months) as subjects gradually increased 
the carbohydrate intake. Reductions occurred in the other two arms but not to as 
extreme levels (12.1, 11.2, 9.5 & 17.5%, LFD; 27.9, 29.4, 27.9 & 17%; LGL) at 
6weeks, 3, 6, & 12 months respectively) (Figure 24).  
Carbohydrates were to make up 50-60% of the total daily energy intake for 
the LFD group and 40% for the LGL group. Both groups remained below these 
targets.  The LFD group achieved 46.5, 47.4, 46.9 & 43.3% at 6 weeks, 3, 6 & 12 
months.  The LGL group initially reduced intake to 33.6% at 6 weeks but values then 
rose to 35.7, 36.8 & 37.5%. 
Although the total amount of refined sugar intake fell in all three groups (84.2, 
19.5, 23.1, 29.7 & 50.8gms/day for LCD; 95.7,81.3, 80.4,  84.3  & 66.9gms/day for 
LFD; 100.7, 74.7, 71.4, 80.8,  & 87.1gms/day for LGL at baseline, 6 weeks, 3, 6 & 
12 months, the proportion of refined sugar making up the total carbohydrate intake 
rose in both the LCD (38.8, 55.8, 57.9, 53.6 & 51.9%) and  LGL (42.3, 49.4, 45, 
49.3& 48.2% ) arms, but remained static in the LFD (41.6, 41.5, 42.6 39.6 & 39.7) 
group. This is in direct contrast to the recommendations of both the LCD and LGL 
diets which encourage the use of complex carbohydrates with low glycaemic loads. 
Changes in refined sugar intake were significant between the LCD and LFD group at 
6 weeks, 3 & 6 months (p<0.01), the LCD and LGL group at all study intervals 
(p<0.01) but not between LGL and LFD at any study interval. 
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Figure 24: Changes in total calories and calories from each source by percentage across the 
three groups 
 






















































































Percentage Calorie reductions among the three groups
Low Carbohydrate Low Fat Low Glycaemic Load
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Table 43:  Variations in caloric intake among the three diets 
 
 Low Carbohydrate Low Fat Low Glycaemic Load 
 Daily Average 
Calories 








Percentage of energy 
intake (%) Total Average Caloric Intake       
Baseline 1998.5± 670.5  2079.8± 641.5  2007.5± 393.1  
6 weeks 1479.8± 435.3*  1532.9± 429.9♥  1709.2± 266.1♦  
3 months 1510.6± 346.3*  1477.0± 412.3♥  1636.5± 301.9*  
6 months 1580.6± 444.9*  1665.5± 316.7*  1632.2± 351.7*  
12 months 1635.9± 434.1  1491.9± 393.3*  1760.5± 409.7  
Protein       
Baseline 395.1± 116.0 20.0± 4.4 384.6± 122.4 18.4± 3.2 386.5± 99.2 18.8± 3.2 
6 weeks 446.0± 166.1♥ 30.1± 7.2 296.2± 111.4 18.6± 3.5 431.3± 82.1♥ 24.9± 4.2 
3 months 437.5± 132.7♥ 28.8± 6.3 284.1± 87.8 18.8± 3.1 426.2± 115.2♥ 25.4± 4.9 
6 months 440.8± 139.5♥ 27.9± 6.1 331.4± 81.3 19.6± 4.2 392.2± 91.0* 23.9± 4.7 
12 months 439.8± 111.9♥ 27.5± 7.1 327.0± 80.2 21.8± 3.9* 408.8± 95.5♥ 22.8± 3.3 
Carbohydrate        
Baseline 826.5± 364.5 40.8± 12.0 855.5± 288.2 40.8± 7.6 888.0± 212.9 43.5± 6.9 
6 weeks 150.8± 114.2♥ 10.2± 7.3 713.8± 191.1♦ 46.5± 9.9 593.2± 175.2* 33.6± 8.7 
3 months 159.5± 125.2♥ 10.5± 7.6 700.3± 161.0♦ 47.4± 9.4 595.2± 138.8* 35.7± 6.5 
6 months 231.3± 161.0♥ 14.1± 9.2 797.0± 166.4♦ 46.9± 6.5 613.4± 146.9♥ 36.8± 4.6 
12 months 427.5± 271.4♥ 24.0± 12.5 660.1± 233.5 43.3± 9.8 675.6± 184.3♦ 37.5± 6.8 
Fat       
Baseline 688.6± 308.2 33.1± 9.2 680.6± 207.5 32.4± 5.6 672.8± 176.3♦ 32.7± 4.5 
6 weeks 860.5± 306.9♥ 56.7± 6.8 433.3± 139.5 27.6± 5.9* 651.9± 147.8 37.6± 8.1 
3 months 863.0± 260.8♥ 55.6± 9.2 402.4± 156.0 26.3± 6.5* 569.3± 129.5 34.0± 5.1 
6 months 839.8± 304.6♥ 51.7± 8.6 458.0± 123.3 27.0± 6.2* 592.8± 173.3 35.3± 4.6 
12 months 730.0± 227.9♥ 43.7± 7.3 440.7± 169.9 28.9± 8.9 635.1± 204.6 35.2± 7.7 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values are for within group comparisons back to baseline) 
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Protein (gms)    
Baseline 99 ± 29 96 ± 31 97 ± 25 
6 weeks 112 ± 42♦ 74 ± 28♥ 108 ± 21 
3 months 109 ± 33 71 ± 22♥ 107 ± 29 
6 months 110 ± 35 83 ± 20♦ 98 ± 23 
12 months 110± 28.0 81± 20.1 102± 23.9 
Carbohydrate (gms)    
Baseline 220 ± 97  228 ± 77 237 ± 57 
6 weeks 40 ± 31♥ 190 ± 51♦ 158 ± 47♥ 
3 months 42 ± 33♥ 187 ± 43♦ 159 ± 37♥ 
6 months 62 ± 43♥ 213 ± 44 164 ± 39♥ 
12 months 114 ± 72♥ 176 ± 62♦ 180 ± 49♦ 
Fat (gms)    
Baseline 77 ± 34 76 ± 23 75 ± 20 
6 weeks 96 ± 34 48 ± 16♥ 72 ± 16 
3 months 96 ± 29♦ 45 ± 17♥ 63 ± 14♦ 
6 months 93 ± 34 51 ± 14* 66 ± 19 
12 months 81 ± 25 49 ± 19* 71 ± 23 
Refined Sugars (gms)    
Baseline 84 ± 42 96 ± 43 101 ±32 
6 weeks 20 ± 16♥ 81 ± 37 75 ±22* 
3 months 23 ± 17♥ 80 ± 30 71 ±26* 
6 months 29.7± 21.9♥ 84.3± 25.1 80.8±25.7♦ 
12 months 50.8± 32.7* 66.9± 24.4♦ 87.1±27.7 
Fibre (gms)    
Baseline 20 ± 8 21 ± 8 22 ± 7 
6 weeks 9 ± 3♥ 21 ± 6  19 ± 8 
3 months 11 ± 4♥ 20 ± 7 20 ± 6 
6 months 12 ± 10* 22 ± 5 18 ± 6♦ 
12 months 17.4± 9.2♦ 18.2± 7.8 21.0± 8.5 
Saturated Fat (gms)    
Baseline 29 ± 15 27 ± 10 27 ± 7 
6 weeks 37 ± 14♦ 15 ± 6♥ 24 ± 7 
3 months 38 ± 13 15 ± 6♥ 21 ± 6* 
6 months 37 ± 17 17 ± 7* 21 ± 6♦ 
12 months 29.2± 9.5 16.0± 6.2* 22.6± 8.3 
Monounsaturated Fats (gms)    
Baseline 27 ± 12 26 ± 8 26 ± 8 
6 weeks 35 ± 13♦ 18 ± 8♥ 27± 6 
3 months 36 ± 12* 15 ± 9♥ 24 ± 7 
6 months 33 ± 13 18 ± 5* 24 ± 8 
12 months 29 ± 10 17 ± 7* 26 ± 10 
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Polyunsaturated Fats (gms)    
Baseline 13 ± 6 12 ± 5 13 ± 5 
6 weeks 14 ± 7 10 ± 5♦ 14 ± 6 
3 months 13 ± 6 9 ± 4♦ 11 ± 4 
6 months 13 ± 4 9 ± 3♦ 12 ± 6 
12 months 14 ± 8 10 ± 6 13 ± 4♦ 
Cholesterol (mgs)    
Baseline 348 ± 149 392 ± 195 312 ± 134 
6 weeks 670 ± 247♥ 185 ± 111* 369 ± 164 
3 months 655 ± 289♥ 197 ± 124* 347 ± 228 
6 months 611 ± 233* 231 ± 178♦ 293 ± 92♦ 
12 months 493 ± 198. * 228 ± 95* 359 ± 138 
Sodium (mgs)    
Baseline 3115 ± 1329 3070 ± 1014 3157 ± 917 
6 weeks 2822 ± 1209 2387 ± 1124* 2801 ± 1060 
3 months 2840 ± 1433 2554 ± 1057♦ 3182 ± 1529 
6 months 3004 ± 1435 2652 ± 933♦ 2867 ± 943 
12 months 3488 ± 1285 2495 ± 1104♦ 3022 ± 1073 
Calcium (mgs)    
Baseline 889 ± 436 881± 217 944 ± 286 
6 weeks 623 ± 271* 726 ± 244* 1005 ± 272 
3 months 522 ± 214♥ 701 ± 120* 941 ± 303 
6 months 642 ± 367♦ 801± 185 878 ± 247 
12 months 700 ± 338 773 ± 294 928 ± 253 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values refer to within group changes from baseline) 
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Changes in nutritional intake throughout the study period
Low Carbohydrate Low Fat Low Glycaemic Load
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7.7. Fat 
A significant reduction in fat intake was noted in the LFD group (75.6, 48.2, 
44.7, 50.9 & 49gms/day) p<0.01) across the 5 study intervals (baseline, 6weeks, 3, 6 
& 12 months) (Table 45, Figure 25). Total fat intake did not change significantly in the 
LGL group (74.8, 72.4, 63.3, 65.9, & 70.6gms/day). Although levels rose among the 
LCD group in concordance with the diet requirements (76.5, 95.6, 95.9, 93.3 & 
81.1gms/day), the changes were only significant at 3 months (p<0.05). 
When looking at targets, all three groups achieved the recommended 
percentage of energy intake as fat, (LCD 56.7%, LFD 27.6%, and LGL just above the 
required 35% with 37.6%) at 6 weeks.  They maintained these proportions with the 
exception of LCD which dropped to 43.7% at 12 months. 
Fat intake was also analysed depending on fat sub-fractions as these were 
expected to be somewhat different among the three study arms. The LCD group who 
had the highest fat intake were expected to have equal intake from saturated, 
monounsaturated and polyunsaturated fats. For the LFD group saturated fat intake 
was restricted to less that 30% of total fat intake (<10% total calories) with the 
remainder of the fat intake divided between monounsaturated and polyunsaturated 
fats with no allocated ratios. The LGL group had a higher total fat intake allowance 
than LFD but similar restrictions on saturated fat. Monounsaturated fats were 
prescribed to be the main source of fats with polyunsaturated fats, particularly omega 
3 forming the rest. 
In keeping with the changes seen in overall fat intake, saturated, 
monounsaturated and polyunsaturated fat intake rose in the LCD group and fell in the 
LFD group across the board Figure 27 & Table 46). Saturated fat levels fell in the LGL 
group but monounsaturated and polyunsaturated levels remained stable.  The changes 
in saturated, monounsaturated and polyunsaturated fat were significant for all stages 
in the LFD group (p<0.01), reached significance in the LCD group for 
monounsaturated fats at 6 weeks and 3 months (p<0.05), and the LGL group for 
saturated fats at 3 & 6 months (p<0.05). Comparing the groups the differences were 
significant between LCD & LFD (p<0.01) at 6weeks, 3 and 6 months, and LCD & 
LGL (P<0.05) at 6weeks, 3 and 6 months.  
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Saturated Fat (%)    
Baseline 36.4±6.2 35.5±5.2 36.2±5.9 
6 weeks 38.8±5.2 32.0±6.3♦ 32.9±6.0 
3 months 39.4±5.2 33.0±5.3♦ 33.5±5.9 
6 months 38.4±6.7 33.1±5.0♦ 31.8±5.1♦ 
12 months 36.5±5.3 33.2±6.2 32.2±5.4♦ 
 
Monounsaturated Fat (%y) 
   
Baseline 34.5±3.3 35.1±3.2 34.1±3.1 
6 weeks 36.9±3.0 36.2±6.3 37.4±3.4♦ 
3 months 36.9±5.0 33.3±6.7 37.4±5.2 
6 months 35.5±4.9 34.6±5.3 36.7±5.3 
12 months 36.2±4.0 34.9±3.8 36.1±4.3 
 
Polyunsaturated Fat (%) 
   
Baseline 16.9±3.9 16.5±4.8 17.2±3.7 
6 weeks 14.5±3.8 20.3±6.9 18.5±4.9 
3 months 13.9±4.0 20.3±5.9 17.0±3.7 
6 months 14.9±5.0 18.1±3.9 18.2±5.0 
12 months 16.1±6.8 18.9±5.9 19.1±4.4 
♦ = p<0.05 - (p-values refer to within group changes from baseline) 
 
Cholesterol intake was calculated from the dietary records at baseline, 6 
weeks, 3, 6 and 12 months. The LCD group almost doubled cholesterol intake within 
the first six months (348, 670, 655, 611 & 493mgs/day; p<0.001 at 6, 12, & 24weeks) 
before moving back towards baseline. Levels in the LFD group fell reaching the 
lowest at six weeks before gradually rising (393, 185, 197, 231 & 228mg/day, all 
p<0.01). Cholesterol levels in the LGL group remained stable (312, 369, 347, 293, 
and 359mgs/day; all p=NS). Changes in cholesterol intake were adequate to maintain 
a difference between LCD and LFD (all p<0.01) as well as LCD and LGL (all P<0.05) 
at all study intervals, and LFD and LGL at 6weeks, and 12 months (p<0.05).






































Percentage changes in fat intake acrross the three diets
 Low Carbohydrate Low Fat Low Glycaemic Load
Figure 26: Percentage change in fat sub-group intake across the three interventions 
 




The average salt intake among the three groups was 3100mg/day. In the LFD 
group sodium levels fell by 22.2% at 6 weeks (p<0.01) and remained low to the end 
of the study period (9.7, 17.5 & 11.1% at 3, 6 & 12 months; all p<0.05). Salt intake 
remained level in the LGL group. Salt intake within the LCD group was stable for 
the first six months (0.3, 3.9 & 1.2% at 6 weeks, 3 & 6 months; p=NS) until the end 
when salt intake appeared to have increased by 24.3%. This change was not 




Changes in calcium was most prominent in the LCD group where levels fell 
by 25, 32, 24 & 21% at 6 weeks, 3, 6 & 12 months (p<0.01 at 6 & 12 weeks, and 
<0.05 at 6 months). A fall in calcium intake was also observed in the LFD group with 
levels dropping by 17, 20, 9 & 11% (p<0.01 at 6 & 12 weeks) for the study intervals. 
Within the LGL group calcium levels initially rose by 7% (not significant) at 6 weeks 
then returned to baseline. Changes between groups were significant for LCD vs. LGL 
at 6 weeks (p<0.05) and 6 months (p<0.01). 
 
7.10. Potential Inaccuracies within the Food Diaries 
 
Although food diaries can be useful to help provide a log of dietary intake 
which could be fed into a computer programme to generate an objective analysis of 
caloric and nutritional intake, there are several disadvantages which are seen in most 
studies using food diaries or recollection for data collection. The first of these being 
a misrepresentation of information supplied within the food diaries. Food diaries can 
help collate a picture of food intake over a number of days, but as the subjects 
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collating the information are conscious of the exercise there tends to be a biased 
record of intake as individuals consciously choose healthier options. An example is 
the alcohol intake which was poorly documented within the majority of diaries. It is 
uncertain whether this is due to lack of regular intake, a conscientious lack of intake 
during the monitoring period, or a lack of appreciation that alcohol may have caloric 
or nutritional significance. Another example is the salt intake. Current 
recommendations are up to 6g of salt per day which is the equivalent of a full 
teaspoon. The average intake at the start of the study was 3g per day, half the 
recommended levels.  
The second issue is the accuracy of the data supplied, as this is subject to 
individual’s ability to correctly weigh and estimate the various food items. Some have 
argued that absolute figures are not necessary as long as the data collated represented 
equal proportions of the entire food spectrum. This argument was for epidemiological 
studies where data is usually collated through 24 hour recall or non-weighed food 
diaries.  
In the majority of the diaries the daily average caloric intake appeared to be 
relatively lower than what was prescribed for those subjects allocated to energy 
restricted diets. Weight loss in a number of these individuals was certainly not at the 
rate that would be expected for the degree of calorie restriction raising the question 
of under-estimating intake or deliberate caloric reductions during the weighed food 
diary exercise. Directly challenging the subjects is unlikely to provide any 
improvements in reducing these biases. Only methods to improve this would be 
through running dietary trial studies in areas where the individuals were 
institutionalized and supplied with pre-prepared meals whose nutritional and caloric 
intake were calculated. 
It is possible to estimate the expected weight loss for most individuals and 
therefore roughly assess the degree of under-reporting within the food diaries. 
Estimation of daily caloric requirements can be made through the calculation of the 
basal metabolic rate. This is a measurement of the daily energy expenditure of a 
human when at rest. Measurements can be made through a formula which was 
originally created in 1919 and named the “Harris-Benedict equation”. This formula 
was  




For men,  
 
For women,  
 
P = total heat production at rest, m = weight, h = height, a =age223. 
 
Over time the equations were modified to account for lean body mass, 
lifestyle changes, and levels of activity. Schofield’s equations were introduced in 
1980s and adopted with some modifications by the Joint Food and Agricultural 
Organization/World Health Organization/United Nations University 
(FAO/WHO/UNU) to be used 475. These were based on a meta- analysis of over 100 
European and North American studies. Individuals’ daily nutritional requirements 
were calculated based on a series of factors including gender, weight, height, 
occupation, and level of activity. They have generally been adopted for use in 
numerous dietary studies although they have been criticised for overestimating the 
basal metabolic rate among Eastern individuals (Indian and East Asian). 
Consequently some modifications were made with the production of the Oxford 
Brookes Basal Metabolic Rate database233. 
Calculating a subject’s basal metabolic rate provides a figure against which 
an estimate of how much caloric intake will affect weight. Those with grossly 
underestimated caloric intake, but no compatible weight loss are thus likely to be 
subjects who were selective with their dietary intake on the food diary data collection 
days, or were intentionally or unintentionally missing recording items or the portion 
sizes. To note these equations are predictive values and not an accurate measure of 
the subject assessed.  
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8. CHAPTER 8: The Effect of the Three Dietary Regimens on 
Insulin Resistance  
 
8.1. Changes in Glucose 
 
Fasting glucose was measured at the four study intervals, baseline, 3, 6 and 
12 months, but a glucose tolerance test was only performed at baseline, 6 and 12 
months. Fasting and 2 hour glucose levels fell among all three dietary arms with 
changes sustained till the end of the 12 month study period. Fasting glucose levels 
fell by 5, 7 & 6% (all p=NS) for LCD, by 7, 7& 4% (p<0.01 at 3 & 6months) for 
LFD, and by 6, 6 & 8% (p<0.05 at 3 & 12 months) for LGL. Post-prandial (2 hour 
post OGTT) reductions at 6 & 12 months were 15 & 13% (all p<0.05) for LCD, 18 
& 6% (p<0.01 at 6months) LFD, and 6 & 19% (all p<0.01) for LGL.  
The number of individuals with diabetes was small and glycosylated 
haemoglobin was only measured in those with diabetes.  There was a trend for HbA1c 
levels to fall among those with diabetes in all three groups, but reductions were only 
statistical significant at three months in the LGL group (p<0.05) (Table 47).  
 
8.2. Changes in Insulin levels 
 
In keeping with reductions in glucose levels, there was an observed fall in 
insulin levels among the three study groups at all study intervals with reductions of 
23, 20 & 29% (all p <0.01) for LCD, 14, 22, & 15% (all p<0.01) for LFD, and 19, 18 
& 30% (all p<0.01) for LGL at 3, 6 and 12 months. At no point in the study were 
there any differences between the groups for glucose, HbA1c, insulin levels or insulin 
resistance (Table 47). 
  
Page | 189 
 








    
Fasting glucose mmol/L    
Baseline 5.8± 1.9 5.9±1.5 5.99±1.8 
3 months 5.3±0.8 5.4±1.0♥ 5.57±1.2♦ 
6 months 5.1±0.73 5.3±0.8* 5.8±2.04 
12 months 5.1±0.8 5.6±1.2 5.2±2.2* 
2 hr Glucose (GTT) mmol/L    
Baseline 7.6±4.1 8.1±4.2 8.0±4.0 
6 months 5.3±1.5♦ 6.2±2.5♥ 6.7±3.3* 
12 months 5.4±1.7♦ 6.9±3.1 6.0±4.2♥ 
HbA1c %    
Baseline 6.7±1.4 7.0±0.9 6.6±0.8 
3 months 5.9±0.8 6.2±0.4 6.2±0.7♦ 
6 months 5.6±0.4 6.1±0.3 6.3±0.8 
12 months 5.6±0.4 6.3±0.6 6.6±1.1 
Insulin levels mIU/ml    
Baseline 22.8±14.9 18.6±9.9 19.6±11.1 
3 months 16.3±8.3♥ 14.8±8.5♥ 15.0±9.3* 
6 months 16.0±10.6♦ 13.3±6.2♥ 13.8±7.0* 
12 months 13.8±6.8♥ 14.4±7.0* 12.2±7.0♥ 
HOMA IR    
Baseline 2.9±1.7 2.4±1.3 2.5±1.4 
3 months 2.1±0.1♥ 1.9±1.1♥ 1.9±1.2* 
6 months 2.0±1.3♦ 1.7±0.8♥ 1.8±0.9* 
12 months 1.7±0.9* 1.8±0.9* 1.7±0.9♥ 
HOMA %B    
Baseline 154.5±79.1 133.4±54.0 134.21±65.01 
3 months 140.9±51.4♦ 129.5±51.9 123.06±56.48 
6 months 145.4±52.1 118.6±31.7♦ 123.3±55.1 
12 months 133.3±51.4♦ 118.9±46.0 112.8±46.3* 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values refer to within group changes from baseline) 
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8.3. Changes in Insulin Resistance 
Improvements in insulin resistance were noted in all three dietary 
interventions (Table 47) with insulin levels falling with improvements in insulin 
resistance. All three diets achieved significant reductions in insulin resistance with 
levels falling by 23, 24 & 28% (all p<0.01) for LCD, 19, 23 & 16% (all p<0.01) for 
LFD, and 20, 18 & 28% (all p<0.01) for LGL. Reductions were maintained in both 
LGL and LCD groups (Figure 27).  No significant changes were noted between the 
groups at any point. 
Improvements in insulin sensitivity were present throughout the study period 
and significant for each group apart from LFD at 3 months where the insulin 
sensitivity figures appear to be disproportionately elevated. Improvements in 
calculated ß-cell function similarly reflected the changes seen in insulin resistance 
and sensitivity. 
 
Figure 27: Reduction in Insulin Resistance (HOMA-IR) 
 










Baseline  3 months 6 months 12 months
Changes in Insulin Resistance 
Low Carbohydrate Low Fat Low Glycaemic Load Combined
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8.4. Correlations of Weight to Insulin and Insulin Resistance 
 
When analysed as a cohort  the reduction in weight positively correlated to 
fasting glucose levels (r= 0.37, 0.23, 0.24;  p<0.05) at start, 6 & 12 months,  and 
insulin levels (r= 0.44, 0.40, 0.50, & 0.37; all p<0.001), insulin resistance (r= 0.45, 
0.37, 0.50 & 0.39; all p<0.001), ß-cell function (r= 0.12, 0.22, 0.22, 0.15; p<0.05 at 
3 & 6 months), and negatively correlated to insulin sensitivity (r= -0.32, -0.10, -0.40, 
& -0.28; p<0.05 at 0, 6 & 12 months) at baseline, 3, 6 & 12 months.  
Waist measurements also demonstrated similar positive correlations to fasting 
glucose (r= 0.40, 0.15, 0.26, & 0.27; p<0.05 at 0, 6 & 12 months), insulin  (r= 0.44, 
0.46, 0.53 & 0.54; all p<0.001), insulin resistance (r= 0.45, 0.44, 0.53, & 0.55; all 
p<0.001), ß-cell function (r= 0.13, 0.30, 0.28, & 0.26; p<0.05 at 3, 6 & 12 months), 
and a negative correlation to insulin sensitivity (r= -0.41, -0.91,   -0.44, & -0.41; 
p<0.001 at 0, 6 & 12 months) at baseline, 3, 6 & 12 months respectively. 
Despite a significant reduction in glucose, insulin levels, improvements in 
insulin resistance and calculated ß-cell function, these effects did not correlate with 
weight loss for either LGL or LFD.  No correlation for weight loss and fasting glucose 
was observed for the LCD group but a strong positive correlation was noted between 
weight and  insulin levels (r =0.68, 0.60, 0.60 & 0.62, all p<0.001) insulin resistance 
(r = 0.67, 0.53, 0.58 & 0.61, all p<0.01) and ß-cell function (r =0.36, 0.52, 0.41 & 
0.48 all p<0.05), and a negative correlation to insulin sensitivity (r= -0.60, -0.53, -
0.59 & -0.59, all p<0.01) at baseline, 3, 6 & 12 months respectively. 
Similarly strong correlations were noted for the LCD group for waist 
circumference and insulin levels (r= 0.72, 0.6, 0.64 & 0.71, all p<0.001), insulin 
resistance (r= 0.72, 0.61, 0.63 & 0.69, all p<0.001) and ß-cell function (r= 0.35, 0.50, 
0.49 & 0.56, p<0.05), and a negative correlation to insulin sensitivity (r=-0.64, -0.56, 
-0.57 & -0.59, p<0.01) at baseline, 3, 6 & 12 months respectively. 
In the LGL group, waist measurements also correlated to insulin (r=0.28, 
0.45, 0.53 & 0.56; p<0.01 at 3, 6 & 12 months), insulin resistance (r= 0.32, 0.44, 0.55 
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& 0.58; all p<0.01), and negatively to insulin sensitivity (r= -0.47, -0.35, -0.55 & -
0.53; all p<0.01) at baseline, 3, 6 & 12 months respectively. No correlation was 
demonstrated for ß-cell function. 
No correlations to waist measurements were demonstrated in the LFD group. 
When looking at correlations of fasting glucose to insulin and insulin 
resistance in the study cohort, these positively correlated to insulin (r= 0.31, 0.29, 
0.32 & 0.25; all p<0.05) and insulin resistance (r= 0.45, 0.37, 0.41, & 0.36; all 
p<0.01), and negatively correlated to ß-cell function (r= -0.55, -0.44, -0.44, & -0.49; 
all p<0.001), and insulin sensitivity (r= -0.37, -0.22, -0.37, & -0.29; all p<0.05) at 
baseline, 3, 6 & 12 months respectively .  
Unlike the correlations demonstrated for weight and waist measurement, the 
strongest correlations for fasting glucose was noted among the LFD group. Fasting 
glucose positively correlated to insulin (r= 0.42, 0.38, 0.67, 0.39; all p<0.05), insulin 
resistance (r= 0.52, 0.46, 0.72, & 0.50; all p<0.01) and negatively correlated to ß-cell 
function (r=-0.57, -0.41, -0.28, &-0.42; p<0.05 at 0, 3, & 12 months) and insulin 
sensitivity (r= -0.36, -0.28, -0.55, & --0.40; p<0.05 at 0, 6, & 12 months) at baseline, 
3, 6 & 12 months respectively. 
In the LCD group reductions in glucose positively correlated with insulin 
resistance (r= 0.50, 0.40, 0.53, & 0.38; p<0.05 at 0, 3 & 6 months), and negatively 
with ß-cell function (r= -0.52, -.047, -0.25, & -0.45; p<0.05 at 0, 3, & 12 months) at 
baseline, 3, 6 & 12 months respectively.  No correlations were demonstrated for 
fasting glucose and insulin levels and insulin sensitivity.  
Fasting glucose in the LGL group was negatively correlated to ß-cell function 
(r = -0.61, -0.45, -0.56 -0.57; all p<0.01) at baseline, 3, 6 & 12 months. No 
correlations were seen for insulin levels, insulin resistance nor insulin sensitivity.  
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9. CHAPTER 9: The Effect of Three Dietary Interventions on 
Cytokine levels  
 
9.1. Changes in Leptin 
 
Leptin levels fell in all three groups (Table 48). Reductions were 35, 39 & 24% 
(all p<0.01) for LCD, at 15, 17 & 9% (all p<0.05) for LFD, and 33, 32 & 29% (all 
p<0.001) for the LGL group at 3, 6 & 12 months respectively. The lowest levels were 
achieved at 6 months. Differences between the groups were only present when 
measuring the degree of leptin reduction from baseline. These differences were 
between LCD and LGL (p<0.05) at 3 months and LCD and LFD at 3 and 6 (p<0.01) 
months.  
The reduction in leptin correlated to weight in the study cohort (r= 0.24, 0.27, 
0.26 & 0.23; all p<0.05) at baseline, 3, 6 and 12 months respectively and waist 
measurements (r= 0.19, 0.23, 0.26, & 0.24; p<0.05 at 3, 6 & 12 months). A 
particularly strong correlation was seen with BMI (r= 0.62, 0.655, 0.65 & 0.62; all 
p<0.001)  
Similar correlations were noted in the LCD group for weight (r =0.54, 0.64, 
0.54 & 0.53; all p<0.01) BMI (r = 0.76, 0.83, 0.77 & 0.80; all p<0.001), and waist 
(r= 0.39, 0.53, 0.45 & 0.47; p <0.05 at 3, 6 & 12 months). These correlations were 
only identified with BMI for LFD (r = 0.54, 0.54, 0.53& 0.46; all p<0.01) and LGL 
(r = 0.54, 0.62, 0.65 &0.54; all p<0.01). No correlations to any of the lipid parameters 
were noted as a cohort or individual groups. 
As leptin is associated with insulin resistance and weight loss, it was expected 
to see a correlation between of the markers of insulin resistance and leptin. As a study 
cohort leptin correlated positively with insulin levels (r= 0.26, 0.22, 0.38, & 0.23; all 
p<0.05), insulin resistance (r= 0.24, 0.21, 0.37, & 0.22; p<0.05 at baseline, 6 & 12 
months), and ß-cell function (r= 0.22, 0.33, 0.29, & 0.23; all p<0.05). Correlations to 
insulin sensitivity and fasting glucose were not clear.  
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With regards to the groups, in our study no correlation was demonstrated for 
fasting glucose levels, insulin resistance or ß-cell function for any of the dietary 
interventions with exception of the LGL group where a positive relationship was noted 
for insulin levels (r =0.33, 0.26, 0.69 & 0.40; p<0.05 at baseline, 6 & 12 months) and 
insulin resistance (r= 0.29, 0.27, 0.39 & 0.39; p<0.05 at 6 & 12 months). 
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Low Carbohydrate Low Fat Low Glycaemic Load 
 Mean ± SD Min Max Mean ± SD Min Max Mean ± SD Min Max 
          
Leptin(ng/ml)          
Baseline 34.7±24.6 6.9 100.3 28.3±19.2 5.3 76.6 35.1±28.2 2.8 113.0 
3 months 24.0±19.3♥ 2.6 79.9 24.9±17.8* 4.1 69.6 21.3±16.1♥ 2.3 80.9 
6 months 22.8±19.3♥ 1.8 69.5 23.1±16.9* 2.6 64.7 21.8±16.3♥ 2.1 67.5 
12 months 26.0±25.8* 3.6 124.1 24.9±18.7 1.0 71.3 23.8±18.4♥ 1.9 81.8 
          
Adiponectin (ng/ml)          
Baseline 7247±4242 2378 19981 10718±8647 2493 45477 6884±4438 2488 25849 
3 months 8567±4313* 2874 20919 11633±10059 2832 52437 7746±5798 3063 35688 
6 months 10226±518* 2254 21688 11795±10171 2428 55467 9469±8697♦ 2968 50143 
12 months 10192±5857♥ 3582 24332 13106±10520* 3447 58074 8922±5001♥ 2497 25721 
          
Resistin (ng/ml)          
Baseline 9.0±2.0 3.2 15.5 10.1±2.6 5.7 16.7 11.6±4.9 5.4 29.6 
3 months 10.0±2.9 6.8 17.5 10.2±2.5 5.9 14.6 10.8±2.9 6.8 16.0 
6 months 11.0±3.2 5.7 19.3 10.7±2.8 6.2 16.3 10.7±3.1 5.1 17.6 
12 months 9.9±2.2 6.4 16.0 9.7±2.4 4.7 16.5 9.6±3.2 4.3 16.6 
          
Visfatin(ng/ml)          
Baseline 1646±2597 0 14263 1267±954 132 4325 2027±2086 109 11935 
3 months 2254±2025♦ 75 8525 1945±1551♦ 112 5088 2366±1690 261 7218 
6 months 2704±2709* 368 10038 2287±1909* 144 7975 2462±1490♦ 886 8614 
12 months 1685±1574♦ 53 6206 1712±1349 106 5485 2203±2046 62 10471 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values refer to within group changes from baseline) 
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9.2. Changes in Adiponectin 
 
The baseline mean adiponectin level for the LFD group was higher than levels 
in the other two arms (Table 48). The difference was large enough to be significant 
between the LFD and LGL group (p=0.02) but not LFD and LCD (p=0.59) or LGL 
and LCD (p=1). The comparatively higher reading was maintained throughout the 
study although the differences between the groups was not maintained beyond the 
baseline.  
Adiponectin levels rose within each group by 24.9, 49.6 & 41.2% (all p<0.01) 
for LCD, 9.5, 9.2 & 28.8% (p=NS) for LFD, and 9.5, 31.2 & 29.6% for LGL (p<0.001 
at 6 & 12 month) at 3, 6 & 12 months respectively (Table 48). Maximum increases 
were at six months for LGL and LCD. The percentage increase in adiponectin at 6 
months was significant between the LCD and LFD group (p<0.01) but otherwise no 
other differences were noted between the groups.  
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Many studies investigating the effects of leptin and adiponectin have reported 
that an inverse relationship exists between the two 354. The data from this study 
demonstrate this inverse relationship with a rise in adiponectin corresponding to the 
fall in leptin (Figure 29). Analysis has failed to show any form of correlation between 
adiponectin and leptin for the whole study cohort or any of the three dietary groups. 
No correlation was present between weight, BMI or waist measurements and 
adiponectin for the study cohort or any of the diets.  
In markers of insulin resistance, adiponectin levels did negatively correlate to 
insulin levels (r= -0.32, -0.32, -0.25, & -0.35; all p<0.05), insulin resistance               
(r= -0.30, --0.32, -0.24 & -0.35; all p<0.05) and positively to insulin sensitivity        
(r= 0.33, 0.13, 030 & 0.23; p<0.05 at baseline, 6 & 12 months) for the whole study 
cohort at baseline, 3 6 & 12 months respectively. No correlations for fasting glucose 
or ß-cell function were noted.  
Within the groups adiponectin negatively correlated to insulin levels for LCD 
(r = -0.53, -0.49, & -0.51 at 3, 6 & 12 months; all p<0.01) and LFD (r= -0.43, -0.365, 
-0.35 & -0.44; all p<0.05 at 0, 3 & 12 months). A negative correlation between insulin 
resistance and adiponectin was noted for LCD (r = -0.54, -0.49 & -0.49; all p<0.05 at 
3, 6 & 12 months) and LFD (r = -0.42, -0.37 & -0.43; p<0.05 at 0, 3 & 12 months). 
For ß-cell function a negative correlation with adiponectin was seen in the LCD group 
(r = -0.32, -0.50, -0.52 & -0.65; all p<0.01) for all study points. This was not noted 
in any of the other dietary interventions nor in the cohort analysis  
Of note no correlation for adiponectin with any of the measures of insulin 
resistance (i.e. fasting glucose, insulin levels, insulin resistance, insulin sensitivity or 
ß-cell function) was evident in the LGL group. 
For lipid parameters, adiponectin positively correlated to HDL-cholesterol 
(r= 0.49, 0.47, 0.54 & 0.45; all p<0.001), and negatively to triglycerides (r= -0.18,   
-0.34, -0.32, & -0.39; p<0.01 at 3, 6 & 12 months) for the whole study cohort at 
baseline, 3, 6 & 12 months respectively. No correlations to total or LDL-cholesterol 
were demonstrated.  
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Within the groups, as with the cohort, no correlation was established between 
adiponectin and total or LDL-cholesterol. Adiponectin correlated positively with 
HDL-cholesterol for LCD (r = 0.66, 0.65, 0.74 & 0.79; all p <0.001), LFD (r = 0.51, 
0.57, 0.61 & 0.60; all p<0.01), and LGL (r = 0.45, 0.52, 0.54 & 0.29; p<0.01 at 0, 3 
& 6 months) at baseline, 3, 6 & 12 months respectively. A negative correlation was 
demonstrated between adiponectin and triglycerides: for  LCD (r = -0.21, -0.50,-0.56 
& -0.48; p<0.05 at 3, 6 & 12 months), for LFD (r = -0.24, -0.47, -0.40 & -0.47; 
p<0.05 at 3, 6 & 12 months) and for LGL (r = -0.30, -0.36, -0.28 & -0.44; p<0.05 at 
3 & 12 months) at the same study intervals. 
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9.3. Changes in Resistin 
 
Resistin levels varied by only small amounts in the study. Changes among 
LCD were -8.9, -11.5, & +0.4% (all p=NS), for LFD -1.6, -4.4, and +4.7% (all p=NS), 
and for LGL -0.4, +0.7 and +9.7% (all p=NS) at 3, 6 and 12 months respectively 
(Table 48, Figure 30). At no point in the study were there any between or within group 
differences.  
As a study cohort no correlations were documented between resistin, 
anthropometric measures, lipid parameters, measurements of insulin resistance or 
other cytokines apart from a correlation to visfatin (r= 0.26, 0.40, 0.42 & 0.0.44; all 
p<0.01), and hsCRP (r= 0.61, 0.31, 0.24 & 0.04; p<0.05 at baseline, 3 & 6 months) 
at baseline, 3, 6 & 12 months respectively.   
Correlations within each dietary group only confirmed a relationship with 
visfatin for LCD and LGL, but the correlation to hsCRP was not clearly evident.  
Visfatin will be discussed next in this chapter. 
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9.4. Changes in Visfatin 
 
Visfatin levels rose in all three groups with levels rising by 60, 92 & 20% in 
the LCD (all p<0.05), 53, 80 & 35% (p<0.01 at 6 months) for LFD, and 30, 35 & 
20% (p<0.05 at 6 months) for LGL. 
For all three groups peak visfatin levels were at the 6 months (Figure 31). No 
between group differences were demonstrated for absolute visfatin levels. The 
differences in percentage reduction was significant for LCD vs. LFD at 6 & 12 
months (p<0.05), and for LCD vs. LGL (p<0.05) for the same study points.  
 
Figure 31: Visfatin levels throughout the study period 
 
 
Graph demonstrates the changes in visfatin at each study interval with standard error 
 
As with resistin, visfatin did not display any correlation to anthropometric 
measurements, markers of insulin resistance, lipid parameters, nor cytokines, with 
exception to the correlation to visfatin that was previously mentioned, as a study 
cohort or in individual dietary groups.  
The positive correlation to visfatin was noted among the LCD (r= 0.40, 0.41, 
0.49, & 0.33; p<0.01 at 0, 3, & 6 months) and LGL (r = 0.25, 0.42, 0.45 & 0.60; 
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9.5. Changes in Retinol Binding Protein-4 
 
Changes in levels of RBP-4 during the study were small with final readings 
all higher than baseline levels (Table 49 &Figure 30). Changes in the LCD were -14, -7 
& 4% (p<0.05 at 3 months), at 3, 6 & 12 months respectively, for LFD -6, -5 & 2% 
and for LGL  3, -6 & 11% at the same study intervals.  
No within group differences was observed apart from an initial fall in RBP-4 
in the LCD group. Between group differences were only present at the three month 
stage, between LCD vs. LFD, and LCD vs. LGL (both p<0.05).  
No correlations were demonstrated for anthropometric measurements, 
markers of insulin resistance, lipid parameters, nor changes among the other 
cytokines with RBP-4 for the whole study cohort or the individual study groups.   
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Low Carbohydrate Low Fat Low Glycaemic Load 
 Mean ± SD Min Max Mean ± SD Min Max Mean ± SD Min Max 
          
Retinol Binding Protein 
4(µg/ml) 
         
Baseline 91.27±42.0 38.6 205.6 94.2±65.7 43.8 421.1 95.4±40.9 32.0 216.0 
3 months 75.9±25.3♦ 31.3 127.2 88.6±35.2 30.5 186.4 96.6±30.2 45.3 162.4 
6 months 88.2±41.3 39.8 199.2 88.9±37.4 0.2 180.3 94.0±46.7 25.0 277.4 
12 months 93.3±59.4 44.9 295.9 95.4±38.2 27.0 180.1 98.7±36.7 38.8 191.0 
          
PAI -1(ng/ml)          
Baseline 95.0±60.8 16.4 269.5 63.3±36.4 22.1 175.8 90.1±62.7 8.2 268.2 
3 months 66.2±65.2 5.9 252.8 50.8±33.0 4.4 176.4 72.5±57.0 14.4 245.5 
6 months 46.3±30.8* 14.8 632.1 49.9±25.9 17.5 110.1 58.3±34.0* 21.0 148.9 
12 months 58.0±36.9♦ 5.9 252.8 61.9±22.5 19.3 707.7 54.3±43.5* 18.2 227.0 
          
Hs CRP(ng/ml)          
Baseline 5286±4610 862 17839 5118±5504 27 21826 5698±11857 361 75422 
3 months 5097±4320 687 16026 4602±6300 203 27680 4231±4943 351 20581 
6 months 4675±4463 954 18316 4540±7099 0 30199 4207±4959 200 25808 
12 months 3881±4387 534 19401 6553±13219 473 70140 3170±3644 401 17056 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values refer to within group changes from baseline) 
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9.6. Changes in PAI-1 
 
PAI-1 levels fell in all three groups at 3, 6 & 12 months (Table 49 & Figure 33) 
as individuals lost weight.  This was by 30, 51 & 39% (p<0.05 at 6 & 12 months) in 
the LCD, by 20, 21 & 2% (all p=NS) in LFD, and by 20, 35 & 39% (p< 0.01 at 6 & 
12 months) in the LGL groups. As with the majority of other cytokines peak changes 
were at 6 months. No differences between the groups were observed at any time point 
for absolute value or the percentage change.  
Despite sustained PAI-1 reductions observed for both LCD and LGL groups, 
no correlations were demonstrated for weight, BMI or waist measurements, lipid 
profile, markers of insulin resistance or any of the measured cytokines for the whole 
study cohort or as individual groups. 
 
 
Graph demonstrates PAI-1 levels within each group at each study interval with standard error 
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9.7. Changes in hsCRP 
 
Changes in hsCRP levels within the three groups were -4, -11 &-27% (all 
p=NS) for LCD group, -10, -11 & +28% for LFD (all p=NS), and -26, -26 & -44% 
(all p=NS) in the LGL at 3, 6 & 12 month respectively (Table 49, Figure 34). None of 
the changes within or between groups were of statistical significance.  
HsCRP levels positively correlated to BMI (r= 0.19, 0.51, 0.35 & .025; 
p<0.05 at 3, 6 & 12 months), and waist measurement (r=0.34, 0.28, 0.22, 0.24; 
p<0.05 at 3, 6 & 12 months) for the study cohort at baseline, 3, 6 & 12 months 
respectively. No correlations were noted for lipid parameters or measurements of 
insulin resistance.  
Within the groups, hsCRP positively correlated to BMI in both LCD (r = 0.47, 
0.49, 0.42 & 0.20; p<0.01 at baseline, 3 & 6 months) and LFD (r = 0.39, 0.78, 0.39, 



























The graph demonstrates hsCRP levels within each group at the study intervals with standard error 
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Positive correlations of hsCRP with both insulin (r = -0.02, 0.42, 0.62 & 0.59; 
p<0.01 at 3, 6 & 12 months) and with insulin resistance (r = -0.09, 0.44, 0.62 & 0.62; 
p<0.01 at 3, 6 & 12 months) at 3, 6 & 12 months were noted in the LGL group but 
not for LCD or LFD. These correlations appeared specific to the LGL group and were 
not demonstrated in the whole cohort. 
Similar to the results observed with most of the adipocytokines, correlations 
between hsCRP and the measured cytokines were not present or not meaningful with 
many of the correlations occurring through chance and not trend.  HsCRP positively 
correlated with resistin (r= 0.61, 0.31, 0.24 & 0.04; p<0.05 at baseline 3 & 6 months), 
leptin (r=0.32, 0.30, 0.25, & 0.13; p<0.05 at baseline 3 & 6 months) when the whole 
study cohort was analysed. This relation was only demonstrated in leptin among the 
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10. CHAPTER 10: Discussion of the Results 
 
10.1. Discussion on changes in Anthropometric Measures and 
components of the Metabolic Syndrome 
 
It is well recognised that all dietary interventions have poor retention with 12 
month concordance rates being low. Most dietary studies report 20- 30% drop-out 
rates at 6 months237;393;588 and 30 to 50% at 1272;133;164;192. A two year study managed 
to retain 95% at 1 year and 84% of all participants at 2 years, but the participants all 
worked within the research faculty, a nuclear research institution, where the clinics 
were in-house and all food was provided and pre-labelled which would have 
encouraged compliance and concordance to study diets482.  
When first recruiting for this study the aim was for it to be an intention to treat 
with all recruited taken into account. Data was intended to be processed in the form 
of last value carried forward. Most individuals dropped out prior to the second blood 
sampling stage which was at 3 months and would not even return for a one of fasting 
blood sample. This would have meant that almost over 20% of the results would have 
been calculated using a baseline sample only, therefore it was felt best to undergo the 
analysis using only the completers. There is an appreciation that using the completers 
only will mean that the study will have been biased in recording the results of only 
the more compliant individuals or those who had been satisfied with their weight loss. 
As the data contained individuals who had effectively loss weight as well as those 
who had put on weight throughout the year study period then it potentially excludes 
that bias. There has been criticism of intention to treat analysis, as the data can be 
potentially diluted by results of those who have dropped out, and the interpretation of 
results will be affected and potentially misguided depending on the heterogeneity 
seen in those who have dropped out or were non-compliant. It is actually advised that 
intention to treat analysis be undertaken when all efforts have been made to minimise 
missing data to reduce heterogeneity in results203;235.  
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10.2. Weight and waist  
 
Most of the dietary studies comparing high-fat low-carbohydrate, or 
Mediterranean-like diets were of a 6 to 12 month duration involving between 20 to 
100 subjects. Average weight loss within these trials ranged between 2-10kg weight 
loss in the low carbohydrate groups, 2-6kg in the low fat groups and 3-5kg in the low 
glycaemic index groups132;164;343;393;466;588. Weight loss within our study followed a   
similar pattern to those of the other studies. In fact when compared to the Dietary 
Intervention Randomized Controlled Trial (DIRECT) which randomised individuals 
to very similar dietary interventions the results here appear to be favourable 482.  
Weight loss in the three study groups reached a maximum trough at 6 months 
then stabilized following patterns seen in diet trials which reported up to a year or 
longer. Figure 34 is the weights of all the participants in the study comparing the 
weights at baseline, 6 and 12 months. A reasonable separation between the Baseline 
and the 6 month line intervals are seen for the majority, the period where weight loss 
is at its peak. On the other hand considerable overlap is noted between the 6 and 12 
month lines which is the maintenance phase where most weight losers had attained 
their maximum weight loss and had slowed down or stabilized.   
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Reproduced with permission from Shai et al 2008482, Copyright Massachusetts Medical Society. 
 
In the DIRECT study, the three study arms were starting to rise at 12 months, 
but the curve remained flat with subjects appearing to maintain weight for up to 24 
months (Figure 36). Recently the 4 year follow up data were published  which revealed 
that the control low fat group had regained 78%, the low carbohydrate 64%, and the 
Mediterranean 30% of the weight lost 476.   
 
 
Figure 35: Weight changes over 2 years in the DIRECT study 
 




















Changes in weight among the three groups
 Low Carbohydrate  Low Fat Low Glycaemic Load
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Similar trends were seen among the subjects studied in this study (Figure 37), 
but as it did not extend beyond 12 months it is difficult to speculate on whether weight 
would have remained stable or returned to baseline. A letter was sent to all subjects a 
year after completion asking for details of weight but very few replied. The results at 
least imply that LCD or LGL methods are superior at achieving initial weight loss 
and maintaining it for a period of time. The LFD group were the group with the lowest 
weight at baseline which may account for them losing less kilogram weight as 
compared to the other groups, but even the percentage weight loss was the least 
among that group. To demonstrate this a multi-centre European trial randomised 700 
individuals after successful weight loss in an initial calorie restriction phase to one of 
5 arms: low protein and low glycaemic index, low protein and high glycaemic index, 
high protein and high glycaemic index, high protein and low glycaemic index, or 
control (standard regulations by country) for a 26 week maintenance phase. All arms 
had regained their weight loss apart from the high protein and low glycaemic index 
group 307. 
Weight loss is very much an individual thing and Figure 29 clearly 
demonstrates that there were individuals who did better than others while some failed 
to show any weight reductions despite regular counselling and adjustments to caloric 
intake as befitted their weight and degree of activity. It would be unfair to assume 
that the lack of response was purely due to lack of compliance as activity levels and 
basal metabolism are other factors that contribute. In this study it was decided not to 
recommend any lifestyle changes in the form of exercise to avoid confounding. It was 
observed that many of the successful participants admitted to increasing their level of 
exercise as they lost weight and began feeling lighter and healthier. Unfortunately our 
data did not identify whether a particular group had adopted exercise more than the 
others. 
Waist circumference is considered a marker of visceral adiposity and as such 
is one of the components of metabolic syndrome. Reductions in waist circumference, 
as such can be a better predictor of CV risk improvement than weight. Studies have 
confirmed the correlation between weight, waist, BMI and visceral adiposity and 
implied that a 3kg weight loss can be equivalent to a 3cm waist circumference 
reduction in men and women371;372. Certainly changes documented in this study were 
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consistent with these findings, with waist reductions in LCD and LGL averaging 1cm 
per kg, and LFD 2cm per kg weight loss. The superior numbers may imply that LFD 
is therefore a better diet for reduction in visceral adiposity, however this will be 
difficult confirm as waist measurement failed to correlate to any markers of visceral 
adiposity or insulin resistance in this group in particular.  
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10.3. Components of the Metabolic Syndrome 
 
The data clearly identifies that the dietary interventions appear to be 
successful in reversing the components of metabolic syndrome.  
 
 
10.4. Blood Pressure 
 
Blood pressure is a variable measurement that can be affected by several 
factors including stress, be it physical or emotional. Attempts at reducing white coat 
hypertension and anxiety were addressed in this study by allowing the subject to rest 
calmly, and supine for five minutes prior to measurements being taken.  
Individuals studied on the Dietary Approaches to Stop Hypertension (DASH) 
diet sustained 5.5 and 3mmHg reductions in systolic and diastolic readings. These 
reductions were up to 8.5mmHg systolic in those who achieved an 8kg weight loss 
equal to reports from a meta-analysis of randomised controlled trials, by Neter el al, 
which suggested that 1kg weight loss equated to a 1mmHg reduction in systolic blood 
pressure. Greater reductions were achieved by the addition of exercise and in those 
already on anti-hypertensive therapy41;44;387. Diastolic readings did not display any 
form of predictable pattern.  Blood pressure reductions among the LCD and LGL 
groups were similar to the numbers reported in the meta-analysis and appear to be 
better than those reported by Nordmann.  In a meta-analysis examining the effect of 
low carbohydrate diets on cardiovascular risk he suggested that although low 
carbohydrate diets may have an initial beneficial effect on systolic blood pressure, 
this was not sustained long term. Blood pressure changes in all but one of the trials 
included in the meta-analysis were small (2.4/1.8mmHg) and the trial durations 
varied between 6 and 12 months. Similarly, results for DIRECT demonstrated no 
difference in blood pressure reduction across their three groups393;482 
 
It was of interest to note the changes in anti-hypertensive therapy during the 
study period. To limit difficulty in interpretation individuals who had required 
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alterations in antihypertensive therapy up to three months prior to the study had been 
excluded. The alterations certainly do affect how the blood pressure data are to be 
interpreted but the positive factor to be established is that approximately 20% of 
individuals were able to discontinue blood pressure medications through dietary 
intervention. These discontinuations were particularly noted among those allocated 
too an LCD or LGL dietary life-style but not the conventional, low fat 
recommendations. Not only did this group show the least reductions in both systolic 
and diastolic blood pressure, it was the group which had the most increases in 
numbers of anti-hypertensive therapy and the least likely to discontinue. This implies 
that, assuming external factors remained unaffected, a LFD may be deleterious or 
unsuitable for individuals known to be hypertensive.   
 
Why did the LFD group do worse?  Were there any dietary causes for this? 
Could they have a higher salt intake in comparison to the other two groups? 
Unfortunately the analysis from the food diaries does not suggest this. Salt intake 
went down among all three groups at the start of the study and for the LFD group in 
particular was persistently and significantly lower than in the LCD or LGL groups. 
This is discussed further in the dietary analysis section. 
  




The rise in total cholesterol seen within the LCD group was not unexpected 
as it is believed to be partly attributable to the increase in LDL-cholesterol which 
could have resulted from the increased intake of saturated fat if individuals were 
following the prescribed dietary recommendations. Of note, the rise in both total and 
LDL-cholesterol was not statistically significant, and at its maximum was 6% for 
total cholesterol and 8% for LDL-cholesterol.  Some studies have reported that 
although LDL-cholesterol rises in low carbohydrate diets, cardiovascular risk may 
not be significantly affected as the particle sizes were larger and more buoyant and 
thus believed to be less atherogenic485.  The reduction in LDL-cholesterol was only 
significantly demonstrated in the LGL group.  
Studies comparing high and low glycaemic index diets have shown that 
lowering the glycaemic load of carbohydrates can lower LDL-cholesterol regardless 
of the degree of weight loss452;500.  Despite the actual total fat intake being the lowest 
among the three groups, by at least 30%, LFD had no effect on total or LDL-
cholesterol. Similar increases in total and LDL-cholesterol among low carbohydrate 
diets were reported in other dietary trials 164;393;467. Many studies have demonstrated 
favourable changes in total and LDL-cholesterol in individuals placed on low 
glycaemic index or load regimens129;259. The evidence has been inconsistent in that 
some have reported low glycaemic regimens to be superior258;482 and others 
equal139;229 to low fat regimens in improving LDL-cholesterol.  
Do these changes in LDL-cholesterol signify much? The report from the 
Cholesterol Treatment Trialists’ (CTT) meta-analyses indicates that for every 
1mmol/l reduction in LDL-cholesterol there is a 12% reduction in CV events with an 
additional 25% reduction for each subsequent year96. If so then CV risk in the LGL 
arm will have been reduced by 4% and in the LCD arm increased by 3%.  This 
assumes that the CTT data, largely from statin trials, apply to LDL-cholesterol 
changes achieved through dietary modification. 
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Cardiovascular outcome studies have all emphasised the importance of LDL-
cholesterol lowering 101;481. In this study LDL-cholesterol reductions were not 
successfully achieved in any of the dietary interventions apart from the LGL group 
which did display a modest reduction of 4.8% (0.3mmol/l).  These results are similar 
to other dietary studies where LDL-cholesterol levels varied little through dieting 
with or without pharmokinetic agents, but appeared to be influenced by the 
incorporation of physical exertion 142;227;426;573;574. 
Dietary studies using low fat, low carbohydrate or a low glycaemic load 
approach have in majority reported positive improvements in HDL-cholesterol and 
triglyceride levels in all the dietary interventions 108;274;393.There is a lot of speculation 
on how important a role does HDL-cholesterol play in improving CV risk. Is the rise 
seen within the three study arms of any real meaningful clinical value?  
The earlier trials looking into addressing HDL-cholesterol and triglyceride 
levels had initially shown some improvement in cardiovascular risk and mortality 
with the use of fibrates 453. The popularity of fibrates lessened with the introduction 
of statins and the focus of management shifted to the lowering of LDL-cholesterol 
which was now achievable with these newer agents. The more recent randomised 
controlled trials have failed to show a significant benefit in improving cardiovascular 
risk outcomes with fibrates 278;525. Critics have suggested that the lack of results is 
possibly due to the fact that most individuals with elevated CV risk will already be 
on a statin and trials looking at lipid-lowering in naïve subjects with high risk will be 
ethically difficult to support. Furthermore, unlike earlier trials most of the recent 
fibrate studies have failed to demonstrate the expected changes in triglycerides and 
HDL-cholesterol that is expected from fibrates278;525.  Alternative pathways for 
regulating the lipid profile by either raising HDL cholesterol 53, or lowering 
triglycerides 141 are currently being considered but success has been poor with many 
studies discontinued due to adverse events. What is important is the functional 
integrity of HDL particles rather than just HDL-cholesterol concentration. How 
HDL-cholesterol is raised is relevant, although one might consider that dietary 
manipulation may be physiological. In the face of current evidence, it is difficult to 
know whether the improvements seen in HDL-cholesterol and triglycerides were 
enough to counteract a potentially deleterious rise in LDL cholesterol. 
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Certainly a LGL diet appears to tick all the boxes for improvements in lipid 
profile, but is it enough to rule out an LCD diet due to its effect on LDL-cholesterol 
levels?  Perhaps any diet that successfully helps an individual to lose a significant 
amount of weight may provide benefits that outweigh these possible disadvantages. 
The lipid changes seen within the study were similarly demonstrated in a trial 
studying the effect of differing glycaemic loads on cardiometabolic factors. The first 
two diets were both high in carbohydrate with one consisting of high glycaemic index 
food (High CHO/High GI) and the other low glycaemic index (High CHO/Low GI). 
The second two diets were high in protein but again varied in the quality of glycaemic 
index carbohydrate (High Protein/High GI and High Protein /Low GI). Individuals 




 Reproduced with permission from Brand Miller et al, 2006 362 
 
Reductions in total and LDL-cholesterol were only present in the low GI arms, 
and particularly noted in the high CHO but low GI group. Increases in both these 
factors were evident in both high GI groups with the largest increase being in the high 
protein, high GI group. HDL-cholesterol universally rose in all the arms and 



































Changes in blood lipid fractions from 0 to 12 weeks in 129 overweight 
young adults randomized to 4 diets of varying glycemic load. 
High CHO/High GI High CHO/Low GI High Protein/High GI High Protein/Low GI
Figure 37: Changes in lipid profiles in diets with varying glycaemic load 
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Mann et al in their trial of 93 obese females on a high carbohydrate (HC), 
high protein (HP) or high fat (HF) diet, followed for 12 months demonstrated that 
Total cholesterol fell in all three groups but to a lesser degree in the high fat arm. 
LDL-cholesterol fell in the high carbohydrate and high protein groups but remained 
stable in the high fat arm. Triglycerides levels fell and HDL-cholesterol rose in all 
three groups with patterns once more similar to what was seen in this study359. 




Adapted from Long-term effects of popular dietary approaches on weight loss and features of insulin resistance359 
HC: high carbohydrate, HP: high protein, HF: high fat 
 
One area we have not explored in this research is analysing lipoprotein sub-
fractions which will assess the quantity and quality of both HDL and LDL particle 
size. Do any of the diets have an effect on altering the particles from small, dense 
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Adjusted means at each time point for lipid profile variables.
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10.6. Cardiovascular Risk Reductions 
 
If the current lipid and cardiovascular protection guidelines are to be strictly  
followed, as in therapy for primary prevention, then only the LFD group would have 
qualified for therapy at the end of the study382. Admittedly both the LFD and LGL 
groups had started with a higher baseline 10 year CV risk calculation as compared to 
the LCD group. In spite of this, both LGL and LCD achieved calculated risk 
reductions of up to 18 and 19% respectively which were sustained up to the end of 
the study, while maximum reductions in the LFD arm were only 9%.  
Dietary trials have all commented on cardiovascular risk by analysing each 
individual risk factor but none appear to have reported on calculated CVD risk 
reductions.  Primary prevention statin trials have all reported reductions in CV risk 
and mortality of 20-30% which heralded their use in adults almost 
empirically100;481;489. A recent meta-analysis on statin lipid lowering reported similar 
results while commenting that the benefits were not sustained and recommended that 
subjects be assessed on an individual basis for statin therapy440.  
If dietary interventions are first line measures for cardiovascular risk 
prevention then certainly it makes sense to ensure that the advice provided helps 
improve outcomes. The Look AHEAD trial was terminated early by the National 
Institutes for Health. This was a multi-centre randomised controlled trial looking at 
cardiovascular outcomes in 5,000 individuals with type 2 diabetes randomised to 
intensive lifestyle intervention or standard. Other care was provided by the 
participants’ regular medical doctors. The study was intended to run for 13 years but 
was stopped at 11 years as no improvement in cardiovascular risk in favour of the 
interventional arm was demonstrated, despite an initial weight loss of 10% that was 
maintained at 5%, and significant improvements in other parameters of 
cardiovascular risk57;255;444;547. 
In a longitudinal review of mortality data from 6,000 survivors of the third 
NHANES (individuals who were known to be healthy), a 15% weight loss was found 
to be associated with an increased risk of all-cause mortality in this reportedly healthy 
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cohort. The increased risk was for non-CV disease among obese men and all-cause 
mortality, favouring CV disease, for overweight females250. The researchers admitted 
to a number of areas of weakness within the study including not recording whether 
the weight loss was intentional or not, inability to follow did some lose more weight 
and regain it, was maximum body weight initially recorded. They had tried to exclude 
underlying sinister disease by excluding all who had passed away within three years 
of recruitment. 
Both LGL and LCD lowered CVD and CHD risk factors by acceptable 
margins in spite of the increase in total and LDL-cholesterol demonstrated in the LCD 
group. Look AHEAD has suggested that dieting and healthy lifestyle interventions 
alone may not be enough to reduce cardiovascular outcomes but can manipulating 
dietary macronutrients be of benefit? If we are to take CV risk as a whole rather than 
independently addressing each individual component than surely we should be 
moving away from low fat,  refined carbohydrate-loaded regimens which display 
modest changes in general but as a whole  do not appear to provide any apparent 
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10.7. Discussion of changes in nutrients (dietary analysis) 
 
Dietary analysis is rarely an absolute representative of actual dietary intake 
unless the food consumed had been prepared and provided by the researchers so the 
exact weights and macro-nutrients could be identified. Even when subjects are 
absolutely meticulous with recording their entire dietary intake within the required 
time, there tends to be a subconscious reduction in food intake on the monitoring 
days. This is partly due to conscious good behaviour and the need to comply on paper 
and secondly, to reduce the inconvenience caused by the weighing and measuring 
process. Although the researchers emphasised the importance of the diaries being 
complete the results will have to be viewed cautiously. Dietary trials which have 
reported on macronutrient intake have used food diaries to check that dietary 
recommendations were achieved and there was compliance295;307;462. The variations 
achieved in the macronutrients in our study for the LCD and LFD were similar to 
those reported in a study from New Zealand who looked at individuals on Atkins, the 
Zone Diet and standard recommendations for a period of 6 months358. 
Although participants randomised to the LCD group were permitted 
unrestricted calories, they actually dropped their intake by approximately one fifth of 
their pre-study average daily caloric intake. This reduction was equivalent to the 
reduction seen in the LFD group and more than that of the LGL group both of whom 
had been prescribed specific energy intakes calculated accommodate to weight, 
gender and level of daily activity. Atkins had professed in his book that the ketosis 
associated with the low carbohydrate intake results in appetite suppression within 48 
hours 40. It is reasonable to assume ketosis may be partially responsible as there had 
been reductions in carbohydrate intake so that it made up only 10% of the daily calorie 
intake. The average carbohydrate intake at both 6 weeks and 3 months was 
approximately 40gm, a fifth of what they had been partaking at baseline and in 
keeping with the initial 20gm restriction followed by a gradual 5gm/week incremental 
rise. 
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More likely the cause would be the increase in protein intake. Daily protein 
intake in both the LCD and LGL groups increased by approximately 12%. Higher 
increases had been expected for the LCD group as the assumption was that the 
carbohydrates would have been substituted with protein products. Although there was 
an increase in protein intake this was surpassed by the 25% increase in fat intake. 
Studies in the past have shown that an increase in protein intake from 15 to 30% of 
the daily food allowance was associated with appetite suppression irrespective of the 
carbohydrate intake267;565. These reports were further supported by a systematic 
review (of 50 articles) of high protein diets which concluded that high protein diets 
did have a positive effect on satiety, thermogenesis, body fat loss and energy 
expenditure212;312. Other studies have implied that the positive effect high protein 
intake had on satiety was unsustained for long periods335. 
Carbohydrate intake is expected to be the largest single source of energy 
intake in today’s diet with current recommendations pronouncing that it should make 
up 45-60% of daily caloric intake6;159;526. The National Diet and Nutrition Survey 
published that the average carbohydrate intake in individuals aged 19-65 years was 
227gm/day comprising 47.7% of total energy intake123. Our cohort of study subjects 
had similar amounts of carbohydrate intake (211, 228 and 237gms/day for LCD, LFD 
and LGL respectively), which was approximately 40% of the total daily intake, a level 
which is below the current national dietary recommendations. Of note carbohydrate 
intake in both LFD and LGL fell to even lower levels and remained so till the study 
end. Is this a true reflection of the cohort? Of course there is the possibility that certain 
items (e.g. snacks or drinks) containing hidden carbohydrate were undocumented. 
To discuss the carbohydrate intake in the LCD group, the recommendations 
as per the Atkins’ book are to restrict carbohydrate intake to less than 20gms per day 
during the induction phase which could last 2 weeks or as long as the candidate 
preferred. Once satisfied with their initial weight loss, individuals would then move 
on to the next phase “on-going weight loss”   followed by “pre-maintenance” during 
which carbohydrate intake is gradually increased by increments of 5gms per week 
until a point at which loss has stabilized. If we assume that most undertook a two 
week induction phase then 40gm/day of carbohydrate at 6 weeks is on target for the 
LCD group. In his book Dr Atkins recommends that the carbohydrates introduced 
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should include salads, fresh cheese, seeds, berries legumes and whole grains, all low 
glycaemic load items40. From the dietary analysis data 50% of the LCD group’s 
carbohydrate intake at all the study intervals with exception of the start was refined 
carbohydrate. Many arguments could justify the reason for the relatively high 
percentage of refined carbohydrate. First, being the lack of knowledge or awareness 
of the quality or quantity of carbohydrates included, despite education being supplied 
when interim food diaries were reviewed at each visit. A second cause is a craving 
for sweet things as a snack which many of the participants reported and were keen to 
gratify as soon as they were allowed any carbohydrate increase. Third is that busy 
lifestyles mean that pre-preparing meals is not usually convenient or desirable.  Easy-
to-obtain snacks will usually contain refined sugars.  If the snack is a fruit which is 
easily obtainable (i.e.  apple, banana or pear) these tend to be more carbohydrate-
laden in comparison to melon or berries. Fourthly, financial restrictions can play an 
important role as most items of a low glycaemic load tend to be dearer. 
Total fat intake reductions among the LFD were expected on the basis that 
this was a low fat diet. Reductions were seen in all types of fat intake with no change 
in the proportion of the different components. Individuals were instructed to choose 
low fat options but had no restrictions on the type of fat chosen which may account 
for the lack of variation. The LGL group had been counselled to specifically alter 
their fat intake by choosing monounsaturated fat rich products e.g. olive oil spreads, 
rapeseed oil or olive oil and avoiding polyunsaturated fats e.g. low fat spreads and 
standard vegetable oils. Despite active advice to alter the type of fat intake there was 
only a small reduction in saturated fats (26.8gms/day to 21.2 & 20.7mgs/day at 3 and 
6 months P<0.05) which was not sustained to 12 months, and no changes in the 
amount or proportions of monounsaturated and polyunsaturated fats. Despite this lack 
of variation the more positive lipid effects were noted within the LGL group 
confirming that the quality and quantity of fat intake was not the major denominator 
in an individual’s lipid profile. Such suggestions had previously been made in a study 
of young children where dietary intake varied in quantity and quality of fat intake. A 
correlation was noted between the caloric amount of carbohydrate intake and aspects 
of the lipid profile but none with the type of fat ingested 297. In a meta-analysis of 14 
studies comparing how monounsaturated or polyunsaturated fats affected lipid 
profiles, no significant changes were noted for total-cholesterol, LDL-cholesterol, or 
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HDL-cholesterol. Polyunsaturated fat were reported to have a superior lowering 
effect on triglycerides183. These changes were not observed in our study but then it 
could be argued that although the intended fat intake was supposed to differ between 
the diets, the actual changes were small.  Additionally the present study did show that 
the LGL (higher monounsaturated fat) group had a more positive impact on total-
cholesterol, and HDL-cholesterol. 
In the LCD group the increase in fat intake was mainly noted in saturated and 
monounsaturated fats which rose by 30 and 32% respectively at 6 weeks from 
baseline levels. The saturated fat intake could potentially account for the rise seen in 
total and LDL-cholesterol levels. Many studies have confirmed that substituting 
saturated fats with monounsaturated or polyunsaturated fats helped improve CV risk 
factors, one of which is the lipid profile 518;558. In a  study looking at high fat ketogenic 
diets in children with epilepsy changing the fat intake from saturated fats to 
polyunsaturated oils helped normalise the lipid profile within the seven month study 
period150. Therefore, should an individual want to follow a low carbohydrate diet in 
the future, they would be best advised to avoid foods high in saturated fat, and choose 
those options which have a higher proportion of monounsaturated or polyunsaturated 
fats. 
When examining the changes noted in blood pressure there was an 
expectation that dietary salt intake might have partially accounted for the variations. 
In fact all groups demonstrated similar reductions in salt intake at the start and this 
appeared to be maintained for the LFD group, which is the group with the least blood 
pressure changes, while levels of salt intake rose back to baseline for the LCD and 
LGL groups, where reductions in systolic readings were up to 5% (8.5mmHg). In 
addition, the LFD group required more up-titration of antihypertensive therapy than 
the other groups. A meta-analysis looking at the effect of salt intake on blood pressure 
suggested that a reduction of six grams of salt per day for four weeks would lower 
readings by 7/4mmHg for hypertensives and 3.5/1.5mmHg for normotensive 
individuals 228. Similar results were noted in the  Exercise and Nutrition interventions 
for Cardiovascular health (ENCORE) study which also documented the superiority 
of a combined exercise, weight loss and salt restriction regimen to any of the 
interventions individually 64. Our study was not geared to look into salt intake or 
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exercise, so it is difficult to assess how much of an impact either of these might have 
had on blood pressure. 
Reduction in calcium intake was expected in the LCD group where 
restrictions in carbohydrate intake meant cutting out dairy products including cheese 
until the induction phase was over. Daily recommendations for calcium intake are 
1000 – 1200grams. None of the groups were achieving this at the start and at 3 months 
the LCD group were only taking 50% of the recommended daily allowance. The only 
group which appear to maintain calcium levels at recommended levels was the LGL 
group which implies that those commencing on diets which potentially restrict dairy 
intake (both LCD and LFD) might need to consider taking supplementary calcium to 
ensure adequate maintenance.  
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10.8. Discussion of changes in Insulin Resistance 
 
10.8.1. Fasting Glucose and Insulin 
 
The majority of the dietary studies have reported improvements in fasting and 
post prandial (2 hour) glucose particularly those advocating a low carbohydrate or 
low glycaemic intake516;568;569;576. The glucose lowering effect in these studies 
appears to be attributed to the caloric intake reduction and weight loss with no 
particular diet showing a sustained significant superiority. Nordmann’s meta-analysis 
favoured the low carbohydrate groups reporting that fasting glucose levels were lower 
in this group at 6 months, but the advantage was not present at 12 months 393. Gannon 
in some short studies compared high protein to high carbohydrate intake and reported 
that fasting glucose levels were reduced by 36% in the high protein groups177;178. 
When studying glucose responses in obese females, Layman reported a superior 
reduction in fasting glucose in the high carbohydrate arm313, findings that were 
replicated in another study comparing a high protein to high carbohydrate intake. 
Fasting glucose levels and glycated haemoglobin in the high carbohydrate group fell 
by 1.5mmol (18%) and 1.3% (15%) while they were unchanged in the high protein 
group469. Layman’s theory for these results was that in order to achieve and maintain 
fasting glucose lowering it was not enough to reduce carbohydrate intake, but to 
achieve a balance between gluconeogenesis and the peripheral utilization of glucose 
without encountering insulin resistance.  In our study, only LFD and LGL were 
statistically effective in reducing fasting glucose. In a Canadian trial, Carbohydrates 
in Diabetes (CCD), 3 month fasting glucose was lower in the low carbohydrate and 
low glycaemic index arms but rose with the high glycaemic index group having the 
greatest effect at the end of the one year trial. Post prandial glucose levels were 
initially lowest in the low carbohydrate groups, but escaped rising to above baseline. 
Only the low glycaemic index arm maintained post prandial levels576. 
Although reductions in post-prandial glucose were present and sustained in 
both the LGL and LCD arms in our study, the differences when compared to the LFD 
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set were never significant.  Reductions in glucose for the LCD group is likely to be 
linked to the decreased carbohydrate intake and hence glucose utilisation and the 
subsequent increase in fat metabolism to compensate for intracellular energy 
requirements. For the individuals on LGL, the lower and slower deliverance of 
glucose from their ingested meals potentially allows for more efficient disposal and 
utilisation glucose without insulin over-stimulation.  




Adapted from McAuley et al359 
 
A substantial and significant lowering of baseline insulin was observed in all 
three of the study arms but none appeared to be superior which is similar to the New 
Zealand study where 93 obese insulin resistant females were placed on Atkins’ (high 
fat), the Zone Diet (high protein) or standard advice for 6 months. Improvements in 
insulin levels were noted in all groups but superior in the high fat and high protein 
arms358. An extension of the study confirmed the improvements to be sustained in the 
high protein and standard arms whilst insulin levels, and post prandial glucose rose 
in the high fat group 359 (Figure 39), whereas in our cohort of subjects the improvement 
in insulin levels was sustained for the three groups. Admittedly the analysis was based 
on the completers within the study and potentially those who were most concordant, 
but in a puritanical way these results can clearly define the outcomes of the 
























Adjusted means at each time point for insulin levels 
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Of note not only were the insulin reductions sustained in those on LCD, this 
was the only group where insulin levels correlated to weight and waist measurements 
in keeping with the whole cohort analysis. LGL had correlated insulin levels to waist 
measurements but this relationship was not identified in the LFD group Was the lack 
of response due to the degree of weight loss not being enough to produce any 
meaningful effects. It was the only group that did not achieve the overall 5% 
recommended target weight loss, managing to reach 4.4% in comparison to 6.9% 
(LGL) and 8.8% (LCD) or is there another mechanism.  
 
10.8.2. Insulin Resistance 
 
Reductions in insulin resistance followed similar patterns noted in other 
dietary intervention trials. Certainly in the meta-analysis looking at the Mediterranean 
diet, it was felt that all individuals who complied with the principles of a low 
glycaemic load intake showed more positive improvements to insulin resistance as 
compared to those with poor compliance 274. The meta-analysis of low glycaemic 
index diets from Brand-Miller did not assess insulin resistance but glycaemic control 
in individuals with Type 2 diabetes, and reported that low glycaemic index diets were 
superior to high glycaemic index diets, reducing HbA1c by an additional 0.43%. 
Analysis from the Nurses’ Health Survey had reported that a high glycaemic load and 
low fibre intake were separately associated with an increased risk of type 2 diabetes 
and when combined the accumulative risk increased 2.5 times464. Similar results were 
reported among the 43, 000 males studied in the Health Professionals Follow up 
Study463. 
Contradicting this was the Insulin Resistance Atherosclerosis Study which 
included approximately 1000 individuals with normal or impaired glucose tolerance, 
and studied the effect that glycaemic index, glycaemic load, and fibre had on insulin 
secretion, insulin resistance and weight. It concluded that no relationship existed 
between carbohydrate and glycaemic load or glycaemic index in relation to markers 
of insulin resistance and that any such findings were coincidental326.  The researchers 
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did find an association with increased insulin resistance in those with a reduced fibre 
intake but in general felt that it was the carbohydrate/caloric load rather than quality 
that really impacted on these markers through their effect on adiposity. 
The relationship between protein intake and insulin resistance has been 
controversial. Studies looking at amino acid infusions have linked high protein intake 
to insulin resistance 179;180;310;539. The European Prospective Investigation into Cancer 
and Nutrition (EPIC)-NL was a multi-centre prospective cohort study which aimed 
to study the aetiology of chronic disease. Recently it examined the association 
between dietary protein and diabetes and reported that animal protein, not vegetable, 
was associated with an increased risk of diabetes, and increasing dietary animal 
protein by 5% at the expense of carbohydrate would increase the risk for type 2 
diabetes by 30%501. 
On the other hand many dietary interventions have identified the benefit of a 
high protein, low carbohydrate diet, at least as a short term option for weight loss, 
improving insulin resistance and other cardiometabolic benefits129;177;178;561.  
Certainly, from the data available in this study, improvements in insulin 
resistance was sustained in all the study arms although it does not clarify what 
parameter has the most influence. Weight appeared to only correlate to LCD, and 
waist measurements to LCD and LGL. Could the improvements be due to weight loss 
and reductions in visceral adiposity which influence insulin resistance?  
To check whether the correlations were related to weight loss, we looked at 
the 24 individuals who had achieved a greater than 10% body weight loss (9 from 
LCD, 4 LFD, & 11 LGL). Insulin levels failed to correlate to weight or waist 
measurements but positively correlated to BMI (r= 0.54, 0.47, 0.45 & .50; all p<0.05) 
in this cohort. Similar patterns were demonstrated for insulin resistance, insulin 
sensitivity and ß-cell function. 
We also looked at the 38 who failed to achieve a 5% body weight loss (8 LCD, 
18 LFD & 12 LGL) of which some were weight gainers. Weight and BMI in this 
cohort failed to correlate to any measures of insulin resistance but waist 
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measurements correlated to insulin levels (r= 0.60, 0.52, 0.58, & 0.49; all p<0.01) 
and insulin resistance (r= 0.61, 0.51, 0.59 & 0.52; all p<0.01).  
Do any of these correlations mean anything? The patterns are variable making 
it difficult to obtain a clear pattern. Clearly insulin resistance is related to fat 
distribution and appears to be more responsive to weight loss achieved through diets 
which have a higher protein, and lower carbohydrate content.  
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10.9. Discussion of changes in Adipocytokines 
 
Certainly the changes seen within the adipocytokines do not reflect the results 
of previous studies, but then the number of dietary interventions reporting on these 
markers are limited and a lot of the theories are extrapolated from animal and 
laboratory studies rather than clinical scenarios.  
Adiponectin and leptin are probably the two most studied as they have been 
identified for a number of years now. Numerous studies have identified that 
adiponectin is an anti-inflammatory agent which appears to positively influence. CV 
risk. It is inversely linked to BMI, waist-hip ratio, insulin resistance, hypertension, 
dyslipidaemia, and coronary artery disease87;166;347;398;432.  
Pischon in the Health Professionals Follow-Up Study, identified that 
adiponectin levels were positively affected by alcohol intake and inversely by 
glycaemic load 424. The lowest adiponectin levels within our study were certainly 
within the groups prescribed a low glycaemic load or had restricted carbohydrate 
intake with instructions to introduce low glycaemic load foods upon completion of 
the induction phase. These differences were present at baseline and cannot as such be 
accounted for purely by dietary allocation. Adiponectin did rise as all three groups 
lost weight with associated improvements in parameters such as insulin resistance 
and dyslipidaemia. Many studies have reported a correlation between insulin levels, 
insulin resistance and changes in lipid profile to adiponectin levels.  In this study the 
effect on insulin resistance was somewhat different. Although as a study cohort 
changes in adiponectin correlated to insulin levels, insulin resistance and negatively 
with insulin sensitivity, these were only clearly demonstrated among the LCD group. 
Graphically there was a trend demonstrating the increase in adiponectin levels 
coinciding with a reduction in insulin levels among the three study groups (Figure 40).  
The relationship of adiponectin to both HDL-cholesterol and triglycerides was 
clearly demonstrated among the three study groups suggesting that these changes are 
likely to be a general weight loss or caloric restriction effect rather than specific to a 
particular diet.  The HDL-cholesterol and adiponectin relation had previously been 
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documented in weight loss with lifestyle intervention, lipid studies, risk assessments 
and chilldren58;193;279;294;552. The relation to triglycerides had been observed in 
laboratory studies and human studies concluding that adiponectin possibly regulated 
triglyceride and VLDL lipoprotein metabolism91;350;433. Therefore, was the reduction 
seen in triglycerides due to the weight loss or mediated by adiponectin? Certainly the 
correlations associated the reductions in triglyceride to have been linked to 
adiponectin specifically and not, weight, BMI or insulin resistance, providing some 
evidence that adiponectin was a key regulatory factor in VLDL metabolism.    
The association between adiponectin and insulin resistance is well established 
which raises a question to the lack of association noted in the LGL group218;271;585. A 
study in Asian teenagers failed to show a correlation between adiponectin and other 
cardiometabolic factors and a similar pattern was seen among a group of South Asian 
females studied in the USA349;502. The authors had concluded that variations in 
ethnicity were responsible for the differences.  This cannot explain our findings as 
the entire cohort was Caucasian.  
Other studies have reported that moderate weight loss can improve insulin 
resistance without affecting adiponectin, but then why was this affect not also noted 
in the LCD group who lost an equivalent amount of weight8. In a review of the effect 
of dietary intervention on adiponectin, no particular correlation was noted for any 
dietary macro-nutrient with adiponectin, the only associations appeared to be for 
weight loss and exercise497.  
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Figure 40: Comparative changes in Insulin, Adiponectin and Leptin 
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Figure 41: Changes in Insulin, Adiponectin and leptin 
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As with adiponectin, leptin is well established to be closely linked to obesity, 
insulin resistance, central adiposity and is used as a predictor of worsening metabolic 
syndrome167;496.  
The strong relationship demonstrated in this study between leptin and BMI 
confirms its association with adiposity.  It was interesting to note that although both 
weight and waist measurements correlated to leptin in the study cohort, as individual 
groups only weight in the LCD group replicated this and the measurement of 
abdominal circumference, which would have been a better indicator of visceral fat, 
failed to establish this link. Only BMI demonstrated any correlations when looking 
at the cohort of those who lost more than 10% body weight and those who failed to 
reach a 5% weight loss target.  
Most studies49;287;363;564 have demonstrated a strong correlation between 
leptin, insulin and insulin resistance which appeared to be present in the whole study 
cohort collectively but failed to be demonstrated in the groups with exception of a 
small association for fasting insulin levels and a tenuous link to insulin resistance in 
the LGL arm. The study numbers were small and therefore patterns that became 
evident when the whole group was analysed as a cohort might have failed to be 
demonstrated due to the numbers within each study arm. 
In addition the study differed from the published evidence in not 
demonstrating a strong negative correlation to adiponectin. Figure 40 demonstrates that 
across the three study groups, adiponectin levels tended to reciprocate the changes 
noted in insulin and leptin. 
Human data for resistin are variable with some reporting raised circulating 
resistin levels in morbidly obese subjects with a positive correlation for BMI and 
central obesity and others showing no correlation to measures of 
adiposity109;118;230;472;496. The numbers of subjects tested are usually small. Most 
studies have demonstrated that resistin levels fell with weight loss and that these 
changes were related to the degree of weight loss with a target of 5% needing to be 
reached initially553. Others believe it is central adiposity which has a greater effect. 
In a study of 41 females treated with either sibutramine or orlistat and followed for 6 
months, the sibutramine group achieved greater weight loss (5.4%) and positively 
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influenced metabolic parameters as well as displaying significant changes in 
adipocytokines including resistin. The orlistat group managed a weight loss of 2.5% 
and failed to show any statistically meaningful changes apart from a superior 
reduction in resistin levels which was assumed to be due to a comparable reduction 
in waist circumference548;553.  Another study of 50 overweight/obese individuals and 
20 normal controls (BMI<25kg/m2) of 4 months duration described an increase in 
resistin levels in association with weight loss and failed to show an association with 
measures of insulin resistance or lipid profile286, while others have failed to show any 
changes or associations to weight, leading  to suggestions that resistin in humans was 
not as important to visceral adiposity as in rat models316;380;578. A cross-sectional 
study of approximately 240 individuals failed to show that resistin correlated to 
markers of adiposity, insulin resistance or lipid profile. Resistin levels were not 
significantly different in the lean, obese, healthy, insulin resistant or in those with 
type 2 diabetes316.  
In our study resistin behaved differently within each group although the 
results are compatible with a previous study which had reported no changes in resistin 
levels following a low carbohydrate diet in 71 obese individuals252. Similar results 
were noted in a study comparing the Lighter-life diet to a low-carbohydrate, high-
protein diet. Whereas the Lighter-life group lost a significantly larger degree of 
weight, resistin levels were no different throughout the nine month study period456. 
Some studies have tried to find a link to variations in resistin levels and 
macronutrient intake but have failed to show such an association for resistin or 
adiponectin. One such cross-sectional study studied fasting blood samples, 
anthropometric measures and 3 day food diaries in 123 healthy Greek students. It 
reported correlations between circulating leptin and leptin receptors, and 
anthropometric measures as well as quality of energy intake, but failed to show 
similar associations with adiponectin or resistin and  tentatively concluded by 
suggesting  that a carbohydrate loaded, high glycaemic index diet could lower 
circulating leptin592. The Oslo Diet and Exercise Study studied 187 men randomised 
to diet only, exercise only, diet and exercise, or control and followed them for a year. 
It failed to demonstrate any variations in resistin levels in relation to dietary intake or 
intervention253. 
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In addition to its association with insulin resistance, resistin is believed to be 
associated with inflammation with levels correlating to those of CRP, TNF-α, and 
interleukin-6442, a fact that was not replicated within this study despite CRP and PAI-
1 levels falling within the LCD and LGL groups, the other measured cytokines which 
are particularly associated with low grade inflammation. 
In this study resistin was noted to positively correlate with visfatin in the LCD 
and LGL groups. Similar correlations had been noted in other studies involving 
individuals with and without type 2 diabetes322;446. As both these cytokines can be 
secreted by macrophages, the authors felt that the relationship between the two 
strengthened the argument for both these cytokines being associated with 
inflammation, particularly those of a low-grade level such as associated with 
metabolic syndrome. 
Few studies looking at dietary interventions and measurements of visfatin 
have been published. Our results are similar to recently published studies which have 
failed to show a correlation between visfatin, dietary intervention or anthropometric 
measures10, but they do differ in that visfatin levels rose in all three arms of our study 
group when it would have been expected to fall in keeping with reductions in visceral 
adiposity, inflammation and insulin resistance. The changes observed with visfatin in 
weight loss studies have not been consistent. A group from Spain had studied the 
effect a three month hypocaloric diet had on visfatin and insulin resistance in a group 
of 80 obese individuals and reported that visfatin levels fell, but did not show any 
correlation to insulin resistance113. They revisited weight loss in 41 morbidly obese 
individuals who were placed on a two month hypocaloric diet. They reported that 
visfatin levels did not change despite a 4.4% average weight loss in this cohort111.The 
same group also studied a set of 27 morbidly obese females who had undergone 
bariatric surgery. The group on average lost 27kg in a year. Despite these changes 
circulating visfatin levels appeared unchanged114. Other studies involving patients 
who had received bariatric surgery had reported increases in visfatin levels66;182. 
These finding were felt to be contradictory as visfatin is released from visceral fat, 
which should have decreased in mass with the extreme weight loss secondary to the 
procedure. The authors were unable to explain why visfatin behaved differently with 
each group and speculated on whether the changes might be related to the surgical 
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procedure, particularly as a different group who had undergone gastric banding had 
demonstrated a reduction in visfatin levels in relation to their weight loss210, but then 
visfatin levels have been reported to decrease in a group who underwent bilio-
pancreatic diversion. Admittedly this was a group of only 10 females and they had 
been followed up to 3 years and had lost approximately 50% body weight345. Interim 
data was unavailable to assess whether the changes were due to longevity of time, an 
effect of the surgery, or the weight loss. 
Studies have remarked on visfatin being a positive marker for visceral 
adiposity. In such circumstances it might be expected to find a relationship between 
visfatin and waist circumference measurement. As individuals lose abdominal 
(visceral) fat, it is their waist measurements that decline and certainly these results 
were successfully achieved with this study. However, contrary to previous 
publications, visfatin levels actually rose within the first 6 months, the time when 
weight loss was greatest29. A cross-sectional study of 500 subjects failed to 
demonstrate a correlation between visfatin and height, weight, waist and hip 
circumferences, waist-to-hip ratio, or blood pressure in both males and females. The 
only positive associations were with HDL-cholesterol, and a negative correlation to 
LDL-cholesterol in females92;599.  
Speculation on what causes the variation in the behaviour of visfatin have 
arisen with some suggesting that as subcutaneous and visceral fat contain differing 
quantities of this adipocytokine, then potentially the effect may depend on  where fat 
reduction was most affected407. Others have suggested that visfatin levels are 
relatively lower in the morbidly obese as compared to leaner individuals, and in 
subjects with diabetes as a consequence of the glucose dysregulation. With weight 
loss and decreasing insulin resistance, visfatin levels rise to return to a normal 
baseline status322. These arguments were strengthened by the fact that rosiglitazone, 
a known insulin sensitizer increased visfatin levels although the same results were 
not seen with other hypoglycaemic agents136;208;243;418.  
Weight loss studies looking at the changes in RBP-4 have reported that levels 
fall with loss of weight in both subjects who have been on diets or those subjected to 
bariatric surgery47;80;209.The reductions in RBP-4 are understood to be correlated  to 
changes in BMI and are associated with the degree of weight loss as a minimum 
Page | 239 
 
reduction of 5% total body weight was required to reveal any significant changes in 
circulating RBP-4 levels although there is a belief that adipose RBP-4 would be more 
likely to show change with these smaller increments of weight loss 256. Other factors 
affecting RBP-4 levels were components of metabolic syndrome. A study 
investigating the changes in RBP-4 in 36 individuals who had been treated with 
bariatric surgery and then followed up for 2 years confirmed similar reductions as to 
other weight loss studies with bariatric interventions (16 – 25% reductions in RBP-
4)209;542. In addition to the changes with weight, they noted that the reductions in 
RBP-4 levels were greater among those who had the least features of metabolic 
syndrome. 
In this study, although the weight loss achieved was greater than 5%, the 
changes in RBP-4 levels with exception to the initial 14% reduction in the LCD group 
were small and not meaningful. At the end of the study RBP-4 levels were no different 
to the Baseline if not marginally higher. 
Correlations with other parameters to RBP-4 were not present with only a 
tenuous link  with the LFD group at the end of the 12 month study period (r= -0.37, 
p<0.05) which is very likely to be an incidental finding as changes throughout the 
intervals had shown no association. Do the dietary interventions have regulatory roles 
which affect incretin secretions that indirectly control RBP-4, does bariatric surgery 
cause alternative modulatory pathways, or is this purely a degree of weight loss 
effect195;209;210? A German group were unable to detect any variation in RBP-4 levels 
associated to weight or glucose levels and concluded that RBP-4 regulation within 
humans is potentially different to what has previously been noted in animal studies. 
The same group had previously reported similarly disappointing results for resistin, 
but in those circumstances it was not under dietary intervention and they had been 
looking at gene expression rather than circulating levels assuming these will be 
interlinked 256. 
The data available for PAI-1 are variable with some studies showing a 
reduction in levels in relation to weight loss and insulin resistance28, and others failing 
to show a response216;348. The Look AHEAD trial demonstrated a 29% reduction in 
PAI-1 among their interventional group in comparison to the control where 
reductions were only 2.5%. These reductions were independent of weight loss and 
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appeared to be associated with improved glycaemic control, fitness and HDL-
cholesterol levels. The authors concluded that these differences potentially indicated 
improvements in cardiovascular fitness and therefore risk reduction, although this 
trial was terminated early for failure to show improvements in cardiovascular 
morbidity and mortality outcomes57 
Some dietary studies have aimed to see if manipulating various dietary factors 
will reduce inflammation and therefore the possibility of atherosclerosis and 
cardiovascular risk. One trial failed to show any change in PAI-1 levels or superiority 
when comparing a low fat, high fibre diet to conventional therapy in a group of 32 
individuals348. Another study of 224 healthy middle-aged men studied the effect of 
triglyceride reduction through supplementation with eicosapentaenoic acid and 
docosahexaenoic acid as triglycerides levels had been shown to be positively 
associated with PAI-1 levels. Once more no changes in  PAI-1 levels were 
recorded216. In the LIPGENE dietary intervention study, a multi-centre European 
trial, the investigators compared the effect of manipulating dietary fat on markers of 
metabolic syndrome and inflammation. Four hundred and eighty individuals were 
randomised to a high saturated fat diet, a high monounsaturated fat diet, a low fat diet 
with sunflower oil supplement or a low fat diet with polyunsaturated fat supplements 
and monitored for twelve weeks. At the end of the study period the use of 
monounsaturated fats improved triglyceride levels but had no effect on PAI-1 
levels532.The use of a low glycaemic load as compared to conventional low fat therapy 
was found to improve PAI-1 levels in a study by Ebbeling132.  
Therefore positive changes seen in PAI-1 particularly in the first half of the 
study is difficult to relate directly to diet and is likely to be associated with the other 
favourable changes which were observed including improvements in insulin 
sensitivity, reductions in triglyceride levels and possibly the weight loss to an extent. 
Despite weight loss being maintained within the three groups, PAI-1 levels in the 
LFD arm rose to almost baseline at the end of the study. The results from this study 
have shown that the changes in both insulin and triglyceride levels were more 
prominent and sustained in the LCD and LGL groups, and this could be a major 
reason for the maintained improvement of PAI-1 levels within the two diet groups. 
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Could this be an effect of the higher carbohydrate load in LFD or as noted by 
Ebbeling, does a low fat diet have no effect on this marker of inflammation? 
HsCRP levels are well documented to be elevated in inflammatory conditions 
as well as obesity and insulin resistance. A trial in 38 obese females looking at the 
relationship between weight, insulin resistance and hsCRP concluded that hsCRP 
levels fell in association with improvements in insulin resistance and not weight 
reduction361. This may explain the improvements in hsCRP seen in the study for the 
LGL and LCD groups, but what explains the large rise noted in the LFD group at 
twelve months? Being a marker of acute stress and inflammation outside factors could 
potentially have affected the outcomes. Other weight loss studies have related the 
reduction in hsCRP directly to the weight loss530. 
A study by an Italian group looked at 180 subjects who were randomized to 
either a Mediterranean style diet or a low fat diet and were followed for two years. 
At the end of the study the Mediterranean arm had lost more weight, abdominal fat, 
showed superior improvements in lipid profile, and reductions in hsCRP and other 
markers of endothelial dysfunction. In addition to these improvements, there was 
demonstrated improvements in the criteria that make up the metabolic syndrome. It 
was the effect of these improvements, which allowed the study group to conclude 
that markers of MS were factorial in variations in hsCRP138. 
A recent systematic review of dietary interventions and the effect they had on 
adipocytokines studied approximately 50 studies which involved dietary 
interventions only, excluding those which included exercise, pharmacological agents, 
or surgical interventions. Weight loss varied between 0.8–20percent of total body 
weight. They reported that leptin levels decreased uniformly in all but three of the 
studies and was a good marker of residual fat mass. Adiponectin levels did not appear 
to be affected by dietary intervention with only seven reporting a rise and one 
showing a decrease. RBP-4 and visfatin fell in the studies where they had been 
measured and PAI-1 as well as other inflammatory adipokines showed mixed results. 
The authors concluded that apart from leptin the results from other adipocytokines 
were too variable to allow characteristic behaviour of the cytokines to be defined 
particularly in response to diet. Of note the classifications used by the authors for the 
diets were low calorie, very low calorie or weight maintenance programmes rather 
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than examining the dietary macronutrient content284. This review along with an 
interventional weight loss study using pharmaceutical agents (orlistat or sibutramine) 
on cardiometabolic markers and adipocytokines.548 have supported the findings in our 
own study, which demonstrated reductions in weight, waist circumference, and 
systolic blood pressure. There was a rise in HDL-cholesterol and fall in triglycerides 
(Table 50). Improvements in insulin resistance were demonstrated (Table 51). With 
regards to adipocytokines we demonstrated a rise in adiponectin, with a 
corresponding fall in leptin. Visfatin and RBP-4 levels were static or rose, and PAI-
1 levels fell (Table 52).  
Some of the change in the various adipocytokines, were not predictable, and 
did not conform to previous findings. In addition, despite what appeared to be 
significant improvements in metabolic parameters, no apparent correlations between 
the cytokines existed.  
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Table 50: Changes in anthropometric measures and lipid profiles among the whole study cohort 
 
 Mean Std. Deviation 
   
Weight (kg)   
Baseline 97.6 17.3 
3months 91.6♥ 16.1 
6months 90.4♥ 16.7 
12months 91.1♥ 16.8 
BMI (kg/m2)   
Baseline 34.4 5.4 
3months 32.3♥ 5.1 
6months 31.9♥ 5.3 
12months 32.2♥ 5.5 
Waist circumference (cm)   
Baseline 108.1 11.1 
3months 101.5♥ 10.7 
6months 99.0♥ 11.1 
12months 98.0♥ 11.6 
Systolic BP (mmHg)   
Baseline 139.7 15.3 
3months 136.4♦ 16.3 
6months 133.5* 16.5 
12months 133.2♥ 16.1 
Diastolic BP (mmHg)   
Baseline 84.7 9.1 
3months 84.0 8.5 
6months 80.9♦ 8.0 
12months 80.7♥ 7.9 
Total cholesterol (mmol/l)   
Baseline 5.7 0.9 
3months 5.6♦ 1.0 
6months 5.7 1.1 
12months 5.7 1.0 
HDL-cholesterol (mmol/l)   
Baseline 1.4 0.4 
3months 1.4 0.4 
6months 1.5* 0.5 
12months 1.6♥ 0.5 
LDL-cholesterol (mmol/l)   
Baseline 3.5 0.8 
3months 3.5 0.9 
6months 3.5 1.0 
12months 3.4 0.9 
Triglycerides (mmol/l)   
Baseline 2.0 0.9 
3months 1.5♥ 0.7 
6months 1.5♥ 0.7 
12months 1.6♥ 0.8 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values refer to changes from baseline) 
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Table 51: Changes in insulin and insulin resistance among the study cohort 
 
 Mean Std. Deviation 
   
Fasting glucose (mmol/l)   
Baseline 5.8 1.6 
3months 5.4♦ 1.0 
6months 5.3* 1.1 
12months 5.5♦ 1.3 
Insulin (mIU/ml)   
Baseline 19.0 10.5 
3months 14.6* 8.0 
6months 14.1♥ 8.0 
12months 13.5♥ 6.9 
HOMA2 IR   
Baseline 2.5 1.4 
3months 1.9* 1.0 
6months 1.8♥ 1.0 
12months 1.7♥ 0.9 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values refer to changes from baseline) 
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Table 52: Changes in Adipocytokines among the study cohort 
 
 Mean Std. Deviation 
   
Adiponectin (ng/ml)   
Baseline 8592 6504 
3months 9367♦ 7432 
6months 10604* 8538 
12months 10736♥ 7711 
Leptin (ng/ml)   
Baseline 31.5 22.2 
3months 22.4♥ 17.7 
6months 21.9♥ 17.1 
12months 24.8♥ 20.6 
Resistin (ng/ml)   
Baseline 10.6 3.4 
3months 10.6 2.6 
6months 10.8 3.0 
12months 9.7♦ 2.7 
Visfatin (ng/ml)   
Baseline 1468 1186 
3months 2133♦ 1760 
6months 2495 2066 
12months 1887 1696 
RBP4 (mcg/ml)   
Baseline 87.3 35.3 
3months 88.2 31.8 
6months 90.8 42.3 
12months 96.0 44.1 
PAI-1(ng/ml)   
Baseline 78.6 53.3 
3months 61.8 50.5 
6months 50.7* 29.0 
12months 58.2* 79.1 
CRP (ng/ml)   
Baseline 5688 8936 
3months 4715 5443 
6months 4494 5716 
12months 4548 8481 
♦ p< 0.05, * p <0.01, ♥ p <0.001 (p-values refer to changes from baseline) 
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11. CHAPTER 11: Concluding Remarks 
 
In the trial described in this thesis the study cohort resulted in a clinically 
significant reduction in weight with improvements in fasting glucose, insulin levels, 
insulin resistance, and triglycerides (Table 50-Table 52).  
All three dietary approaches have produced clinically meaningful 
improvements in the primary outcome, weight as well as in anthropometric measures.  
Changes in the secondary outcomes demonstrated a reduction in the 
prevalence of metabolic syndrome across the three groups with the greatest change 
noted within the LCD group in all 5 components of MS. LFD changes were 
conservative with the number of individuals with impaired fasting glycaemia 
unchanged and only a modest fall in those with systolic blood pressures >130mmHg. 
Positive outcomes in the lipid profile was most prevalent within the LGL 
group where there were improvements in HDL-cholesterol, LDL-cholesterol and 
triglycerides. Positive changes in triglycerides and HDL-cholesterol were 
demonstrated among the LCD group but not LDL-cholesterol.  
The improvements in fasting glucose, insulin levels and markers of insulin 
resistance among the three groups were clinically meaningful. The changes in glucose 
and insulin were particularly maintained within the LGL and LCD groups, implying 
that the reduced refined carbohydrate load recommended by both these regimens may 
exert additional benefits in improving insulin resistance compared to LFD diets.  
These benefits are the reduction in insulin resistance, and calculated 
improvement in ß-cell function which in the long term may help delay, if not preserve 
ß-cell function, and potentially, prevent the progress to diabetes in these MS 
individuals.  
The changes noted among the tertiary outcomes, adipocytokines, were 
variable with some following patterns demonstrated in previous studies and others 
failing to provide any form of concordance. 
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The study period was only 12 months and although adequate to help reflect 
some short and medium term outcomes cannot reflect long term changes, particularly 
cardiovascular outcomes which are important.  The subject numbers were relatively 
small. Longer term follow-up is required to see whether the reductions in circulating 
insulin and insulin resistance may be maintained along with weight loss maintenance, 
and to assess the impact this would have on other cardiovascular risk factors. 
A reduction in leptin and an increase in adiponectin in response to weight 
changes and improvements in insulin resistance were seen in all the groups. 
Correlations (between cytokines and weight change) were not always clearly 
demonstrated although trends followed patterns seen in other dietary studies. 
Low-fat diets as currently advised for healthy lifestyles certainly do result in 
a modest degree of weight loss with some improvement in parameters making up the 
metabolic syndrome, but changes are modest and potentially lead to early 
dissatisfaction and poor compliance. In this study a low fat diet had a small positive 
effect on serum triglycerides and HDL-cholesterol, changes which are likely to be 
weight related as they were seen across the groups but in greater effect with the other 
regimens. 
Of concern was the effect seen on blood pressure within the LFD group.  The 
reduction in systolic blood pressure were the lowest in the LFD group despite its 
participants requiring more up-titration of anti-hypertensive therapy than the other 
two groups.  They were also the group with the greatest reduction in salt intake as 
well as the least overall salt intake within the study period. Although diastolic blood 
pressure reductions were greatest with the LFD the importance of this alone in 
cardiovascular risk protection is unclear. Certainly LFD failed to demonstrate any 
benefits in CVD and CHD risk reduction through standard risk calculations. 
Compliance on the LFD was generally good and weight appeared to be 
maintained throughout the study period making it suitable for those who may seek a 
weight maintenance method. Regardless of current recommendations we have 
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certainly failed to demonstrate an advantage over other methods for this particular 
diet for those individuals who are seeking to reduce their cardiovascular risk. 
 A high-fat, low-carbohydrate approach did result in the greatest reductions in 
weight among the groups, with most of individuals who were considered the best 
weight losers being among this group. This diet positively influenced such markers 
as HDL-cholesterol, triglycerides, systolic blood pressure, and improvements in 
insulin resistance which was reflected in the reductions in calculated 10 year risks for 
cardiovascular disease. In addition, if the high fat intake could be modified to types 
which are potentially helpful (i.e. the monounsaturated fats benefits may be more 
attractive).  
The strict carbohydrate measures within the LCD diet meant it encouraged 
early failure with withdrawal, among those randomised to it, due to the inability to 
follow the carbohydrate restrictions. In individuals motivated to succeed, weight 
reductions were significant although long term maintenance may be a challenge.  
The LCD group showed favourable effects on insulin levels and insulin 
sensitivity. It demonstrated steady improvements in inflammatory markers and 
cytokines with the exception of resistin and RBP-4. The lack of overall change in 
those two cytokines was a trend that was seen in all the dietary groups.  
LCD diets, although controversial should not be completely discounted, as 
numerous studies including this one, have identified many parameters which these 
diets have positively affected. As a diet to facilitate the start of weight loss, there 
appears to be no reason why they should not be used as long as contraindications such 
as renal dysfunction have been assessed. Evidence has shown that their benefits are 
mainly within the first six months and this may be where they should be considered. 
Concordance is poorer than for other dietary regimens and weight is generally 
regained quickly unless individuals are able to maintain some form of controlled 
carbohydrate intake.  
A diet low in glycaemic load certainly appears to incorporate the best qualities 
for most parameters. It appeared to be tolerable with drop-outs being equal to those 
on a low fat diet. Concordance to diet was reasonable with the only issues being 
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meeting the criteria for intake of monounsaturated fats. In the study these individuals 
were encouraged to use spreads that were higher in monounsaturated fats but the 
polyunsaturated or saturated fats were still the major components in those products. 
The use of natural products (i.e. olive oil or rapeseed oil) rather than “Clover” or 
“Bertoli” is likely to help improve the quality of fat intake and positively influence 
this dietary regimen  
The LGL group was effective at weight reduction despite the highest overall 
average calorie intake of the groups, improvements in insulin sensitivity, blood 
pressure reduction, as well as overall improvements in the lipid profile. Those on 
LGL were the only group to demonstrate reductions in total and LDL-cholesterol with 
improvements in the HDL-cholesterol to total cholesterol ratio that was equal to that 
seen in the LCD group. These positive changes were reflected in the reductions in the 
10 year cardiovascular and coronary heart disease risk calculations.  
The effect of LGL on cytokines and sub-clinical inflammation is unclear. The 
trends demonstrate improvements in these markers although many of the changes 
were not significant.  
As part of a lifestyle intervention programme for cardiovascular risk 
modification for the overweight or insulin resistance, a low glycaemic load or 
Mediterranean approach is certainly a favorable regimen for nutritional intake and 
even weight loss.  It provides improvements in all markers of cardiovascular disease, 
and favourable changes in inflammatory markers. The nutritional intake is varied 
avoiding the strict restrictions in the LCD group which was a limiting factor for 
compliance and long term maintenance.   
The Look AHEAD trial was discontinued for failing to demonstrate the 
benefits of an intense lifestyle intervention on cardiovascular morbidity and 
mortality. The dietary interventions used were the recommended standards with the 
intensification being through regular follow up and other life-style changes including 
exercise. A long term cardiovascular outcome trial studying the effect that different 
dietary programmes exert on these parameters would be of importance for the 
development of dietary recommendations that are more strongly evidence based. 
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Figure 42: GP Invitation Letter 
         Wolfson Centre, 
        Royal United Hospital, 
        Combe Park, 
         Bath, BA1 3NG 
Dr A N Other,  





Dear Dr Other 
 
A Randomised Study comparing the effect of 3 dietary approaches on 
Cardiovascular Risk in Subjects with the Metabolic Syndrome    
 
The prevalence of the metabolic syndrome within the UK is steadily increasing with 
over 16% of adult men and women fulfilling the diagnosis. Associated are various 
components that collectively or individually increase the risk of cardiovascular 
disease (Type 2 Diabetes, hypertension, obesity and dyslipidaemia).Studies have 
proposed that early and aggressive treatment of the metabolic syndrome decreases 
these risks significantly and we are becoming increasingly obliged to intervene early. 
Management can take the form of various methods i.e. diet, exercise, and oral therapy.  
 
We are particularly interested at investigating the diet aspect of management and are 
currently undertaking a randomised controlled study comparing the effect of three 
differing diets on cardiovascular risk in subjects with the metabolic syndrome.  
 
The study will be over a period of 6 months with a potential extension to a year. 
Subjects will be seen at the Wolfson Centre, Royal United Hospital. 
 
During this time individuals will be counselled to follow one of three dietary 
approaches and seen at regular intervals to assess their compliance, make adjustments 
to their dietary regimes or for a physical examination and blood tests including fasting 
glucose, lipids, urea and electrolytes, and liver functions. 
 
We are looking to recruit men and women aged between 18 – 75 years who will fit 
the diagnosis of the metabolic syndrome – i.e. they should fulfil 3 of the 5 following 
criteria- 
 
1. abdominal obesity (waist circumference >102cm (40in) in men and >88cm 
35in) in women) 
2. triglyceride level >150mg/dL (1.7mmol/L) 
3. HDL cholesterol <40mg/dL (1mmol/L) for men and <50mg/dL (1.3mmol/L) 
for women 
4. Blood pressure >130mm systolic or 85mm diastolic 
5. fasting plasma glucose > 110mg/dL (6.6mmol/dL) 
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Please may you contact Dr Rasha Mukhtar at the Wolfson Centre on 01225 824127/ 
824125 with the details of any suitable subjects. Alternatively you may e-mail the 
details to mpxrm@bath.ac.uk. 
 






Dr J P D Reckless, Dr A M Robinson, Dr E R Higgs,   
Dr R Y A Mukhtar 
Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital 
  
Page | 254 
 
Figure 43: Patient Invitation Letter 
 








Dear Mr/Ms Other 
 
I am writing to invite you to take part in a research study looking at the effect of 
different diets on weight and on the factors that might increase the risk of developing 
a heart attack. We are looking for people who may fulfil the criteria of the metabolic 
syndrome (assessed by blood pressure, waist measurements, cholesterol and fatty 
acid levels, and blood sugar readings) and have some of the risk factors that can go 
with an increased risk of heart disease, stroke or associated complications. 
 
This study is researching three different weight-reducing diets, to see as weight loss 
occurs if they have different effects on blood pressure and on blood sugar and 
cholesterol levels 
 
Taking part in the study is entirely up to you and your future care will not be affected 
by your choice. If you are interested in taking part, then we would ask you to come 
up to the Wolfson Centre at the Royal United Hospital to discuss the study and answer 
any queries. We will be able to provide you with transport and reasonable travel 
expenses for your visits if required. 
 
I have taken the liberty to include a copy of the study information sheet (criteria on it 
do not necessarily describe you), consent form and a questionnaire that will assist us 
in seeing if you are eligible.  
 
Should you agree to the study then please return the signed consent form and 
completed questionnaire in the enclosed self-addressed envelope so that we may 
contact you with an appointment or to discuss the study further. 
 
If not interested then please indicate so on the questionnaire without completing the 
medical part so that we do not disturb you again.  
 




Dr Rasha Mukhtar 
Research Registrar, Wolfson Centre, Royal United Hospital on behalf of  
Dr W H Other at Somewhere Else Surgery and  
Dr John Reckless, Dr Tony Robinson and Dr Lynn Higgs at the Royal United 
Hospital 
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Figure 44: Initial details form 
A Randomised Study comparing the effect of three dietary approaches on 
Cardiovascular Risk in Subjects with the Metabolic Syndrome  
 
Name:–____________________________________________________________ 






Please delete as appropriate - 
I am interested in taking part in this study / 
I am not interested in taking part in this study. 
----------------------------------------------------------------------------------------------------- 
Do not complete following unless you intend to take part in this study. 
 
Height    Weight     
 
Do you have   Diabetes   Yes / No / Do not know 
    Hypertension  Yes / No / Do not know 
    Angina  Yes / No / Do not know 
    High Cholesterol Yes / No / Do not know 
     
 





Are you a vegetarian?   Yes / No 
Do you have any allergies?   Yes / No   
If yes then please list what allergies 
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Figure 45: Consent Form 
Patient Consent 
 
A Randomised Study comparing the effect of three Dietary Approaches on 
Cardiovascular Risk in Subjects with the Metabolic Syndrome  
 
Please initial each of the boxes 
 
1. I confirm I have read and understand the patient information sheet.   
 
2. I understand that my participation is voluntary and that I am free to  
 withdraw at any time without my medical care or legal rights being  
 affected          
 
3. I am willing to allow access to my medical records but understand that  
 strict confidentiality will be maintained.  
 
4. I agree to take part in the above study. 
 
 












Name of person taking consent  
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Table 53: Baseline Dietary Questionnaire 
 
Dietary Questionnaire 
The aim of this questionnaire is to help us understand your current eating habits. We 
can then guide you on the dietary changes that you will need to make to participate 
in the study. 
 
How often do you eat the following foods (put a tick in the appropriate box): 
 
Food Most days 2-3 times a 
week 






Potatoes      
Sweet Potato      
Pasta      
Rice      
Couscous      
Crispbreads such as ryvita      
Noodles      
Oven chips      
Home cooked chips in deep 
fryer 
     
Fruit      
Vegetables 
(excluding potatoes) 
     
Yogurt      
Hard Cheese      
Cheese spread      
Cottage cheese      
Oily Fish (salmon, pilchards, 
sardines, mackerel, trout) 
     
White Fish (ie cod etc)      
Baked beans       
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Lentil or pulses      
Nuts      
Beef      
Lamb      
Chicken      
Turkey      
Duck      
Sausages      
Burgers      
Mince      
Quorn      
Tofu      
Commercially prepared 
cooking sauces 
     
Ready meals      
Crisps      
Cake      
Biscuits      
Chocolate      
Sweets      
Ice cream      
Cream 
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1. Do you generally eat 3 meals a day? 
a. Yes   No 
 
2. If No which meal(s) do you often skip (circle one or more) 
a. breakfast 
b. midday meal 
c. evening meal 
 
3. How often do you have snacks during the day between meals such as mid-
morning, mid-afternoon, or a supper in the evening. 
a. Most days Occasionally  Rarely  Never 
 
4. Do you do the food shopping? 
a. Yes 
b. No, if not who does:_________________________ 
 
5. Do you usually do the cooking? 
a. Yes 
b. No, if not, who does:_______________________ 
 
6. What type of bread to you mostly use (please circle): 
a. White bread 
b. Brown bread 
c. Wholemeal bread 
d. Granary bread (with visible grains) 
e. White bread with added fibre 
f. Other, please specify:_________________________________________ 
 
7. If you eat breakfast cereals, name the brand(s) you normally 
eat:_________________________________________________________ 
 
8. What type of milk do you drink: 
a. Whole milk (blue top) 
b. Semi skimmed (green top) 
c. Skimmed milk (red top) 
d. Soya milk 
e. Other, please specify:__________________ 
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9. How much milk do you think you would drink on an average day 
:_____________ 
 
10. If you eat yogurt what type do you usually buy (name the 
brands):______________________________________________________ 
 
11. Do you usually cut the fat off the meat: 
a. Yes, before cooking 
b. Yes, after cooking 
c. No 
 
12. How many eggs would you normally eat each week:___________ 
 
13. What type of margarine or fat spread to you usually use: __________________ 
 
14. What type of oil or fat do you use in cooking: 
a) Sunflower oil (vegetable oil) 
b) Olive oil 
c) Rapeseed oil (vegetable oil) 




15. Do you drink alcohol 
Yes   No 
 
16. If YES, please indicate how much of each of these alcoholic beverages you would 
have on a typical week. 
 
a. Beer/Lager/Cider :  ________ pints 
b. Red Wine   _______ glasses  
c. White Wine   _______ glasses 
d. Spirits               _______ nips 
e. Sweet Liquors   _______ nips 
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17. How often do you buy your lunch out? 
a. Most days  
b. 2-3 times a week   
c. once a week or less   
d. once a month or less  
 
18. How often to you buy takeaway foods (such has pizza, fish and chips, Chinese, 
Indian, McDonalds etc) 
a. Most days  
b. 2-3 times a week   
c. once a week or less   
d. once a month or less  
 
 
19. How often do you eat out at a restaurant, pub, café etc) 
a. Most days  
b. 2-3 times a week   
c. once a week or less   
d. once a month or less  
 
20. How often do you eat at other peoples homes (ie family, friends etc): 
a. Most days  
b. 2-3 times a week   
c. once a week or less   




Thank you for taking the time to complete this. Please bring this with you to your next 
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BOB Trial – Battle of the Bulge 










-2 (screening)  X  X X X    
7 days (food scales) 
 Consent 
 Medical history 
 Physical examination 
 Food questionnaire 
0 (randomisation)     X (height) X X X X   Randomised to dietary 
plan, info given 
 Food diary 
2   X X X      Food diary 
4   X X X      Food diary 
6   X X X     4 days (food scales)   
8   X X X      Food diary 
10   X X X      Food diary 
12  X X X X X  X 3days (food scales)   
14   X X X      Food diary 
16   X X X      Food diary 
18   X X X      Food diary 
20   X X X      Food diary 
22   X X X      Food diary 
24  X X X X X X X  3 days (food scales)   
28   X X X      Food diary 
32   X X X      Food diary 
36   X X X      Food diary 
40   X X X      Food diary 
44   X X X      Food diary 
48   X X X      Food diary 
52  X X X X X X X 3 days (food scales)   
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Wt (kg) Wt (Stone) Inact Light Mod Heavy 
60-65 9' 6 - 10' 5 1500 1800 2200 2200 
66-70 10' 6 - 11' 1 1500 2000 2200 2200 
71-75 11' 2 - 11' 12 1500 2000 2200 2200 
76-80 11' 13 -12' 9 1800 2200 2200 2200 
81-85 12' 10 - 13' 6 1800 2200 2200 2200 
86-95 13' 7- 15' 0 2000 2200 2200 2200 
96-110 15' 1- 17' 5 2200 2200 2200 2200 
111-125 17' 6 - 19' 10 2200 2200 2200 2200 
126-135 19’11 - 21' 4 2200 2200 2200 2200 
>135 > 21' 4 2200 2200 2200 2200 
 
 
Light Activity: Some daily activity (at work or 
tasks about the house or garden) with at least 2 









Wt (kg) Wt (Stone) Inact Light Mod Heavy 
60-65 9' 6 - 10' 5 1500 1800 2200 2200 
66-70 10' 6 - 11' 1 1500 2000 2200 2200 
71-75 11' 2 - 11' 12 1500 2000 2200 2200 
76-80 11' 13-12' 9 1800 2000 2200 2200 
81-85 12' 10 - 13' 6 1800 2200 2200 2200 
86-90 13’ 7- 14’ 3 1800 2200 2200 2200 
91-110 14’ 4- 17’ 5 2000 2200 2200 2200 
111-120 17’ 6- 18’ 13 2200 2200 2200 2200 
121-150 19’0– 23’9 2200 2200 2200 2200 
151-160 23’10-25’4 2200 2200 2200 2200 
>160 > 25’4 2200 2200 2200 2200 
 
 
Moderate Activity: Assumes 6 hours on their feet 








Over 60 years: 
 
Wt (kg) Wt (Stone) Inact Light Mod Heavy 
60-65 9' 6 - 10' 5 1200 1500 1800 2000 
66-70 10' 6 - 11' 1 1200 1500 1800 2200 
71-75 11' 2 - 11' 12 1200 1500 2000 2200 
76-80 11' 13 -12' 9 1500 1800 2000 2200 
81-85 12' 10 - 13' 6 1500 1800 2200 2200 
86-95 13' 7- 15' 0 1500 2000 2200 2200 
96-100 15' 1- 15’11 1800 2000 2200 2200 
101-110 15’ 12-17’5 1800 2200 2200 2200 
111-125 17’ 6- 19’10 2000 2200 2200 2200 
126-135 19' 11 - 21' 4 2200 2200 2200 2200 
136-165 21’ 5- 26’ 1 2200 2200 2200 2200 
>165 > 26’ 1 2200 2200 2200 2200 
 
 
Heavy: Those in heavy labouring jobs or serious 


















Wt (kg) Wt (Stone) Inact Light Mod Heavy 
60-70 9' 6 -11' 1 1200 1500 1500 2000 
71-75 11' 2 - 11' 12 1500 1800 2000 2300 
76-80 11' 13 - 12 ' 9 1500 2000 2000 2300 
81-85 12' 10 - 13' 6 1500 2000 2000 2500 
86-90 13' 7- 14, 3 1500 2000 2200 2200 
91-100 14' 4 - 15 ' 11 1800 2200 2200 2200 
101-114 15 ' 12 - 18 '0 2000 2200 2200 2200 
115-125 18’1- 19' 10 2200 2200 2200 2200 
>125 >19 ' 10 2200 2200 2200 2200 
 
 
Light Activity: Some daily activity (at work or 
tasks about the house or garden) with at least 2 













Wt (kg) Wt (Stone) Inact Light Mod Heavy 
60-70 9' 6-11' 1 1200 1500 1500 1800 
71-75 11' 2- 11' 12 1200 1500 1800 2000 
76-80 11' 13- 12 ' 9 1200 1800 1800 2000 
81-95 12' 10 - 15’0 1500 1800 2000 2200 
96-114 15’1 -18’0 1500 2000 2200 2200 
115-130 18' 1- 20’ 7 1800 2200 2200 2200 
131-150 20’ 8 - 23’ 9 2000 2200 2200 2200 
151-170 23’ 10- 26’ 12 2200 2200 2200 2200 




Moderate Activity: Assumes 6 hours on their feet 











Over 60 years: 
 
Wt (kg) Wt (Stone) Inact Light Mod Heavy 
60-65 9' 6- 10’ 5 1200 1200 1500 1500 
66-75 10’ 6 - 11' 12 1200 1500 1500 1800 
76-85 11' 13 - 13’ 6 1200 1500 1800 2000 
86-95 13' 7- 15’0 1500 1800 2000 2000 
96-100 15’ 1 -15 ' 11 1500 2000 2000 2200 
101-110 15 ' 12 - 17’ 5  1500 2000 2000 2200 
111-120 17’ 6- 18’ 13 1500 2000 2200 2200 
121-135 19’0 - 21’ 4 1800 2200 2200 2200 
136-165 21’ 5 - 26’1 2000 2200 2200 2200 
>165 > 26’1 2200 2200 2200 2200 
 
 
Heavy: Those in heavy labouring jobs or serious 
athletes in training.
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Figure 46:  The four phases of Atkins 
A brief summary of the phases of the Atkins diet 
 
1. Phase 1: Induction  
This is the period where the body generates energy through the burning of fat and 
therefore results in ketosis. It is expected to be a minimum period of fourteen days 
but can be extended for longer. Carbohydrate intake is restricted to no more than 
20gms per day (e.g. 120gm of salad vegetables).  Meat, fish, shellfish or poultry, fats 
and eggs are allowed to be taken unrestrictedly. Cheese is limited initially as it does 
contain milk products. Individuals are encouraged to drink plenty of fluid in the form 
of water and avoid large quantities of caffeine which may potentially induce low 
blood glucose. Atkins claims that the induction phase helps regulate blood glucose 
levels, improve satiety and curb the cravings for sugary substances. 
 
2. Phase 2: Ongoing weight loss 
Ongoing weight loss is the stage where ketosis is ongoing but, there is a gradual 
increase in the daily carbohydrate allowance. Individuals are expected to introduce 
more variety of salads and low glycaemic load products such as yoghurts, nuts and 
possibly berry fruits.  The recommendations is that the carbohydrate intake is 
increased by 5gms per week until a point is reached where weight loss has slowed 
down but continues at a steady and satisfactory rate. This phase is expected to allow 
the dieter understand what their carbohydrate threshold is, allow them to experiment 
with a wider variety of food products, adopt alternatives for favourite carbohydrate 
products  and prepare them for long term weight management. Ongoing weight loss 
can continue for many months until an individual feels they have achieved their target 
weight. 
 
3. Phase 3: Pre-maintenance 
In the third phase, carbohydrate intake continues to gradually rise to the point where 
weight loss stops, “critical carbohydrate level for maintenance” a point above which 
any further carbohydrate intake is likely to cause weight gain. It has been designed to 
allow the gentle transition into ongoing weight maintenance and avoid an individual 
returning to their previous eating habits. By this point dieters would be expected to 
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have become accustomed for their carbohydrate intake to be composed of nuts, seeds, 
berries, low carbohydrate fruit and vegetables, some milk products and legumes. 
 
4. Phase 4: Life time maintenance 
The final stage of the diet is life time maintenance by which an individual will have 
identified their carbohydrate allowance, and have reached their target weight loss. 
Refined carbohydrates should have been eliminated from the individual’s intake and 
healthier, low glycaemic load carbohydrates introduced instead.  
There will be times that weight starts rising and the general advice from the books 
appears to be returning to ongoing weight loss and rebuilding the steps. 
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Table 56: List of allowed foods in Atkins adapted from 40 
Examples of foods allowed on Atkins
 












All fowl including:  









Eggs in any style 
 
All shellfish including:  







 *Oysters and mussels are 
higher in carbs  
 
All meat including:  







Some processed meat, bacon, and ham is 




Cheese Serving Size Grams of net carbs 
Blue cheeses 2 T 0.4 
Cheddar 1 oz 0.4 
Cow, sheep and goat 1 oz 0.3 
Feta 1 oz 1.2 
Gouda 1 oz 0.6 
Mozzarella 1 oz 0.6 
Parmesan 1 oz 0.9 
Swiss 1 oz 1.0 
Vegetable Serving Size/Prep grams of net carbs 
Alfalfa sprouts ½ cup/raw 0.2 
Bok Choy 1 cup/raw 0.4 
Celery 1 stalk 0.8 
Chives 1 tablespoon 0.1 
Cucumber ½ cup 1.0 
Iceberg lettuce 1 cup 0.2 
Mushrooms ½ cup 1.2 
Parsley 1 tablespoon 0.1 
Peppers ½ cup/raw 2.3 
Radicchio ½ cup/raw 0.7 
Radishes 6/raw 0.5 
Romaine lettuce 1 cup 0.4 
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 Vegetables:  
 
You should be eating approximately 12 to 15 grams of net carbs per day in the form of vegetables, 
which is equivalent to several cups depending on the actual carb content of the veggies you select.  
 
 
Vegetable Serving Size/ Prep Net Carbs 
Artichoke 1/2 medium 3.5 
Asparagus 6 spears 2.4 
Avocados ½ whole (raw) 1.8 
Bamboo shoots ½ cup 1.2 
Broccoli ½ cup 1.7 
Broccoli raw ½ cup 0.8 
Brussels sprouts ¼ cup 1.8 
Cabbage ½ cup (raw) 1.6 
Cauliflower ½ cup (raw) 1.4 
Eggplant ½ cup 2.0 
Green String Beans 1 cup 4.1 
Hearts of palm 1 heart 0.7 
Leeks ½ cup 3.4 
Olives green 5 0.1 
Olives black 5 0.7 
Onion ¼ cup 4.3 
Pumpkin ¼ cup 2.4 
Rhubarb ½ cup (unsweetened) 1.7 
Sauerkraut ½ cup (drained) 1.2 
Snow peas and snap peas in pod ½ cup with pods 3.4 
Spinach ½ cup 2.2 
Tomato ¼ cup 4.3 
Turnips ½ cup 3.3 
Zucchini ½ cup 1.5 
Sage 1 tbs 0.0 
Tarragon 1 tbs 0.0 
 
Salad Dressings - Any prepared salad dressing with no added sugar and no more than 2 grams of net 
carbs per serving (1-2 tablespoons) is acceptable. Or make your own. 
Blue cheese 2 tbs 2.3 
Caesar 2 tbs 0.5 
Italian 2 tbs 3.0 
Lemon juice 2 tbs 2.8 
Lime juice 2 tbs 2.8 
Oil and vinegar 2 tbs 1.0 
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Fats and Oils  
 
There are no carbs here, but keep in mind that the serving size is approximately 1 tablespoon. 
1. Butter 
2. Mayonnaise – make sure it has no added sugar 
3. Olive oil 
4. Vegetable oils – Those labelled “cold pressed” or “expeller pressed” are especially 








Do not allow any oils to reach overly high temperatures when cooking. Use olive oil for sautéing 




 Splenda – one packet equals 1 gram of net carbs  
 
Beverages 
 Clear broth/ bouillon (make sure it has no sugars added) 
 Club soda 
 Cream, heavy or light. 
 Decaffeinated or regular coffee and tea – one two cups only 
 Diet soda (be sure to note the carb count) 
 Flavoured seltzer (must say no calories) 
 Herb tea (without added barley or fruit sugar added) 
 Unflavoured soy/almond milk 
 Water – at least eight 8-ounce glasses per day  
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Figure 47: Copy of the eating plan given to those on the LGL Diet 
Metabolic Plan 
 
You have been selected to participate in this study as you have a  
number of risk factors for disease such as high blood pressure,  
cholesterol, larger than ideal waist measure, and higher sugar  
levels. 
 
You have been randomly allocated to follow the Metabolic  
Syndrome Eating Plan. This plan is based on eating less starchy  
food, with more protein (meat/meat products & fish) and  
monounsaturated fats found in olive oil, rapeseed oil, avocado,  
nuts etc. 
 
This eating plan has been personally designed for you to be lower 
 in calories than what you need, and you should lose at least 
 1/2kg or 1Ib per week. 
 
It is very important that you stick to the plan as closely as  
possible and if you experience difficulties to speak your study  
monitor. 
 
Your name:      _________________________ 
 
Your study monitor is:_________________________ 
 
Telephone:     _________________________ 
Eating Plan 
 
   
 
Starchy Foods 
Servings per day 
 
 
A Serving is: 
 3 tbsp. breakfast cereal / muesli   
 3 tbsp. dry porridge oats*    
 1 slice of bread or toast (granary is best)* 
        
 2 crispbreads    2 rice cakes 
 ¼ baguette (granary is best)*  ½ bread roll/ bagel 
 2 ryvita’s* or crisp breads   ½ pita or 1 mini pita* 
 
 ½ English muffin    1 crumpet   
 ½ plain scone    ½ fruit scone* 
 ½ English fruit muffin*   1 scotch pancake 
  9 small rice crackers   3 cream crackers 
   
 3 heaped tbsp. boiled pasta*   1/2 chapatti*   
 2 egg sized boiled potatoes (75g)  2 heaped tbsp. boiled rice 
 ½ cup boiled noodles*   1 small corn cob or ½ cup* 
 1/4 plain naan bread   3 papadums (microwaved)
  
 3 cups plain popcorn   ½ cup cooked parsnip 
 ½ tortilla bread*   ¼ large tin spaghetti (100g) 
 3 heaped tbsp cooked couscous* 
  
* Slow acting starch. 
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Starchy Foods – Fast or Slow Acting? 
 
Some starchy food digests slowly which means your blood sugar  
levels rise slowly and gradually. Other starch food causes a  
faster rise in your blood sugar because it digests quicker. The  
SLOW ACTING foods are better because they fill you up for  
longer and help to reduce the amount of insulin your body makes. 
 
Try to have at LEAST ONE SLOW ACTING food each day 
These are example of slow acting foods 
Breakfast cereal: 
Porriage oats, all bran, Special K, Just right, 
Muesli with dried fruit (check fat is less than 10g per 100g) 
 
Breads: 
Granary breads and rolls containing visible seeds. 
















    
Servings per day 
   
         A serving is: 
 1 medium size piece of fresh fruit 
 2-3 small pieces of fruit 
 1 handful of grapes (or ½ cup) 
 1 small banana, ½ large banana 
 1 ½ cups of melon such as cantaloupe or water melon 
 1 ½ cups of berries such as strawberries, raspberries. 
 1 cup of cherries 
 2 tablespoons fruit (stewed or tinned in juice) 
 a small glass of fruit juice (125 ml) 
 1 tablespoon of dried fruit (3 dates, 4 figs). 



















   
Servings per day 
 
A serving is: 
 3 tablespoons of fresh or frozen vegetables (excluding potatoes, 
corn, parsnips or yam, see starchy foods) 
 1 cup of leafy vegetables (eg lettuce, 
spinach) 







Milk and Yoghurt: 
 
   Servings per day 
 
 A serving is: 
 
 1/2 pint (200ml or 1 glass) of semi-skimmed or skimmed milk 
 1 small pot of low fat no added sugar yoghurt/ fromage frais (eg 
muller light, shape). 








Servings per day 
 
A serving is: 
 30g (1 oz) raw lean beef, pork, lamb, mince, chicken, turkey or fish 
(canned or fresh) 
 1 thin slices of lean cold meat. 
 1 egg (limit to 5 eggs per week) 
 1 match box size piece of hard cheese (30g/1 
oz). 
 60g (2 oz) of cottage or ricotta cheese 
 60g (2oz) of low fat soft cheese. 
 60g (2oz) of tofu 










 Choose lean cuts of meat and trim all fat off meat 
before cooking. 
 Aim to have oily fish twice a week (canned or fresh 
salmon, makeral, sardines, herring, trout, pilchards). 
Choose canned fish in brine, water, or tomato sauce 
 Have beef or lamb no more than twice a week 
 Limit hard cheese to 3-4 oz per week 
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Pulses and Lentils: 
These foods contain both protein and starch. You need to  
count these as part of your protein and starch allowance. 
 
 ½ cup of kidney beans, lentils, chick peas and other pulses 
     = 1 protein & 1 starchy serving. 
 1 small tin baked beans (200g) = 1 protein & 2 starchy  
servings 
 
Fats and Oils: 
  Servings per day    
A serving is: 
 1 teaspoon of margarine 
 1 teaspoon oil (olive or rapeseed) 
 2 teaspoons of peanut butter 
 1 teaspoon mayonnaise or salad cream 
 2 teaspoons low fat spread / low fat dressing 
 1 tablespoon cream 
 ⅛ avocado 
 3 teaspoons of pesto 
 1 teaspoon tahini 
 
 Try to use a margarine high in monounsaturated fats such as olive oil 
spreads eg olivio,, butterley, clover, I can believe  
     its not butter. 
 Use olive oil or rapeseed oil in your cooking. 
 Limit cream to less than once a week.  





 Tea and coffee can be drunk freely, but remember to count the 
milk in the milk allowance. If you have sugar in your tea or coffee try 
using an artificial sweetener such as canderal or hermesetas  
  Water, sugar free squashes and diet or sugar free fizzy drinks 
can be drunk freely. 





If you drink alcohol, aim to limit to no more than 2 units per day for 
women and 3 units for men. You should also try to have 2 alcohol free 
days each week. 
 
You will need to count any alcoholic drinks as part of your portion plan: 
 
 Fat Portion Starch Portion 
1 pint beer or lager 
 
2 1 
Small glass wine (125 ml) 2 0 
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Free Foods (Unlimited) : 
 water 
 tea or coffee (with milk from allowance) 
 sugar free squashes and sugar free fizzy drinks 
 Marmite, Oxo, Bovril, Vegemite  
 stock cubes, herbs and spices 
 
 
Cooking Sauces and Ready Meals : 
 
Look at how much carbohydrate, fat and protein is contained in the 
portion of food you will eat. This will usually be the whole meal for a 
ready meal or ¼ jar of cooking sauce. 
 
15g carbohydrate = 1 starch portion 
7g protein  = 1 protein portion 
5g fat   = 1 fat & oils portion 
 
For example: Ready made lasagne (1/2 pack): 
32g carbohydrate  = 2 starch portions 
20g protein   = 3 protein portions 
13g fat   = 3 fat and oil portion 
   
½ frozen pizza: 
40g carbohydrate   = 3 starch portions 
20.5g protein  = 3 protein portions 




Miscellanous Foods and Snacks: 
 
Some foods contain a combination of starch/sugar and fat. For these 
foods you will need to count these as part of your eating plan. Try to have 
these foods occasionally (1-2 times a week) and count as part of your 
portion plan. 
 
 Fat Portion Starch Portion 
Crisps (1 small bag, 25g) 1 1 
2 Plain biscuit (ie digestive, rich 
tea) 
1 1 
1 Chocolate biscuit, shortbread 1 1 
Chocolate bar (50g) 3 2 
Fun size chocolate bar (eg two 
finger kit kat, milky way 
1 1 
sweet muffin (eg chocolate) 3 2 
Fruit tart 1 2 
Small piece of plain cake 1 2 
Croissant 1 3 
Do nought 2 2 
Apple pie (1/6 of pie) 3 3 
Cheese cake (1/6 of cake) 2 3 
Ice cream (one scoop) 1 1 
Jam / marmalade (3 tsp) 0 1 
Low calorie hot chocolate 0 1/2 
Tomato based pasta sauce 0 1 
Stir in tomato pasta sauce 1 1/2 
Stir in creamy pasta sauce 2 0 
   
Nuts 3 1 protein 
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 Daily Eating Plan 
 You have been allocated specific number of servings of each of the 
food groups. Here is a sample meal plan for you:     
  Food group  Example 
 Breakfast 
 ___   Starchy 
 ___   Milk & yoghurt 
 ___   Fats & Oils 
 ___   Fruit 
 ___   Protein  
  




 ___   Starchy 
 ___   Protein 
 ___   Fats & Oils 
 ___   Fruit 
 ___   Vegetable  
 ___   Milk & yoghurt 
  
  




 ___   Starchy 
 ___   Protein 
 ___   Fats & Oils 
 ___   Fruit 
 ___   Vegetable  
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Figure 48: Copy of the eating plan given to those on a HC diet 
 
Healthy Eating Plan 
 
 
You have been selected to participate in this study as you have a  
number of risk factors for disease such as high blood pressure,  
cholesterol, larger than ideal waist measure, and higher sugar  
levels. 
 
You have been randomly allocated to follow the Healthy  
Eating Plan. This plan is based on eating plenty of starchy foods,  
moderate amounts of protein foods and less fatty foods. 
 
This eating plan has been personally designed for you to be lower in calories than 
what you need, and you should lose at least 1/2kg or 1Ib  
per week. 
 
It is very important that you stick to the plan as closely as  
Possible and if you experience difficulties to speak your study 
 monitor. 
 
Your name:      _________________________ 
 
Your study monitor is:_________________________ 
 






            
Servings per day 
A Serving is: 
 3 tbsp. breakfast cereal / muesli   
 3 tbsp. dry porridge oats    
 1 slice of bread or toast  
        
 2 crispbreads    2 rice cakes 
 ¼ baguette     ½ bread roll/ bagel 
 2 ryvita’s or crisp breads   ½ pita or 1 mini pita 
 
 ½ English muffin    1 crumpet   
 ½ plain scone    ½ fruit scone 
 ½ English fruit muffin   1 scotch pancake 
  9 small rice crackers   3 cream crackers 
      
 3 heaped tbsp. boiled pasta  1/2 chapatti   
 2 egg sized boiled potatoes (75g)  2 heaped tbsp. boiled rice 
 ½ cup boiled noodles   1 small corn cob or ½ cup 
 1/4 plain naan bread   3 papadums (microwaved)
  
 3 cups plain popcorn   ½ cup cooked parsnip 
 ½ tortilla bread    ¼ large tin spaghetti 
(100g) 
 3 heaped tbsp cooked couscous 





    
Servings of fruit per day 
   
         A serving is: 
 1 medium size piece of fresh fruit 
 2-3 small pieces of fruit 
 1 handful of grapes (or ½ cup) 
 1 small banana, ½ large banana 
 1 ½ cups of melon such as cantaloupe or water melon 
 1 ½ cups of berries such as strawberries, raspberries. 
 1 cup of cherries 
 2 tablespoons fruit (stewed or tinned in juice) 
 a small glass of fruit juice (125 ml) 
 1 tablespoon of dried fruit (3 dates, 4 figs). 


















Servings per day 
 
 
A serving is: 
 30g (1 oz) raw lean beef, pork, lamb, mince, chicken, turkey or fish 
(canned or fresh) 
 1 thin slices of lean cold meat. 
 1 egg (limit to 5 eggs per week) 
 1 match box size piece of hard cheese (30g/1 oz). 
 60g (2oz) of cottage or ricotta cheese 
 30g (1oz) of low fat soft cheese. 
 60g (2oz) of tofu 















 Choose lean cuts of meat and trim all fat off meat 
before cooking. 
 Have beef or lamb no more than twice a week 
 Limit hard cheese to 3-4 oz per week 
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Pulses and Lentils: 
These foods contain both protein and starch. You need to count these as 
part of your protein and starch allowance. 
 
 ½ cup of kidney beans, lentils, chick peas and other pulses 
     = 1 protein & 1 starchy serving. 
 1 small tin baked beans (200g) = 1 protein & 2 starchy servings 
 
 
Fats and Oils: 
  Servings per day    
 
A serving is: 
 1 teaspoon margarine 
 1 teaspoon oil  
 2 teaspoons of peanut butter 
 1 teaspoon mayonnaise or salad cream 
 2 teaspoons low fat spread / low fat dressing 
 1 tablespoon cream  
 ⅛ avocado, 
 1 teaspoon tahini 
 3 teaspoons pesto 
 






   
Servings of vegetables per day 
 
A serving is: 
 3 tablespoons of fresh or frozen vegetables (excluding potatoes, 
peas, corn, parsnips or yam, see starchy foods) 
 1 cup of leafy vegetables (eg lettuce, spinach) 
 1 tomato, 4-5 cherry tomatoes 
 
Milk and Yoghurt: 
 




A serving is: 
 1/2 pint (200ml or 1 glass) of semi-skimmed or skimmed milk 
 1 small pot of low fat no added sugar yoghurt/ fromage frais (eg 
muller light, shape). 










 Tea and coffee can be drunk freely, but remember to  
 count the milk in the milk allowance. If you have sugar in your tea 
or coffee try using an artificial sweetener such  
 as canderal or hermesetas  
  Water, sugar free squashes and diet or sugar free fizzy drinks 
can be drunk freely. 
 Count any fruit juice (even 100% pure) as part of your  




If you drink alcohol, aim to limit to no more than 2 units per day for 
women and 3 units for men. You should also try to have 2 alcohol free 
days each week. 
 
You will need to count any alcoholic drinks as part of your portion plan: 
 
 Fat Portion Starch Portion 
1 pint beer or lager 
 
2 1 
Small glass wine (125 ml) 2 0 
 







Free Foods (Unlimited) : 
 water 
 tea or coffee (with milk from allowance) 
 sugar free squashes and sugar free fizzy drinks 
 Marmite, Oxo, Bovril, Vegemite  
 stock cubes, herbs and spices 
 
Cooking Sauces and Ready Meals : 
 
Look at how much carbohydrate, fat and protein is contained in the 
portion of food you will eat. This will usually be the whole meal for a 
ready meal or ¼ jar of cooking sauce. 
 
15g carbohydrate  = 1 starch portion 
7g protein  = 1 protein portion 
5g fat   = 1 fat & oils portion 
 
For example:  Ready made lasagne (1/2 pack): 
32g carbohydrate  = 2 starch portions 
20g protein   = 3 protein portions 
13g fat   = 3 fat and oil portion 
   
½ frozen pizza: 
 40g carbohydrate   = 3 starch portions 
 20.5g protein  = 3 protein portions 




Page | 280 
 
Miscellanous Foods and Snacks: 
Some foods contain a combination of starch/sugar. For these foods you 
will need to count these as part of your eating plan.  Try to have these 
foods occasionally (1-2 times a week) and count as part of your portion 
plan. 
 
 Fat Portion Starch Portion 
Crisps (1 small bag, 25g) 1 1 
2 Plain biscuit (ie digestive, rich 
tea) 
1 1 
1 Chocolate biscuit, shortbread 1 1 
Chocolate bar (50g) 3 2 
Fun size chocolate bar (eg two 
finger kit kat, milky way 
1 1 
sweet muffin (eg chocolate) 3 2 
Fruit tart 1 2 
Small piece of plain cake 1 2 
Croissant 1 3 
Do nought 2 2 
Apple pie (1/6 of pie) 3 3 
Cheese cake (1/6 of cake) 2 3 
Ice cream (one scoop) 1 1 
Jam / marmalade (3 tsp) 0 1 
Low calorie hot chocolate 0 1/2 
Tomato based pasta sauce 0 1 
Stir in tomato pasta sauce 1 1/2 
Stir in creamy pasta sauce 2 0 
   
Nuts (30g, 1oz) 3 1 protein 
Daily Eating Plan 
You have been allocated specific number of servings of each of the food 
groups. Here is a sample meal plan for you     
      
   Food group Example 
Breakfast 
___   Starchy 
___   Milk & yoghurt 
___   Fats & Oils 
___   Fruit 







___   Starchy 
___   Protein 
___   Fats & Oils 
___   Fruit 
___   Vegetable  







___   Starchy 
___   Protein 
___   Fats & Oils 
___   Fruit 
___   Vegetable  
___   Milk & yoghurt 
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Table 57: Visit Crib Sheet 
 
Plan of action at each visit 
 








-4 Y Y        
-2   Y Y Y Y Y Y(7) Y 
0   Y Y Y    Y 
2    Y     Y 
4    Y     Y 
6    Y Y   Y(4) Y 
8    Y     Y 
10    Y     Y 
12   Y Y  Y Y  Y(3) Y 
Month          
4    Y     Y 
5    Y     Y 
6  Y Y Y Y Y Y Y(3) Y 
7    Y     Y 
8    Y     Y 
9   Y Y Y    Y 
10    Y     Y 
11    Y     Y 
12  Y Y Y Y Y Y Y(3) Y 
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Figure 49: Joint British Societies cardiovascular risk prediction charts for men and 
women without diabetes579 
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